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INTRODUCTION 
 
1 Introduction 
Manufacturers of medicinal products need to know and follow specific legal and 
regulatory requirements if they want to place their medicinal products on the 
European Union (EU) or United States of America (USA) market. In the EU, 
medicinal products shall be safe, effective and consistent in quality. [1] Medicinal 
products in the USA are required to be safe and effective for its intended use and 
additionally, with regard to biological medicinal products; scientific evidences must 
show that the manufactured product meets the determined requirements of safety, 
purity, and potency. [2]  [3] 
Additionally, for biosimilar products, the imitator products of the biological innovator 
products which are available after the biological innovator´s product patent has 
expired, the biosimilarity to the reference product, the biological innovator product, 
must be established in a comparable manner. Typically this is done through specific 
non-clinical and clinical testing as outlined in the applicable scientific guidance 
documents published by the regulatory authorities. In contrast to the biological 
innovator product, the marketing approval requirements for the biosimilar products 
are simplified in terms of reduced dossier requirements and the clinical study 
requirements are also simplified. [4] 
Evidence that all these requirements are met must be submitted with the product 
application and will be reviewed during the applicable regulatory approval 
procedure. [5] 
The EU and USA have their own distinct regulatory requirements and procedures 
that must be met prior to placing medicinal products on the market. These market-
specific pre-authorization safety requirements include most importantly drug 
product-specific requirements to clinical and non-clinical testing. In addition, other 
general safety-relevant regulatory requirements and quality considerations 
impacting the safety profile of a biological or biosimilar medicinal product must be 
met prior to medicinal product gaining access to the market. 
After the marketing approval has been granted for the desired market, there are 
market-specific post-authorization regulatory requirements. For example, extended 
monitoring requirements, post-authorization safety (PASS) or -efficacy studies 
                                               
 
[1] 
Regulation (EC) No 726/2004 "Whereas" chapter (14); OJ L 136, 30.4.2004, p. 1, Consolidated version 
05.06.2013; http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
 [2] 21 CFR §310.303(a); April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-
title21-vol5-chapI.pdf 
 [3] 
42 USC §262(a)(2)C)(i); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:262%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section262%29&f=treesort&edition=prelim&num=0&jumpTo=true 
 [4]
 ICH GCG ASEAN Training Workshop on ICH Q5C, 30-31 May 2011, Kuala Lumpur; Alberto Ganan 
Jimenez & Brigitte Brake; 
http://www.ich.org/fileadmin/Public_Web_Site/Training/ASEAN_Q5C_workshop_May_2011/SESSION_IVa_
Biosimilars.pdf 
 [5] 
21 CFR §601.2(a); April 2015; https://www.gpo.gov/fdsys/pkg/CFR-2015-title21-vol7/pdf/CFR-2015-title21-
vol7-part601.pdf 
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(PAES), may have to be performed to further monitor and prove the ongoing safety 
and effectiveness of the approved medicinal product.  
In addition to these requirements, various other safety-related regulatory 
requirements apply in both, the pre- and post-authorization phase. Examples include 
authority inspections, naming and labeling requirements, and variation reporting 
requirements. 
All member states of the European Union are subject to the European Economic 
Area (EEA) law. On the European Union level the Regulation (EC) No 726/2004 and 
the Directive 2001/83/EC are the most essential and comprehensive regulations for 
medicinal products within the EU. The Regulation (EC) No 726/2004 covers the 
authorization and surveillance of safety of medicinal products. The Directive 
2001/83/EC covers a broad range of requirements for all human medicinal products 
and it defines the essential requirements that must be met.  
In addition to the applicable EU-Regulations and EU-Directives, EU-Decisions are 
also legally binding to the EU-member states. To complete the European 
pharmaceutical regulatory framework, several other instruments (e.g., 
Recommendations, Opinions, or European Medicines Agency (EMA) guidelines) 
which are not legally binding, are available for and applicable to medicinal products 
in the EU. [6] 
In the USA, the Federal Food, Drug, and Cosmetic Act, (FD&C Act) is federal law 
and the basic regulation for medicinal products. The FD&C Act is enforced by the 
Code of Federal Regulations (CFR). These legally binding rules and regulations, 
also named administrative law, regulate most of the medicinal products under the 
FD&C Act. The regulations for the marketing approval of these, typically chemically 
synthesized products, are found in 21 CFR Parts 300 – 499. [7] In addition, certain 
biological medicinal products are also regulated thereunder.  
As indicated, some biological medicinal products, e.g., products containing 
biotechnology-derived enzyme human Imiglucerase as active ingredient, are also 
subject to the FD&C Act. [8] These types of biological products gain their marketing 
approval through the “New Drug Application” (NDA) process like chemically-
synthesized products. But many biological medicinal products (e.g., medicinal 
products containing the biotechnology-derived enzyme human Galsulfase as active 
ingredient or medicinal products containing biotechnology-derived monoclonal 
antibodies (mAbs) as active ingredient such as Infliximab) are not primary subject to 
the FD&C Act but rather to the Public Health Service Act (PHS Act). [9] [10] Section 
351 of the PHS Act serves as the basic regulation for biological products which are 
                                               
 [6] Procedure for European Union Guidelines and related Documents within the Pharmaceutical legislative 
Framework; Doc. Ref. EMEA/P/24143/2004 Rev. 1 corr; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004011.pdf 
 [7] Food and Drugs, Parts 200 – 499; PART 314; April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-title21-
vol5/pdf/CFR-2014-title21-vol5-chapI.pdf 
 [8] CEREZYME, (NDA) 020367; May 1994; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=C 
 [9] NAGLAZYME, (BLA) 125117; May 2005; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=N 
 [10] REMICADE, (BLA) 103772; August 1998; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=R 
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not regulated under the FD&C Act. [11] Products covered by the Public Health 
Service Act obtain marketing approval through the Biologics License Application 
(BLA) process. The Public Health Service Act is federal law and is enforced by the 
Code of Federal Regulations as well. The FDA regulations for marketing approval of 
these biological medicinal products are established in the 21 CFR Parts 600 – 680. 
[12] To complete the US-American pharmaceutical regulatory framework, several 
other instruments like FDA guidance documents which are not legally binding, are 
available for and applicable to medicinal products in the USA. 
In addition to the EU- and US-market specific binding and non-binding regulatory 
requirements the overarching guidelines of the International Council on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) are applicable to both markets as well. [13] 
Both the EU- and the US-market have complex pharmaceutical legislation and 
various regulations. Opportunities for the improvement of safety standards are 
available in both markets; especially in the area of biosimilar products. 
In the following, a regulatory overview is provided of how a biotechnology-derived 
medicinal product is brought to both, the EU- and the US-market. The applicable 
legislation and relevant scientific documents to identify safety relevant requirements 
is analyzed, and differences between both markets with respect to the identified 
safety standards, namely overall safety-related regulatory standards, clinical safety -
and non-clinical safety requirements and quality considerations are critically 
examined. A special focus is made on [1] the information that is available for 
biosimilar monoclonal antibodies (mAbs), and [2] the overall improvement of safety 
standards for biosimilar products. 
Within the introductory chapter, a scientific and regulatory overview is given that 
introduces in the regulatory framework and the complexity of biotechnology-derived 
medicinal products.  
The main chapter identifies significant overall safety requirements established by 
legislation and gives attention to the specific safety requirements established in 
EMA- and FDA scientific guidance documents which were categorized into [1] 
overall safety-relevant regulatory requirements, [2] clinical safety and [3] non-clinical 
safety testing requirements and [4] quality considerations. The chapter analyzes the 
available information to the mentioned categories of safety standards for biosimilar 
products. Finally, potential improvements to the safety standards of biosimilar 
products are addressed.  
The final chapter summarizes and discusses the most significant safety relevant 
facts and provides a conclusion and outlook.  
  
                                               
 [11] 
42 USC § 262; April 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF&edition=prelim 
 [12] 
Title 21 Food and Drugs Parts 600-799; April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-title21-
vol7/pdf/CFR-2014-title21-vol7.pdf 
 [13] About ICH, Steering Committee; http://www.ich.org/about/organisation-of-ich/steering.html 
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2 Historical background 
This chapter introduces the biological medicinal products of today; starting with the 
historical beginning of the development of biotechnology through the development of 
the first biotechnology-derived medicinal products.  
 From the beginning of biotechnology to the first therapeutic 2.1
monoclonal antibody 
It all began with beer. The cradle of modern biotechnology is more than 6.000 years 
old and began when the Sumerian in Mesopotamia started brewing beer with 
sprouted grain and after fermentation obtained the first alcoholic beverage. The first 
beer recipes were documented 4.000 years ago and up to 20 different beer varieties 
were produced. [14]  [15] 
A couple of thousand years later, the medic Robert Koch (1843-1910) developed 
bacteriological techniques like culture plate technology with solid, transparent 
nutrient media, and the incubator. He also discovered the tuberculosis pathogen. [16] 
In parallel, the “Father of genetics" Johann Gregor Mendel (1822-1884), performed 
research in the field of genetics and formulated the rules of heredity. [17] 
Then, in 1908, medic and Nobelist Paul Ehrlich (1854-1915) formulated the potential 
of antibodies and the concept of “magic bullets” during his cancer research work. He 
was searching for chemical substances with particular affinities for morbifical 
organisms, like the antitoxin-toxin (antibody-antigen) relationship, where the 
chemical substances would go directly to the organisms for which they are aligned. 
[18] An important method for the production of monoclonal antibodies was the 
hybridoma-technology developed by G. Köhler and C. Milstein in 1975. [15] [19] For 
further information please refer to Appendix A. 
Of significant importance for the drug sector was the year 1977. Genentech, the 
pioneer biotechnology-company, produced the first human protein (Somatostatin) in 
E. coli bacteria. [20] [21] Later, in 1982, the same company produced the first 
recombinant DNA-derived human insulin which was licensed to Eli Lilly and received 
FDA approval in 1985 for the recombinant growth hormone Protropin®. [20] [21] In 
1986, the murine Muromonab-CD3 (trade name Orthoclone OKT3®) by Janssen-
Cilag received FDA approval; this was the worldwide first monoclonal antibody for 
therapeutic purpose and was intended to treat acute steroid-resistant rejection 
                                               
 [14] 
Frühgeschichte; February 2016; http://www.brauer-bund.de/index.php?id=21 
 [15] „Biotechnologie für Einsteiger“; Renneberg, Reinhard; Berkling, Viola; 2013; ISBN: 978-3-8274-3047-2 
 [16] 
Robert_Koch; https://de.wikipedia.org/wiki/Robert_Koch 
 [17] 
Gregor_Mendel; https://de.wikipedia.org/wiki/Gregor_Mendel 
 [18] 
Paul Ehrlich – Biographical; http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/ehrlich-
bio.html 
 [19] Hybridom-Technik; https://de.wikipedia.org/wiki/Hybridom-Technik 
 [20] 
A History of Firsts; http://www.gene.com/media/company-information/chronology 
 [21] 
Genentech; https://de.wikipedia.org/wiki/Genentech 
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reactions. [22] For more information on the historical development of biotechnology, 
please refer to Appendix B. Currently, monoclonal antibodies are produced by 
recombinant methods using the DNA cloning in expression systems as explained in 
Appendix C in which antibodies are produced in-vitro in bacteria- or cell cultures 
and selected by phage-display-screening. [15] 
Major developments in production techniques and scientific methods resulted in 
pharmaceutical achievements. Since the first mAb-approval in 1986, many other 
biotechnology-derived monoclonal antibodies have been developed and approved 
for a broad range of diseases. In Germany and the EEA 46 monoclonal antibodies 
have been approved as of February 12, 2016. [22]  [23] According to the information of 
the organization Biotech within Research-Based Pharmaceutical Companies, known 
as vfa.bio, as of January 20, 2016, a quantity of 191 medicinal products, including 
biosimilar products, with 151 active substances have been approved in Germany 
that are genetically-engineered. Such products are also called biopharmaceuticals. 
[24] In the USA, 56 biological medicinal products obtained Biologics license (BLA) 
from the FDA between 2008 and 2015. [25]  
                                               
 [22] 
Muromonab-CD3; https://de.wikipedia.org/wiki/Muromonab-CD3 
 [15] „Biotechnologie für Einsteiger“; Renneberg, Reinhard; Berkling, Viola; 2013; ISBN: 978-3-8274-3047-2 
 [23] 
Monoklonale Antikörper; Februar 2016; http://www.pei.de/DE/arzneimittel/immunglobuline-monoklonale-
antikoerper/monoklonale-antikoerper/monoklonale-antikoerper-
node.html?gts=3257586_list%253Dtitle_text_sort%252Bdesc 

 [24] 
Zugelassene gentechnische Arzneimittel in Deutschland; Januar 2016; http://www.vfa.de/de/arzneimittel-
forschung/datenbanken-zu-arzneimitteln/amzulassungen-gentec.html
 
 [25] 
NDA and BLA Calendar Year Approvals; (February 2016; 2014 and older reports are in the FDA Archive) 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiol
ogicApprovalReports/NDAandBLAApprovalReports/ucm373413.htm
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3 Meanings and exemptions  
This chapter describes the term safety standards for biological medicinal products 
and provides information on exempted biological medicinal products. 
 Meaning of the term safety standards 3.1
Safety standards are established in both the EU and the USA in the form of 
requirements and considerations established by legislation, regulation and 
regulatory and scientific guidance documents which apply to a medicinal product 
during the different authorization phases. The pre-authorization phase occurs before 
a biological medicinal product gains market access; the post-authorization phase 
occurs after the medicinal product has successfully obtained marketing approval. 
Some safety requirements such as the Good Manufacturing Practice (GMP) apply in 
both phases, pre- and post-authorization. 
The term safety standard relates to the safety relevant regulatory and scientific 
requirements that must be met prior and within the regulatory approval process of 
biotechnology-derived drug products in order to gain marketing approval and post-
authorization. Some post-authorization safety requirements, like the extended 
monitoring and post-authorization studies, may apply only to certain specific 
biotechnology-derived products such as to novel active substances, others may be 
applicable to all marketed medicinal products (e.g., reporting requirements). To 
receive marketing approval, the safety, efficacy and quality of a biotechnology-
derived drug product must be demonstrated. In addition, for biosimilar products, 
biosimilarity to the reference product, the biological innovator product, must be 
established in a comparable manner. Typically this is done through specific non-
clinical and clinical testing as outlined in the applicable scientific guidance 
documents about non-clinical, clinical and quality issues, published by the EMA and 
FDA, the regulatory authorities of the European Union and the USA. Overall safety 
relevant regulatory requirements are established by legislative documents and may 
also potentially impact the safety of biotechnology-derived products.  
 Exemptions  3.2
Immunological medicinal products, (e.g., vaccines, toxins, serums, allergen 
products), human blood and plasma products, (e.g., clotting factors), advanced 
therapy medicinal product like gene – and cell therapeutics are exempted and not 
discussed. Further, therapeutic synthetic peptide products of 40 or fewer amino 
acids covered by the US PHS Act and biotechnology-derived products covered 
under the FD&A Act are not considered. 
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4 Definitions 
This chapter defines the terms “biotechnology-derived”, “medicinal product”, 
“biological product” and “biosimilar” within the European Union and the USA. Please 
note, the term biotechnology-derived product refers to both, the biological innovator 
product and the biosimilar product. All definitions of this chapter can be found cited 
in Appendix D.  
 Biotechnology-derived 4.1
Biotechnology-derived medicinal products are products like high-molecular-weight 
proteins and polypeptides which themselves or their active substance is produced 
by biotechnological production processes. These biotechnology-derived products 
are typically produced by genetically-engineered living systems. In the European 
Union, the concerned products are mentioned in Article 3(1) of Regulation (EC) No 
726/2004 and defined in point 1 of the Annex of the mentioned Regulation and 
include for example products developed by recombinant DNA technology and by 
hybridoma and monoclonal antibody methods. [26] 
Within the USA, the considered biotechnology-derived products are covered by the 
Public Service Health Act and they are defined by the regulations of the Food and 
Drug Administration as “specified biological products”. [27] Those products include for 
example therapeutic recombinant DNA-derived products and monoclonal antibodies 
for in vivo use. 
 Definitions in the European Union 4.2
The Directive 2001/83/EC provides the regulatory basis and legal definition of the 
term “medicinal product”. [28] 
The term “biological” legally is defined in Appendix I of Directive 2001/83/EC and the 
regulatory basis is provided there. The active substance of biological products is a 
biological substance that comes from a biological source. [29] 
The term “biosimilar” is defined in the EMA similar products guidance document in 
section 3.1. A biosimiliar product contains a version of the active substance of an 
EEA authorized biological innovator product and therefore, is biosimilar and not bio-
identical to that reference product. Similarity of the biosimilar product to the 
                                               
 [26] Regulation (EC) No 726/2004 Article 3(1) and Point 1 of the Annex; OJ L 136, 30.4.2004, p. 1, Consolidated 
version 05.06.2013 ; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
 [27] 21 CFR §601.2(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol7/pdf/CFR-2014-title21-
vol7-part601.pdf 
 [28] 
Directive 2001/83/EC Title I, Definitions of Article 1; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012 ; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [29] 
Directive 2001/83/EC Part I, Appendix I, section 3.2.1, subsection 3.2.1.1(b); OJ L 311, 28.11.2001, p. 67, 
Consolidated version 16/11/2012; http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
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reference product must be established by comparative testing regarding the quality 
properties, biological activity, safety and efficacy. [30] 
 Definitions in the USA 4.3
The definition of “drug” in the Federal Food, Drug and Cosmetic Act (FFD&C Act) 
also applies for biological products which are covered under the PHS Act. [31] The 
PHS Act provides the regulatory basis and legal definition of the term “biological 
product” and “biosimilar”. [32] The term “biological product” comprises various 
biological sources such as virus, toxin, blood, proteins or trivalent organic arsenic 
compounds, etc. The term “biosimilar” refers to a biosimilar product that is highly 
similar to a FDA approved biological innovator product and for which no clinically 
meaningful differences were observed between the biosimilar product and the 
reference product with regard to its safety, purity, and potency. 
                                               
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [31] 
21 USC §321(g); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:21%20section:321%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title21-section321%29&f=treesort&edition=prelim&num=0&jumpTo=true 
 [32] 
42 USC §262 (i)(1), 42 USC §262 (i)(2)(A),(B); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:262%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section262%29&f=treesort&edition=prelim&num=0&jumpTo=true 
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5 Current status and market figures for biotechnology-
derived products  
The chapter describes the importance of biotechnology-derived products in 
medicine, their impact on the health expenses and market trends. Please note, the 
overall term biopharmaceutical products refer to all recombinant-DNA derived 
medicinal products. 
 Current market figures and future trends  5.1
The range of the recombinant DNA-derived medicinal products is huge and 
includes, for example [1] hormones (e.g., insulin, erythropoietin); [2] monoclonal 
antibodies like the biologic response modifiers (BRMs); [3] recombinant clotting 
factors; [4] enzymes such as -Glucosidase; and [5] diverse recombinant vaccines 
e.g., against Hepatitis B and cervical cancer. The therapeutic application of these 
products is multifarious and covers a broad range of diseases such as auto-immune 
generated diseases like rheumatoid arthritis, multiple sclerosis and diabetes; types 
of cancer like Non-Hodgkin-Lymphoma; as well as metabolism- and clotting 
disorders and osteoporosis. [24] 
It is very likely that the market of biopharmaceutical products (biological products 
including mAbs, other recombinant DNA-derived proteins; and biotechnological and 
genetically engineered vaccines) will continue to grow in the future. According to the 
information provided in the vfa.bio 10th Biotech Report summarizing the 
development of the German medical biotechnology, 155 biopharmaceutical products 
were approved in 2005 compared to 226 products in 2014. [33] Simultaneously, 
biopharmaceutical sales rose from 2.6 billion Euros in 2005 to 7.5 billion Euros in 
2014. [33] Biopharmaceutical sales rose by 7% in 2014 from 2013 in real terms 
compared to the total pharmaceutical market with a grow rate of 6.6% in 2014 from 
2013 in real terms. The percentage of Biopharmaceuticals in the pharmaceutical 
market grew from 21.4% to 22.0%. [33] 
With respect to monoclonal antibody products, the vfa.bio 10th Biotech Report 
describes an increasing number of mAbs in the pipeline; in 2005 there were 79 
mAbs and in 2014 there were 357 mAb products. [33] In addition, the 
biopharmaceutical share of the market rose from 12% in 2005 to 22% in 2014. [33] 
The US-market is the market leader in the production of biopharmaceuticals 
followed by Germany. [34]  [35] According to the forecast information of IMS institute 
                                               
 [24] 
Zugelassene gentechnische Arzneimittel in Deutschland; Januar 2016; http://www.vfa.de/de/arzneimittel-
forschung/datenbanken-zu-arzneimitteln/amzulassungen-gentec.html 
 [33] Medizinische Biotechnologie in Deutschland 2005 - 2015 - 2025: Bedeutung für Patienten, Gesellschaft und 
Standort; 10.Biotech-Report ; June 2015; http://www.vfa-bio.de/download/bcg-report-2015.pdf 
 [34] Biopharmazeutika - Hightech im Dienst der Patienten; October 2010; http://www.vfa-bio.de/vb-de/aktuelle-
themen/branche/biopharmazeutika-hightech-im-dienst-der-patienten.html 
 [35] Global Outlook for Medicines Through 2018; Murray Aitken; Michael Kleinrock; Jennifer Lyle; Deanna Nass; 
and Lauren Caskey from imsHealth; November 2014; http://www.imshealth.com/en/thought-leadership/ims-
institute/reports/global-outlook-for-medicines-through-2018#ims-form 
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for healthcare informatics (IMS Health™) published in November 2014, it is 
anticipated that the total global expenses for medicinal products will increase to $1.3 
Trillion from 2014 to 2018 (an increase of approximately 30% from 2013), and that 
specialty drug products, e.g., biotechnology-derived products, will constitute 40% of 
the total global growth. [35] 
According to Transparency Market Research, another market research company, 
the US biopharmaceuticals market value was estimated with US$ 90 billion in 2012 
and is expected to grow at a compound annual growth rate (CAGR) of 11% by 2018 
which means further expansion of the biopharmaceutical market. [36] This is also 
supported by the fact that while the FDA licensed only four biological products via 
Biologics License Application (BLA) approval in 2008, they licensed 11 in 2014 and 
12 in 2015. [25] Information to increasing growth of the global biopharmaceuticals 
market is also provided in a global market study published by the company 
Persistence Market Research (PMR). Here, the value of the global 
biopharmaceuticals market was estimated with US$ 161,851.6 billion in 2014 and is 
now expected to grow at a compound annual growth rate (CAGR) of 9.4% to 
achieve US$ 278,232.9 billion by 2020. [37] 
Growth of the total US-pharmaceutical market is expected to be 5-8% compound 
annual growth rate (CAGR) through 2018 compared to the German market which is 
expected to be 2-5% CAGR while 1-4% CAGR is expected for the five EU countries 
Germany, France, Italy, U.K. and Spain together through 2018. [35] Global spending 
growth is expected to be 4-7% compound annual growth rate through 2018. [35] 
While the value of the biopharmaceuticals market is steadily growing, the financial 
resources that the statutory health insurances (GKV) dedicate for prescribed 
biotechnology-derived products are also increasing. [38] According to information 
from the German Barmer Gmünder Ersatzkasse (Barmer GEK) annual report of 
2015, 13% of drugs expenditures are spent for biopharmaceutical products with 
increasing trend. [39] Between the years 2013 - 2014, the Barmer GEK spent 39.2 % 
of their total expenses, which was 1.73 billion Euros, for 3.5 % of prescribed 
biological products. [39] Annual financial expenditures of 30 000 Euros and more per 
patient (e.g., Lenalidomid therapy for cancer treatment) for biological products are 
typical. [39] The high prices in the biological products sector are caused by their high 
                                               
 [35] 
Global Outlook for Medicines Through 2018; Murray Aitken; Michael Kleinrock; Jennifer Lyle; Deanna Nass; 
and Lauren Caskey from imsHealth; November 2014; http://www.imshealth.com/en/thought-leadership/ims-
institute/reports/global-outlook-for-medicines-through-2018#ims-form 
 [36] US Biopharmaceutical Market - Global Industry Size, Market Share, Smart Trends, Analysis And Forecast 
2012 – 2018; http://www.transparencymarketresearch.com/us-biopharmaceutical-market.html 
 [25] 
NDA and BLA Calendar Year Approvals; February 2016; (2014 and older reports are in the FDA Archive); 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiol
ogicApprovalReports/NDAandBLAApprovalReports/ucm373413.htm 
 [37]
 Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020; Years 2014-2020; 
May 2015; http://www.persistencemarketresearch.com/market-research/biopharmaceutical-market.asp 
 [38] Pressemitteilung; December 2015; http://presse.barmer-
gek.de/barmer/web/Portale/Presseportal/Subportal/Laender/Einstieg-BaWue/Pressemitteilungen-
Archiv/Archiv_202015/151230-arzneimittelreport-ulm/151230-pm-download,property=Data.pdf 
 [39] BARMER GEK ARZNEIMITTELREPORT 2015; Schriftenreihe zur Gesundheitsanalyse Band 32, 
Arzneimitteldaten aus den Jahren 2013 bis 2014 ; June 2015; 
https://www.barmer.de/blob/37954/60143006d7108440f02512a6a80fcaea/data/pdf-arzneimittelreport-
2015.pdf 
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development- and manufacturing costs which are up to US$ 1.6 billion for novel 
biopharmaceuticals until market access is achieved. [40]  [33] 
Due to the high cost of biological products and the desire to widen patient access 
and choice, great hopes are being set in biosimilar products, the imitator products of 
the biological innovator products. Biosimilar products may access the market after 
the patent expiration of the first-in-market product that is intended to be used as 
reference product. The active substance of these imitator products may be a version 
of that of the reference product and therefore it is bio-similar but not bio-identical to 
those of the reference product. [30] While their production is also cost intensive as 
they are not as inexpensive to manufacture as most chemically-synthesized generic 
drugs; they tend to be cheaper than the biological innovator product. [41] 
The first EMA approved biosimilar was Omnitrope® (Somatropin) in 2006, and the 
first EMA approved biosimilar monoclonale antibodies were InflectraTM by Hospira 
and Remsima by Celltrion in June, 2013. [42]  [43] Currently the EMA has approved 19 
biosimilar products within the EEA region. [44] A list of EMA-approved biosimilar 
products and innovator biological products as of January 2016 is available on the 
vfa-bio website. [24] 
In the US- market the first biosimilar product was approved by the FDA on July 24, 
2014 (Zarxio by Sandoz, a Filigrastim preparation). [45]  [46] Currently, there is one 
FDA approved biosimilar mAb product “Inflectra”. [47] And a few regulatory 
submissions have been accepted by the FDA for review. [48]  [49] 
                                               
 [40] The current State of Innovation in the Pharmaceutical Industry; Wilsdon, T; Attridge, J.; Chambers, G., 
Charles River Associate (CRA) International, June 2008 
 [33] 
Medizinische Biotechnologie in Deutschland 2005 - 2015 - 2025: Bedeutung für Patienten, Gesellschaft und 
Standort; 10.Biotech-Report ; June 2015; http://www.vfa-bio.de/download/bcg-report-2015.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014 ; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [41] Kostenvorteil; Februar 2016; http://probiosimilars.de/biosimilars/kostenvorteil/ 
 [42] 
Omnitrope somatropin Authorization details; EMEA/H/C/607; April 2006; 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/000607/WC500043689.pdf 
 [43] 
EMA Approves First MAb Biosimilars; July 2013; http://www.biopharma-reporter.com/Markets-
Regulations/EMA-Approves-First-MAb-Biosimilars 
 [44] Originalpräparate und Biosimilars (zugelassen in der EU); Januar 2016; 
http://www.vfa.de/download/biosimilars-uebersicht-originalpraeparate.pdf 

 [24] 
Zugelassene gentechnische Arzneimittel in Deutschland; Januar 2016; http://www.vfa.de/de/arzneimittel-
forschung/datenbanken-zu-arzneimitteln/amzulassungen-gentec.html 
 [45] FDA Accepts First Biosimilar Application Filed under Section 351(k) of the Public Health Service Act; Jula 
2014; http://www.klgates.com/fda-accepts-first-biosimilar-application-filed-under-section-351k-of-the-public-
health-services-act-07-28-2014/ 
 [46] Court allows Sandoz to launch first US Biosimilar in September; Zachary Brennan; July 2015; 
http://www.biopharma-reporter.com/Markets-Regulations/Court-allows-Sandoz-to-launch-first-US-biosimilar-
in-September 
 [47] 
FDA approves Inflectra, a biosimilar to Remicade; April 2016; 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm 
 [48] 
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept; Novartis; October 2015; 
https://www.novartis.com/news/media-releases/fda-accepts-sandoz-regulatory-submission-proposed-
biosimilar-etanercept 
 
[49]
 Hospiras Remicade copycat up for review as US biosimilars March on; Dan Stanton; February 2015; 
http://www.biopharma-reporter.com/Markets-Regulations/Hospira-s-Remicade-copycat-up-for-review-as-
US-biosimilars-March-on 
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6 Biological products and biotechnology-derived medicinal 
products 
This chapter provides an overview to biological products, biosimilar products and the 
structural specialties and complexity of biotechnology-derived products that may 
explain their regulatory handling.  
 Biological products  6.1
The active substance of all biological products is of biological nature which comes 
from a biological source and this includes products like immunological medicinal 
products, human blood and plasma products, and advanced therapy medicinal 
products, which are exempted and not further and discussed. [28] Although many 
biological and biosimilar products are produced with biotechnological methods 
today, three examples for biological products which were produced with non-
biotechnological methods in the past will be provided below to demonstrate the 
timely and financial effort their production has needed. The examples include 
biological products exempted in section 3.2.  
 Clotting factor VIII 
The genetic disease Hemophilia A affects only males. The defect leads to a 
shortage of the clotting factor VIII which causes that already a minor injury could 
lead to life-threatening bleeding. In the past, the clotting factor VIII was extracted 
from human donor blood. A bleeder needs a clotting factor VIII amount of 2 mg per 
week and about 6 litres of human donor blood contain only 1 mg of clotting factor 
VIII which means that 24 blood donors are necessary per week to provide the 
needed clotting factor assumed each donor gives 500 ml blood. [15] Beside of the 
huge production costs there are several health risks associated with this way of 
production such as serious virus infections with AIDS or Hepatitis. Currently, 
recombinant clotting factor VIII is biotechnologically produced e.g., in genetically-
engineered Chinese Hamster Ovary (CHO) cells, and on market since 1992. [15]  [50] 
 Interferon 
Another example is the production of Interferon. Interferon is a protein produced by 
the human body, and among other things, responsible to stimulate the immune 
system in order to defense viruses and tumor cells. Interferon was identified by A. 
Isaacs and J. Lindemann in 1957. In the 70s K. Cantell developed a technique to 
produce interferon from human blood by infecting leucocyte of human blood donors 
with a virus. Then, the interferon which was produced by the human cells was 
collected and purified. To produce 0,5 Gramm of interferon with this method, a 
                                               
 [28] Directive 2001/83/EC Title I, Definitions of Article 1; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012 ; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [15] „Biotechnologie für Einsteiger“; Renneberg, Reinhard; Berkling, Viola; 2013; ISBN: 978-3-8274-3047-2 
 [50] Rekombinante Blutgerinnungsfaktoren; https://de.wikipedia.org/wiki/Rekombinante_Blutgerinnungsfaktoren 
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volume of 50 000 litres of donor blood plasma was needed. [15] In 1979, C. 
Weissmann succeeded to produce interferon by bacterial synthesis in E. coli. In 
contrast, now a volume of only 10 litres bacteria culture solution were enough to 
produce 0,5 Gramm interferon. Since 1983 different types of biotechnology-derived 
interferon and recombinant interferon are available on market and used in various 
therapeutic areas such as autoimmune diseases, virus infections or cancer. [15]  [51] 
 Paclitaxel 
Paclitaxel is an extract of the bark of the pacific yew tree and was identified in 1962 
by A.S. Barclay and is used in the chemotherapeutic Taxol which was first approved 
by the FDA in 1992 for the therapy of metastatic ovarian. [52] The Paclitaxel is able 
to block cancer cells but is only in limited quantity available in one tree. The bark of 
12 yew trees would be necessary to extract 1 Gramm of the active substance with 
the initial production process. [53] So, bark of hundred thousands of old and slow 
growing pacific yew trees would be needed for the extraction of the active substance 
to treat US-American patients with ovarian cancer for one year. [15] To save natural 
resources several researches were done and in 1992 a semisynthetic method 
developed by R. Holton was patented which used needles of the European yew 
tree. [15] Since 2002 it is possible to produce the active substance biotechnologically 
in fermenters by using cell cultures of the yew tree. [54] The Paclitaxel production in 
bacteria or yeast is still in research. [55] 
Today, many biological innovator products and biosimilar products are produced by 
complex biotechnological genetically-engineered processes on the basis of 
biological living source materials, e.g., animal or plant cells, and microorganism 
such as bacteria or yeast. These biotechnology-derived products are complex in 
their molecular structure.  
 Biosimilar products  6.2
After the biological innovator´s product patent has expired biosimilar products may 
apply to gain market authorization. Biosimilar products are imitator products of the 
chosen reference biological innovator product, and contain a version of the active 
substance. Due to unavoidable minor differences in the production of biosimilar 
products (e.g., diversified production processes, differing production parameters or 
producing source organisms- or cell-lines), it is not possible to make biosimilar 
products bio-identical to their biological innovator products. Thus, the non-identical 
structure of the active substance of biosimilar products may lead to differences in 
strength with consequences to the dose needed for the same efficacy as the 
referenced innovator product has, or to a different retention time in blood; but also to 
                                               
 [15] „Biotechnologie für Einsteiger“; Renneberg, Reinhard; Berkling, Viola; 2013; ISBN: 978-3-8274-3047-2 
 [51] Interferone; https://de.wikipedia.org/wiki/Interferone 
 [52] Success story Taxol® (NSC 125973); December 2016; 
https://dtp.cancer.gov/timeline/flash/success_stories/s2_taxol.htm 
 [53] Paclitaxel; https://de.wikipedia.org/wiki/Paclitaxel 
 [54] Paclitaxel aus Fermentern; 2002, Ausgabe 34; http://www.pharmazeutische-
zeitung.de/index.php?id=pharm5_34_2002 
 [55] Biologische Pharmaproduktion; Max-Planck-Gesellschaft, München, April 2015; 
https://www.mpg.de/9169009/biologische_pharmaproduktion 
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clinical safety relevant differences (e.g., differences in or as yet unknown unwanted 
adverse effects). [56] The EMA guidance document for similar products – non clinical 
and clinical issues mentions those differences in the qualitative or quantitative 
nature of product-related versions could impact biological functions of the 
biotechnology-derived product and may have an effect on immunogenicity and 
hypersensitivity potential. Thus, such potential should be evaluated in clinical 
studies as animal studies are not suitable to predict such potential. [57] 
Therefore, it is of major importance to establish comparable biosimilarity from the 
proposed biosimilar product to the chosen reference product by demonstrating 
comparability of their quality attributes and biological activity, as well as clinical 
safety and efficacy. If differences between the proposed biosimilar product and the 
reference product are detected during testing, it must be demonstrated that these 
differences have no relevant impact to the biosimilar product clinical safety and / or 
its efficacy.  
Theoretically, any biotechnology-derived product may be demonstrated to be 
biosimilar to a chosen reference product, especially highly purified products that can 
be thoroughly characterized. [30] However, in practice, the biosimilar approach is not 
feasible for all biotechnology-derived products. Not all products proposed to be 
biosimilar are physico-chemically and biologically characterizable to the extent 
needed to establish comparable biosimilarity between both products. For other 
biotechnology-derived products again, only little clinical and regulatory experience is 
available to use this approach. [30] 
Many biosimilar products are intended for the long-term treatment of chronic 
diseases; but clinical safety studies conducted prior to authorization are normally not 
sufficient to detect and to identify rare adverse effects. Therefore, many biosimilar 
products are subject to an extended and strict pharmacovigilance course. Typically, 
during the biosimilar products post-approval phase, the marketing authorization 
holder (MAH) is required to closely monitor the clinical safety of the biosimilar 
product in a continuous fashion and also to evaluate the products benefit-risk-
balance. [57] Additionally, post-authorization safety and / or efficacy studies may be 
necessary and more intensive monitoring and labeling may be required by 
regulatory decision.  
 Specialties of biotechnology-derived products  6.3
In contrast to chemically-synthesized products, biotechnology-derived products 
(e.g., mAbs, recombinant DNA-derived proteins) are manufactured using 
genetically-engineered living production systems in biotechnological manufacturing 
processes of high complexity. Three major facts can be identified for biotechnology-
derived showing the differences to common medicinal drugs, and each fact may 
                                               
 [56] Biopharmazeutika Hightech im Dienst der Patienten; vfa - Die forschenden Pharmaunternehmen, December 
2010 http://www.vfa.de/download/broschuere-biopharmazeutika.pdf 
 [57] Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014 , 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 [30] Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014, 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
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impact the final biological product. These three facts are: [1] the application of living 
and genetically-engineered production systems for production purpose; [2] the 
complexity of the biotechnological manufacturing process; and [3] the structural 
complexity of the manufactured biological product.  
There are various living systems such as bacteria, yeast, animal or human cells, 
viruses, or transgenic animals or plants used as production systems for biological 
products. These living and genetically-engineered systems react very sensitively to 
variability in environmental parameters like temperature, ph- value, nutrient supply, 
or concentrations of oxygen or carbon dioxide gas; and to contamination like 
adventitious agents introduced from outside by accident into the bio-system, or any 
impurities from inside the bio-system itself arose from lysis of dead cells. Therefore, 
it is of high importance to adequately and continuously control the biotechnological 
manufacturing process conditions including the cell culturing process of the source 
material. Here, the inheritance of the living system should be known in terms of any 
possible prior contacts with viruses or any other contaminations. Uncontrolled 
process conditions may change cell functions or characteristics (e.g., protein 
synthesis, glycosylation’s or cell metabolism) and this may lead to different product 
results than expected.  
The manufacturing process provides a range of uncertainties and differences that 
may impact the biotechnology-derived product and its molecular structure, including 
its primary structure, any higher order structures, glycosylation’s and other (post-
translational) modifications, as well as product-related- and process-related 
impurities. Typically, the molecular conformation of a biological product protein is a 
three-dimensional structure (3D-structure) that results from molecule folding. 
Several interactions influence the folding of the molecule such as different types of 
bonding (e.g., amide bonding, disulfide bonding, hydrogen bonding) or other 
physicochemical interactions (e.g., van der Waals force, hydrophobic interactions). 
Proteins may be unstable in their molecular structure which leads to the 
circumstance that their molecular conformation can be impacted and shifted easily. 
This may happen by subtle environmental events such as varying temperatures, 
sheer forces, energy exposure (e.g., sunlight) or by minor changes to any process 
steps such as the used culture media, type of aqua or stirring rate in the fermenter. 
In consequence, the overall considerations regarding the manufacturing process 
should be comprehensive in nature and should include process steps like cultivation 
parameters and medium including starting / source material and raw materials, 
fermentation, purification, filtration, active substance, and final product. 
The differences of biotechnology-derived products in comparison to chemically-
synthesized products and the challenges of biotechnological manufacturing 
processes are recognized in published guidance documents by both, the FDA and 
the EMA. [58]  [59] 
                                               
 [58] Frequently Asked Questions About Therapeutic Biological Products, Question 10: How is the manufacturing 
process for a biological product usually different from the process for drugs?; July 2015; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/%20HowDrugsareDevelopedandApproved/Approv
alApplications/TherapeuticBiologicApplications/ucm113522.htm 
 [59] EU guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use; Ref. 
Ares(2012)778531 - 28/06/2012 ; http://ec.europa.eu/health/files/eudralex/vol-4/vol4-an2__2012-06_en.pdf 
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Resulting from interactive processes and other process influences (e.g., varying 
parameters, impurities) during the biotechnological manufacturing process or after, 
the produced biotechnology-derived product may vary in its complexity, structure 
and properties. These differences may be a result from amino acids modifications to 
the N-or C-terminus ends of the intact protein molecule; from diverse carbohydrate 
moieties attached to the protein (e.g., by post-translational glycosylation’s) that 
resulting in protein heterogeneity or by modifications of any higher order structures.  
Overall, any (post-translational) modifications or degradations of changing the 
protein structure, including modifications to the amino acid sequence, may raise 
clinical safety issues such as triggering immunogenicity. Immunogenicity is 
considered a significant clinical safety concern for biotechnology-derived products 
as it may cause a loss of efficacy or may lead to serious adverse events such as 
anaphylaxis or cytokine release syndrome. [60]  [61] Other factors to be considered 
due to their role in inducing immune reactions include the final product formulation 
and packaging, protein aggregation; adduct generation and impurities. [61] 
The most significant specifics of biotechnology-derived products are listed below: 
 Large molecules of high complexity 
 Typically high molecular weight 
 Complex source/starting material and raw material 
 Produced/synthesized in or extracted from living cell or microorganisms 
 Many critical manufacturing process steps that are more challenging to 
control 
 Multistep purification process aiming removal of a broad range of product –
and process related impurities and adventitious agents 
 Characterization of molecule structure less easily and limited due to high 
protein molecule variability, difficult to reproduce 
 Molecular structure may remain partially unknown / incomplete defined, high 
complex and dynamic 3D- structure often instable and influenced by 
environmental parameters, posttranslational modifications likely, high natural 
and process induced variability of function and structure of the molecule 
 Heterogeneous compositions, variants may be included 
 Potentially immunogenic due to structural differences or alterations of the 
protein molecule, any impurities / adventitious agents, any environmental 
events, or formulation related issues 
 The manufacturing process of biotechnology-derived 6.4
products 
Biotechnology-derived products are typically produced by genetically-engineered 
living systems by means of genetically modifications to cell-lines or cell-constructs. 
There are various genetically-engineered living systems used as production systems 
(expression systems) for recombinant proteins such as bacteria, yeast, animal or 
                                               
 [60] Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2015; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
 [61] Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
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human cells, viruses and even insect cell lines. [62] Also the use of transgene plants 
and transgene animals like goats is common in the production of biotechnology-
derived products. [63] Typically, after the living organism (e.g., bacterial cells) has 
been genetically modified by inserting the necessary amino acid sequences into the 
host cell, the host cell can produce the desired protein. The most suitable 
genetically-engineered cell-line is then further processed in a biotechnological 
process of high complexity. The commercialized culturing of the cell-lines is typically 
carried out in large scale bio-reactors, also called fermenters. There are various 
types of bioreactors available that can be classified based on their mode of 
production; for example, batch process-, continuous process- and fed-batch (semi-
continuous) process. The most established bioreactor-model is the continuous 
stirred-tank reactor (CSTR). [15] After cell-culturing and fermentation, the harvested 
proteins are purified and formulated into the final product.  
The typical biotechnological production process can be separated into two main 
sections, the first step “up-stream” process followed by the second step “down-
stream” process. [64]  [65] This is visualized in Figure 1. It should be noted that any 
changes to the up-stream process steps (e.g., cell bank preparation or fermentation) 
may influence the downstream process steps such as production and purification, 
and ultimately influence the final product.  
                                               
 [63] EPAR ATryn antithrombin alfa; EMA/403685/2016, EMEA/H/C/000587, June 2016; 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/000587/WC500028255.pdf 
 [15] „Biotechnologie für Einsteiger“; Renneberg, Reinhard; Berkling, Viola; 2013; ISBN: 978-3-8274-3047-2 
 [64] Vorlesung „Biotechnisch hergestellte Arzneimittel“, Unterlagen zum Weiterbildenden Studiengang „Master 
of Drug Regulatory Affairs“; Folie 43 von 183, May 2012; Brake, Frau Dr. Brigitte 
 [65] Overview of Upstream and Downstream Processing of Biopharmaceuticals; Prof. Ian Marison; March 2016; 
http://www.engineersirelandcork.ie/downloads/Biopharmaceuticals%2020Jan09%20-%202%20-
%20Ian%20Marison%20DCU.pdf 
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Figure 1 Major steps in production of biotechnology-derived products  
Each process step must be well controlled because the entire production process 
defines the quality of the final product. The biotechnological production process 
must fulfill the strict requirements of the Good Manufacturing Practice (GMP) as 
described in the relevant ICH Q7 guideline at an early stage of the process as 
shown in Figure 2 and presented in the ICH Q7 guideline. [66] The GMP 
requirements are further detailed in the CFR regulations in 21 CFR 210 and 211 and 
in the European GMP guidelines. [59] 
                                               
 [66] Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients; ICH Q7; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf 
 [59] EU guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use; Ref. 
Ares(2012)778531 - 28/06/2012; http://ec.europa.eu/health/files/eudralex/vol-4/vol4-an2__2012-06_en.pdf 
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Figure 2 Application of GMP-requirements to active pharmaceutical ingredients  
©by ICH [66] 
 
                                               
 [66] Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients; ICH Q7; November 2000; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf 
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7 The regulatory framework in the European Union and the 
USA 
Within this chapter, information is provided on the regulatory environment, 
framework and information on the responsible regulatory authorities in the European 
Union and the USA.  
 Institutions and structures within the European Union 7.1
The European Union today consists of 28 sovereign and independent member 
states which together form a joint federation of countries. [67] The EU and Norway, 
Liechtenstein and Island constitute together the European Economic Area (EEA). 
The early structures of the European Union were established in 1950 by Belgium, 
France, Germany, Italy, Luxembourg and the Netherlands. [68] The joint federation of 
the member states of the European Union works in the following way; the member 
states delegate some of their powers, in terms of decision making, to the institutions 
of the European Union with the aim that decisions that are of interest for the 
European Union level, can be made democratically at that level. The three main 
institutions involved in EU legislation and their primary responsibilities are listed 
below: [69] 
 The European Parliament: Represents the EU´s citizens and is involved in 
law-making procedures and acts;  
 The European Council: Represents the governments of the individual 
member countries and is involved in law-making procedures and setting 
political orientation; and 
 The European Commission: Represents the interests of the European Union 
as a whole and is involved in law-making procedures. 
The legally binding acts created and released by the European Union are usually 
adopted through the “Ordinary legislative procedure” in which the European 
Commission proposes the legislation in question and the European Council and the 
European Parliament passes the acts. [70]  [71] Finally, the passed acts of the 
European Union need to be implemented by the individual EU-member states.  
                                               
 [67] Alle EU-Länder im Überblick; Generaldirektion für Kommunikation der Europäischen Kommission; March 
2015; http://europa.eu/about-eu/countries/member-countries/index_de.htm 
 [68] Die Geschichte der Europäischen Union; Generaldirektion für Kommunikation der Europäischen 
Kommission ; March 2015; http://europa.eu/about-eu/eu-history/index_de.htm 
 [69] EU institutions and other bodies; Communication department of the European Commission; March 2015; 
http://europa.eu/about-eu/institutions-bodies/index_en.htm 
 
[70]
 Ordinary legislative procedure; European Parliament; February 2015; 
http://www.europarl.europa.eu/external/appendix/legislativeprocedure/europarl_ordinarylegislativeprocedure
_howitworks_en.pdf 
 [71] Consolidated Version of the Treaty on the Functioning of the European Union; Article 289, Official Journal C 
326, 26/10/2012 P. 0001 – 0390; December 2007; http://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:12012E/TXT&from=EN 
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 Regulatory overview 7.2
All member states of the European Union are subject to the European Economic 
Area (EEA) law. On the European Union level, Regulation (EC) No 726/2004, and 
Directive 2001/83/EC are the most essential and comprehensive regulations for 
medicinal products within the EU that establish important overall safety relevant 
regulatory standards. 
Regulation (EC) No 726/2004 covers the authorization and surveillance of safety of 
medicinal products. The purpose of the Regulation is to make the same approval 
conditions available to medicinal products in the entire European Union. 
Furthermore, the Regulation has established some regulations concerning the 
European Medicines Agency (EMA) with the aim, to provide groundbreaking and 
safe medicinal products within the shortest time frame as possible. [72] As with all 
EU-Regulations, Regulation (EC) No 726/2004 is a legally binding act that is valid to 
all EU-member states without transposing it into national law this means, it may 
break national law. [73] Regulation (EC) No 726/2004 requires that biological 
products as defined in the Annex of the Regulation be authorized by the European 
Commission, which means that medicinal products like biotechnology-derived 
products, gain marketing approval trough the Centralized Procedure as laid down in 
the respective Regulation. The Regulation links to Directive 2001/83/EC in regards 
to principles related to manufacturing, marketing and distribution and monitoring of 
medicinal products.  
Regulation (EC) 726/2004 consists of three sections: 
1. An Introduction section called the “Whereas” section;  
2. The Article section which defines 90 Articles within 5 (V) Titles; and  
3. The Appendix section which contains 1(I) Appendix.  
The Directive 2001/83/EC acts as an important community instrument and cover a 
broad range of requirements for all human medicinal products. The Directive defines 
the essential principles and requirements for manufacturing, authorization, 
marketing and distribution, labeling, inspections, monitoring and postmarketing 
surveillance with the intention of the protection of community safety by ensuring the 
safety, effectiveness and quality of medicinal products. The goal of the Directive is 
to eliminate trade barriers through mutual recognition of state specific marketing 
authorizations and to harmonize applied rules and standards for medicinal products 
amongst each EU-member state for the marketing approval of medicinal products 
that are outside the scope of the Centralized Procedure (CP). To implement the 
Directive, each member state of the European Union must transpose the 
requirements of Directive 2001/83/EC into national law. [73] For example, in Germany 
national law is the German Drug Law (AMG). The EU-requirements may be 
tightened, within the transposition into national law; however, the requirements may 
not be reduced.  
                                               
 [72] Zulassung und Überwachung von Arzneimitteln – Europäische Arzneimittel-Agentur; Zusammenfassung 
des Dokumentes: Verordnung (EG) Nr. 726/2004; European Union, November 2013; http://eur-
lex.europa.eu/legal-content/DE/TXT/HTML/?uri=URISERV:l22149&qid=1421153176058&from=EN 
 [73] European Union; Regulations, Directives and other acts; European Union January 2015; 
http://europa.eu/european-union/eu-law/legal-acts_en 
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Directive 2001/83/EC consists of three sections: 
1. An Introduction section called the “Whereas” section; 
2. The Article section which defines 130 Articles within 14 (XIV) Titles; and  
3. The Appendix section contains 3 (I-III) Appendices. 
There are a number of additional Regulations and Directives that are important for 
biological products as well as for other human medicinal products (e.g. new 
chemical entities (NCE)). [74]  [75]  [76] 
Beside of Directives and Regulations, EU-Decisions are also legally binding to the 
EU member states, with the difference that a Decision is only binding to a definite 
addressee, e.g., an EU-member state, or a specific single business. [73] 
 Other important documents  7.3
To complete the pharmaceutical regulatory framework, several instruments, many of 
them legally non-binding, but some with mandatory character are available for 
medicinal products in the European Union. The following list represents the most 
significant of them by their publisher and provides information on their legal 
applicability:  
 The European Council or the European Parliament: legally non-binding 
Resolutions, Conclusions, Recommendations, Opinions; [77] 
 The European Council: legally non-binding Notifications;  
 The European Commission: legally non-binding Communications;  
 The European Commission: legally non-binding EC-Guidelines (e.g., Notice 
to Applicants); and 
 The European Medicines Agency (EMA): EMA-Guidelines (e.g., CHMP 
(Committee for Medicinal Products for Human Use) EMA scientific guidelines 
(e.g., quality-, safety- and efficacy guidelines)  
o In principle, EC- and EMA- guidelines are non-legally binding but they 
represent the position adapted by the Community and thus guidelines 
may be quasi-binding. [6] The quasi-binding character of a guideline 
may convey from the legislative basis in cases where the guideline´s 
purpose is to detail and specify how to execute a statutory duty (e.g., 
Article 106 of Directive 2001/83/EC) [6] 
o If medicinal product manufacturers or applicants of marketing 
authorizations decide to use alternative options to the recommended 
                                               
 [74] Clinical trials; European Commission, Directorate-General for Health and Food Safety ; February 2015; 
http://ec.europa.eu/health/human-use/clinical-trials/index_en.htm 
 [75] Legal framework governing medicinal products for human use in the EU; Directorate-General for Health and 
Food Safety; February 2015; http://ec.europa.eu/health/human-use/legal-framework/index_en.htm 
 [76] EudraLex Volume 1 - Pharmaceutical Legislation Medicinal Products for Human Use; Directorate-General 
for Health and Food Safety; February 2015; http://ec.europa.eu/health/documents/eudralex/vol-
1/index_en.htm 
 [73]
 European Union; Regulations, Directives and other acts; European Union January 2015; 
http://europa.eu/european-union/eu-law/legal-acts_en 
 [77] 3.3. The legal system of the European Union; Nicholas Moussis; February 2015; 
http://www.europedia.moussis.eu/books/Book_2/2/3/3/index.tkl 
 [6] Procedure for European Union Guidelines and related Documents within the Pharmaceutical legislative 
Framework; Doc. Ref. EMEA/P/24143/2004 Rev. 1 corr; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004011.pdf 
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guidelines they are allowed to do so provided they can rationalize 
their alternative approach and their deviation from the guidelines in 
an appropriate fashion within the application [6]  [78] 
 The European Directorate for the Quality of Medicines and HealthCare 
(EDQM): European Pharmacopoeia monographs 
o In principle and according to the “General Notices (1.1)” of the 
European Pharmacopoeia 8th Edition, the information in monographs 
represents legally binding requirements unless otherwise stated.  
 Other institutions: Non-legally binding guidelines published by the 
International Council on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), guidelines published 
by the Organization for Economic Co-operation and Development (OECD) or 
guidelines published by the World Health Organization (WHO). 
  
                                               
 [78] Scientific guidelines; European Medicines, June 2015; 
Agencyhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000043.js
p&mid=WC0b01ac05800240cb 
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 Responsible Authorities 7.4
The European Medicines Agency  
On the basis of Council Regulation (EEC) No 2309/93 the European Medicines 
Agency (EMA) was founded in 1993 by the EU-member states and began its work in 
1995. [79] The EMA has a broad range of tasks related to the safeguarding of public 
health and the safety of medicinal products. The EMA takes a main role within the 
drug approval processes through the Centralized Procedure. Further, the EMA 
works closely with the European Commission by providing them scientific opinions 
obtained by assessing the drug dossier documents submitted by the applicants of 
marketing authorizations.  
Other important tasks of the EMA, include but are not limited to maintaining the 
pharmacovigilance system of medicinal products, running the EudraVigilance 
database, providing scientific advice to applicants of marketing authorizations and to 
the EU- bodies and -member states, compiling and issuing scientific guidance 
documents, collaborating internationally to achieve globally harmonized 
requirements on drug regulation, and providing scientific evaluation of drug dossier 
documents within the framework of the Centralized Procedure that serves the basis 
for the drug approval decision made by the EU-Commission. [80] To ensure that the 
most current science-based recommendations are provided to the EU-Commission, 
the EMA is structured into seven specialized scientific committees namely:  
1. The Committee for Medicinal Products for Human Use (CHMP); 
2. The Pharmacovigilance Risk Assessment Committee (PRAC); 
3. The Committee for Medicinal Products for Veterinary Use (CVMP); 
4. The Committee for Orphan Medicinal Products (COMP); 
5. The Committee on Herbal Medicinal Products (HMPC); 
6. The Committee for Advanced Therapies (CAT); and  
7. The Pediatric Committee (PDCO). 
The European Commission 
The European Commission is an important body of the European Union with a wide 
purpose and is comprised of one commissioner per member state. Within the 
Centralized Procedure, the European Commission has the final authority in the 
approval or denial of a marketing authorization.  
  
                                               
 [79] First general Report on the Activities of the European Agency for the Evaluation of Medicinal Products; 
EMEA/MB/065/95, 15 January 1996; 
http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2009/12/WC500016821.pdf 
 [80] A consistent approach to medicines regulation across the European Union, EMA/437313/2014; 
http://apps.who.int/medicinedocs/documents/s22187en/s22187en.pdf 
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The National Competent Authorities 
Each EU-member state has a national competent authority (NCA) that regulates 
aspects related to medicinal products on the national level according to their 
national law. In Germany, the German Drug Law appoints the Federal Institute for 
Drugs and Medical Devices (BfArM) to be the German national competent authority 
for most medicinal products and the Paul-Ehrlich-Institute (PEI) to be the national 
competent authority for some other medicinal products such as advanced therapy 
medicinal products, vaccines and blood products. [81] 
The national competent authorities of each member state fulfill many important pre-
and post-authorization tasks like managing the pharmacovigilance system, 
conducting GxP- inspections and communicating and collaborating with the 
European Medicines Agency. The national competent authorities are also 
responsible to regulate and manage the National Procedure (NP) for medicinal 
products which is used when only national approval in a single member state shall 
be achieved. Furthermore, the national competent authorities of the EU-member 
states cooperate in the Mutual Recognition Procedure (MRP) and in the 
Decentralized Procedure (DCP) to approve medicinal products in more than one 
EU-member state.  
Other institutions: The Heads of Medicines Agency  
The Heads of Medicines Agency (HMA) is a European institution that affiliates the 
leading persons of the national regulatory competent authorities and the EMA, and 
liaises with the European Commission. One of its main functions is to facilitate the 
drug regulatory approval procedures, specifically the DCP and the MRP, as well as 
the overall regulatory system of the EU. [82] 
 The role of the International Council on Harmonization  7.5
The International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) was founded in 1990 by drug regulatory- and 
industry representatives from Europe, Japan and the USA with the aim to ease the 
processes of drug development and new drug approval by harmonization of the 
country specific technical requirements with regard to the safety, efficacy and quality 
of new medicinal products and to make these processes and regulations more 
effective through the harmonization of the given technical standards for registration. 
The ICH guidelines (e.g., on safety, efficacy, quality and multidisciplinary topics) are 
theoretically of a recommendatory nature, but the ICH guidelines are widely 
recognized by industry and regulatory authorities in the ICH and in many non-ICH 
regions. They also strongly influence the European and national pharmaceutical 
legislation as many ICH guidelines ultimately become implemented legislation. [83] 
                                               
 [81] Gesetz über den Verkehr mit Arzneimitteln, AMG §77 (1) und § 77(2); Neugefasst durch Bek. v. 12.12.2005 
I 3394;Zuletzt geändert durch Art. 45 G v. 29.3.2017 I 626; https://www.gesetze-im-internet.de/amg_1976/ 
 [82] 
About HMA; Heads of Medicines Agencies March 2015; http://www.hma.eu/abouthma.html 
 [83] "Transnationalisierung der Arzneimittelregulierung: Der Einfluss der ICH-Guidelines auf das deutsche 
Arzneimittelzulassungsrecht"; September 2010, Volume 28, Issue 9, Engelke, K. MedR (2010) 28: 619. 
doi:10.1007/s00350-010-2743-9 http://link.springer.com/article/10.1007%2Fs00350-010-2743-9#page-1 
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 Clinical Trials 7.6
Typically, clinical trials (CT) are conducted prior to a medicinal product´s marketing 
approval with the purpose of gathering reliable evidence on drug safety and efficacy 
as well as for detection and verification of new and probable side effects. As such, 
clinical trials represent an important pre-authorization safety standard. Clinical trials 
may also be used after marketing authorization is granted to follow-up on long term 
effects (post-authorization safety standard) and to collect clinical data for off-label 
usage. Clinical trial results must be provided to the authorities (e.g., EMA) in order to 
perform the review and evaluation of the submitted drug dossier for the marketing 
approval. [84] 
Currently clinical trials are regulated under Directive 2001/20/EC. Under this 
Directive, clinical trials must be applied for and authorized by the responsible 
national competent authority and the country specific ethic commission. The 
Directive 2001/20/EC defines the term clinical trial and requires that they be 
conducted under good clinical trial conditions as laid down in the Commission 
Directive 2005/28/EC. [85] Further, Directive 2005/28/EC requires that the 
manufacturing of the investigational medicinal products be performed under Good 
Manufacturing Practice (GMP) conditions. [86] 
Since Directive 2001/20/EC must be transformed into the national law of the EU-
member states’ some member states may tighten the requirements of this Directive 
and other member states may implement them into national level as they are. This 
can lead to country specific differences in clinical trial conditions (e.g., varying 
details on country specific requirements on clinical trials, delays, deadlines).  
To resolve these issues, Directive 2001/20/EC will be replaced by Regulation (EU) 
No 536/2014 which entered into force on 16 June 2014. [87] This will lead to a 
harmonization of modalities on clinical trials (e.g., only one clinical trial application 
for multinational trials) once the regulation becomes applicable, it will ease the 
application process and lead to more transparency and efficiency because all 
clinical trial applications will be centralized with the EU-portal managed by the EMA. 
The most significant changes to clinical trials with Regulation (EU) No 536/2014 are 
summarized in Appendix E. 
In Germany, the German Drug Law (AMG) regulates clinical trials and requires 
approval of clinical trials by the responsible national competent authority (e.g., the 
BfArM or PEI) on the basis of an Investigational Medicinal Product Dossier (IMPD). 
[88] In addition, an acceptance letter from the German ethics committee and a 
                                               
 [84] Directive 2001/83/EC of 6 November 2001; Article 8; Article 8(i); OJL 311, 28.11.2001, p.67, Consolidated 
Version 16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [85] Directive 2001/83/EC of 6 November 2001; Article 1; OJ L 121, 1.5.2001, p. 34, 18.07.2009; 
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [86] Commission Directive 2005/28/EC of 8 April 2005; Article 10; L 91/13, 09.04.2005; 
http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2005_28/dir_2005_28_en.pdf 
 [87] Clinical trials - Regulation EU No 536/2014; General information section; December 2016; 
https://ec.europa.eu/health/human-use/clinical-trials/regulation_en 
 [88] Gesetz über den Verkehr mit Arzneimitteln; §§40 – 42; Neugefasst durch Bek. v. 12.12.2005 I 3394;Zuletzt 
geändert durch Art. 45 G v. 29.3.2017 I 626; https://www.gesetze-im-internet.de/amg_1976/ 
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European Clinical Trials Database (EudraCT) number is required prior to beginning 
a clinical trial. Via the unique EudraCT- number, the registered clinical trial and 
relevant study information may be found in the EudraCT- database.  
Further in Germany, clinical trials must be in compliance with the provisions of Good 
Clinical Practice (GCP-V) in which the requirement for a EudraCT-number and 
information on the content of the application documents may be found. [89] The 
German Drug Law (AMG) defines that a planned clinical trial for biological medicinal 
products (e.g., mAbs) must receive an explicit written approval by the NCA prior to 
beginning the clinical trial. For some other medicinal products an implicit non-written 
approval of the NCA within 30 days is adequate unless more data are requested. [90] 
As indicated above, a complicating factor which may lead to delays in initiating and 
conducting multinational clinical trials is the fact that under the current legislation the 
approvals mentioned above must be obtained from each country´s NCA 
accommodating a multinational clinical trial. In particular, this means that the IMPD 
must be submitted to each EU-country NCA accommodating the multinational 
clinical trial, and each NCA may request various modifications to the IMPD.  
To improve this situation, the HMA in its function as Clinical Trials Facilitation Group 
(CTFG) worked on the implementation of harmonized modalities for multinational 
clinical trials and has published a voluntary procedure guidance document that 
provides information on the parallel review of IMP dossiers in multinational CT. [91] 
However, Regulation (EU) No 536/2014 will render this voluntary procedure 
unnecessary in the future.  
For clinical trials with biological products, the EMA provides documented guidance 
on the specific requirements and information to be provided in documentation of 
clinical trials with biological investigational products. [92] A further EMA guidance 
document provides information to the various virus related safety requirements of 
IMPs. [93] Finally, the EudraLex Clinical trials guidelines and the ICH-guideline on 
Good Clinical Practice provide some further information on clinical trials. [94]  [95]  
                                               
 [89] Verordnung über die Anwendung der Guten Klinischen Praxis bei der Durchführung von klinischen 
Prüfungen mit Arzneimitteln zur Anwendung am Menschen; §5, §7; Zuletzt geändert durch Art. 8 G v. 
19.10.2012 I 2192; http://www.gesetze-im-internet.de/gcp-v/ 
 [90] Gesetz über den Verkehr mit Arzneimitteln; AMG § 42(2) 7; §42(2) 4; Neugefasst durch Bek. v. 12.12.2005 I 
3394;Zuletzt geändert durch Art. 45 G v. 29.3.2017 I 626; https://www.gesetze-im-internet.de/amg_1976/ 
 [91] Guidance document for sponsors for a Voluntary Harmonisation Procedure (VHP) for the assessment of 
multinational Clinical Trial Applications; Version 4, Doc. Ref.: CTFG//VHP/2016/Rev.6; 
https://lakemedelsverket.se/upload/foretag/humanlakemedel/klinisk-provning/VHP sponsor version 4 
final_16.06.2016.pdf 
 [92] Guideline on the requirements for quality documentation concerning biological investigational medicinal 
products in clinical trials; EMA/CHMP/BWP/534898/2008; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127370.pdf 
 [93] Guideline on Virus Safety Evaluation of biotechnological investigational medicinal products; Doc. Ref. 
EMEA/CHMP/BWP/398498/2005; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf 
 [94] EudraLex - Volume 10 Clinical trials guidelines; European Commission, Directorate-General for Health and 
Food Safety; http://ec.europa.eu/health/documents/eudralex/vol-10_en 
 [95] Integrated addendum to ICH E6(R1): Guideline for good clinical Practice E6(R2); 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_St
ep2.pdf 
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 USA institutions and structures 7.7
The Federal Government of the United States consists of three branches:  
 The Legislative branch: Known as Congress and enacts the laws;  
 The Judicial branch: Consists of the courts and reviews the laws made by 
the Congress; and 
 The Executive branch: Headed by the President, Vice-President and the 
Cabinet responsible for implementing the laws [96] 
The US laws that have been passed by the congress of the Federal Government of 
the United States are assigned to certain titles and collected in the United States 
Code (U.S.C.) by the Office of the Law Revision Counsel. Currently the United 
States Code comprises 54 titles. [97] The Law related to medicinal products is found 
in Federal Food Drug and Cosmetic Act (FFDCA) and in the Public Health Service 
Act (PHSA). The United States Code does not contain any other laws or 
administrative rules made by state- or local administrations (state laws), regulations 
published by the offices of the executive branch or by one of the two other federal 
governmental branches listed above. [98] The latter mentioned rules and regulations 
may be found in the Code of Federal Regulations (CFR).  
The duties and responsibilities of the executive branch are to execute and to enforce 
federal laws of the US including the regulations published in the CFR. To carry out 
these laws the executive branch uses various executive departments, 15 cabinet 
departments in total, and the service of independent commissions of the Federal 
Government as well as of executive agencies. [99]  [100] 
The FD&C Act is also enforced by the Code of Federal Regulations which further 
specifies and details the implementation of the requirements of the FD&C Act and 
other federal laws (e.g. the PHS Act). [101] The CFR consists of rules that have been 
developed by various departments and agencies of the Federal Government (e.g., 
the FDA) and that have been published in the Federal Register. Regulations for 
medicinal products issued by the FDA are enforceable administrative laws 
authorized by legislation enacted by the Congress and approved by the President. 
In order for the FDA to issue rules and regulations, the FDA must comply with the 
procedures stipulated by the Administrative Procedure Act (APA). [102] [101] The CFR 
contains 50 titles and is regulates a broad range of affairs subject to Federal laws. 
                                               
 [96] How the U.S. Government Is Organized; USA.gov, U.S. government's official web portal; 
http://www.usa.gov/Agencies/federal.shtml#How_the_U.S._Government_Is_Organized 
 [97] United States Code; U.S. Government; http://uscode.house.gov/browse.xhtml 
 [98] United States Code; U.S. Government Publishing Office (GPO); 
http://www.gpo.gov/fdsys/browse/collectionUScode.action?collectionCode=USCODE 
 [99] A-Z Index of U.S. Government Departments and Agencies; United States Government; 
https://www.usa.gov/federal-agencies/a 
 [100] The Executive Branch; The White House (USA); https://www.whitehouse.gov/1600/executive-branch 
 [101] About FDA; U.S. Food and Drug Administration; 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194909.htm 
 [102] 5 USC PART I, Chapter 5, Subchapter V: Administrative Conference of the United States, Administrative 
Conference of the United States; U.S. Government; 
http://uscode.house.gov/view.xhtml?path=/prelim@title5/part1/chapter5/subchapter5&edition=prelim 
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Within these 50 CFR titles, title 21 refers to medicinal products. The Code of Federal 
Regulations is binding until they are revised or withdrawn and is updated annually. 
 Regulatory Overview 7.8
The Federal Food, Drug, and Cosmetic Act (FD&C Act) was signed into law in 1938 
and is the basic regulation for medicinal products. The FD&C Act is legally binding 
to the FDA and Industry and is effective until modified or expired. Biological products 
including certain biotechnology-derived medicinal products such as medicinal 
products containing biotechnology-derived enzyme human Imiglucerase as an 
active ingredient or biological products like insulin and somatropin represent a 
subcategory of drugs, and therefore are regulated under the provisions of the FD&C 
Act. [8]  [58] Despite their obvious biological nature, these products currently achieve 
marketing approval through the New Drug Application process which is the typical 
regulatory approval pathway for chemically-synthesized medicinal products that are 
not generics. This is substantiated by specific legal conditions of the “Patient 
Protection and Affordable Care Act”. [103] The generic versions of those biological 
products regulated under the FD&C act are called follow-on biologics. The FDA 
regulations (CFR) for biological medicinal products approved under the FD&C Act 
are established in 21 CFR Parts 200 – 499. [7] 
Biological medicinal products whose licensing is not covered under the FD&C Act 
but under the Public Health Service Act are regulated in Title 42 of the U.S. Code. 
The PHS Act as federal law is also enforced by the Code of Federal Regulations. 
Section 351 of the PHS Act provides the legal definition for biological products and 
serves as the basic regulation for the licensing of these products. [11] The FDA 
regulations for these biological medicinal products are established in 21 CFR Parts 
600-680. Examples for such biological products are drugs containing the 
biotechnology-derived enzyme human Galsulfase as active ingredient and medicinal 
products containing biotechnology-derived monoclonal antibodies as active 
ingredient, e.g., Infliximab. [9]  [10] These biological products gain marketing approval 
trough the Biologics License Application. [5] The imitator versions of such biological 
                                               
 [8] CEREZYME, (NDA) 020367; May 1994; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=C 
 [58] Frequently Asked Questions About Therapeutic Biological Products, Question 10: How is the manufacturing 
process for a biological product usually different from the process for drugs?; July 2015; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/%20HowDrugsareDevelopedandApproved/Approv
alApplications/TherapeuticBiologicApplications/ucm113522.htm 
 [103] Patient Protection and Affordable Care Act 42 USC 18001 note; Section 7002(e)(2) of the “Patient 
Protection and Affordable Care Act” from 03/23/2010; 03/23/2010, PUBLIC LAW 111–148; 
https://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf 
 [7] Food and Drugs, Parts 200 – 499; PART 314; April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-title21-
vol5/pdf/CFR-2014-title21-vol5-chapI.pdf 
 [11] 42 USC § 262; April 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF&edition=prelim 
 [9] NAGLAZYME, (BLA) 125117; May 2005; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=N 
 [10] REMICADE, (BLA) 103772; August 1998; 
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=R 
 [5] 21 CFR §601.2(a); April 2015; https://www.gpo.gov/fdsys/pkg/CFR-2015-title21-vol7/pdf/CFR-2015-title21-
vol7-part601.pdf 
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products are called biosimilar products. The approval pathway of chemically-
biologically combined drug products such as conjugated mAbs is also the BLA. [104] 
The title 21 of the Code of Federal Regulations consists of three chapters in total. 
Like the other Parts, the Part 600-680 of the CFR is direct binding legislation for 
manufacturers of biological medicinal products within the US- market and must not 
be transposed or adapted any further. Pharmaceutical manufacturers that intend to 
market their medicinal product within the US- market must comply with requirements 
defined in the Code of Federal Regulation. Thus, the manufacturer must incorporate 
the CFR requirements into its quality system. 
 Other important documents 7.9
Besides the previously mentioned federal laws and CFR regulations, other 
regulatory documents are important to manufacturers and holders of marketing 
authorizations (MAH) for medicinal products. The following list represents the most 
significant additional regulatory documents by their publisher and provides 
information on their legal applicability: 
 Food and Drug Administration: FDA Guidance documents e.g., CDER/ 
CBER Guidance for Industry published in the Federal Register  
o FDA guidance documents are not legally binding but their intention is 
to explain how the regulation requirements could be met. If medicinal 
product manufacturers or applicants of marketing authorizations 
decide to use alternative options to the recommended guideline 
documents they are allowed to do so provided the approach that is 
used meets the applicable laws and set of regulations [105]  
o Other legally non-binding FDA documents: Points to consider, 
recognized consensus standards, Inspection Guides, Letters to 
Industry 
 The Congressional committees and Federal agencies: Congressional 
Committee Reports and Regulation Preambles (legally not-binding) 
 The U.S. Pharmacopeial Convention (USP): The drug standards of the U.S. 
Pharmacopeia (USP) and of the National Formulary (NF) are monographs 
that are officially recognized and enforceable by the FDA. [106] Medicinal 
products marketed in the US must comply with the USP-NF standards.  
 Other institutions: Guidelines published by the International Council on 
Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, guidelines published by the Organization 
for Economic Co-operation and Development (OECD) or guidelines 
published by the World Health Organization (WHO). 
                                               
 [104] Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price 
Competition and Innovation Act of 2009, Question Q II.3.; Draft Guidance, Revision 1, May 2015; 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdf 
 [105] Code of Federal Regulations (Annual Edition 2015), 21 CFR 10.115(d)(2); April 2015; 
https://www.gpo.gov/fdsys/pkg/CFR-2015-title21-vol1/pdf/CFR-2015-title21-vol1.pdf 
 [106] About USP; The United States Pharmacopeial Convention; April 2015; http://www.usp.org/about-usp 
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 Responsible Authorities 7.10
On the basis of the FD&C Act of 1906, the former Bureau of Chemistry became a 
regulatory agency in addition to its scientific functions. In July 1927, the Bureau of 
Chemistry changed its name to Food, Drug, and Insecticide Administration which 
was shortened to FDA three years later. [107] Currently, the FDA is the federal 
regulatory authority responsible for ensuring, protecting and enhancing the health of 
US consumers. The agency regulates a broad range of products such as medicinal 
drugs, cosmetics, biologics, food, medical devices, radiation-emitting electronic 
products, and veterinary products. With regard to biological medicinal products, the 
FDA functions cover inter alia the pre- and post-authorization phase by, for example, 
approving investigational human clinical studies, reviewing and evaluating drug 
applications, conducting manufacturer inspections, providing scientific advice and 
monitoring the safety of approved medicinal products. The FDA is empowered by 
both federal laws, FD&C Act and PHS Act, to create and enforce rules and 
regulations for medicinal products and to supervise this sector. [108] The FDA is part 
of the U.S. Department of Health and Human Services and is comprised of four 
divisions: [1] Medical Products and Tobacco, [2] Foods and Veterinary Medicine, [3] 
Global Regulatory Operations and Policy, and [4] Operations. [109] 
The Office of Medical Products and Tobacco oversees four centers and one office: 
[1] the Center for Devices and Radiological Health (CDRH), [2] the Center for 
Biologics Evaluation and Research (CBER), [3] the Center for Drug Evaluation on 
and Research (CDER), [4] the Center for Tobacco Products and [5] the Office of 
Special Medical Programs. Both, CBER and CDER are responsible for the 
regulation of biological medicinal products. [109] 
The CBER regulates classical biological products like blood, vaccines and 
allergenics as well as tissues, cellular and gene therapy products. [110] 
Many biological products with therapeutic application which are subject to either the 
FD&C Act or the PHS Act are regulated by CDER since being transferred from 
CBER to CDER in June 2003. [111] 
Specifically, this includes: 
 Monoclonal antibodies intended to be used in vivo;  
 Therapeutically used proteins and novel proteins;  
 Products intended to modulate the immune system; and 
                                               
 [107] 
About FDA; FDA's Origin; John P. Swann, Ph.D., June 2014; 
http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm124403.htm 
 [108] 42 USC 262: Regulation of biological products, 42 USC §262 (a)(2)(A); December 2016; 
http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section262&num=0&edition=prelim 
 [109] About FDA; FDA Organization Overview; April 2015; 
http://www.fda.gov/downloads/AboutFDA/CentersOffices/OrganizationCharts/UCM432556.pdf 
 [110] About FDA; Biologics Regulated Products; June 2009; 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm123205.htm 
 [111] About FDA, Transfer of Therapeutic Products to the Center for Drug Evaluation and Research (CDER); April 
2015; 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133463.htm#
1 
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 Growth factors, cytokines and monoclonal antibodies intended to influence 
the in vivo production of hematopoietic cells.  
 Clinical Trials 7.11
Prior to the application for marketing approval of the biological medicinal products 
an investigational human clinical trial must be conducted. [112] 
Before beginning such a clinical investigation, an investigational new drug 
application (IND) as defined in 21 CFR 312 must be filed in order to [1] allow 
transport and distribution of non-approved drug products through the states of the 
USA; [2] address any safety and efficacy issues related to the medicinal product 
intended to be investigated; and [3] ensure the safety and rights of the human 
subject’s participating the clinical trial. The CFR defines when an IND is applicable, 
and defines exemptions for already FDA approved medicinal products. [113] 
The FDA has the overall responsibility and oversight for the review, assessment, 
and approval of IND applications including the safety monitoring of clinical 
investigations under IND within the US. Similar to the EU-requirements, the review 
and study approval by an independent ethics committee (IEC), e. g., an Institutional 
Review Board (IRB) is required. [114] The IRB must be in compliance with the 
requirements established in 21 CFR 50 and 56 and must ensure the rights and 
safety of the human subjects participating in the clinical trial.  
Thirty days after IND submission, the clinical investigation under the applied IND 
may be started if the FDA has not requested further information. [115] Similar to the 
European EudraCT-database, relevant information on IND clinical investigations 
(and other clinical trials) as well as their results may be entered into the clinical trial 
register database “ClinicalTrials.gov”. [116] Further, the CFR requires a statement 
within the informed consent that sponsors are required to use the ClinicalTrials.gov 
database when applicable for their relevant clinical investigation. [117] 
Appendix F shows the most significant differences between Regulation (EU) No 
536/2014 and 21 CFR 312.  
                                               
 [112] Code of Federal Regulations (Annual Edition 2014), 21 CFR 601.25 (d)(2); 21 CFR 601.25 (d)(3); 
http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol7/pdf/CFR-2014-title21-vol7-part601.pdf 
 [113] Code of Federal Regulations (Annual Edition 2014), 21 CFR 312.2(a); 21 CFR 312.2(b); 
http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5-part312.pdf 
 [114] 
Code of Federal Regulations (Annual Edition 2014), 21 CFR 312.23; https://www.gpo.gov/fdsys/pkg/CFR-
2014-title21-vol5/pdf/CFR-2014-title21-vol5.pdf 
 [115] Code of Federal Regulations (Annual Edition 2014), 21CFR§312.40(b)(1); 
http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5-chapI-subchapD.pdf 
 [116] 42 USC 282: Director of National Institutes of Health, 42 U.S.C. §282(j); May 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:282%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section282%29&f=treesort&edition=prelim&num=0&jumpTo=true 
 [117] Code of Federal Regulations (Annual Edition 2014), 21 CFR§50.25(c); http://www.gpo.gov/fdsys/pkg/CFR-
2014-title21-vol1/pdf/CFR-2014-title21-vol1-part50-subpartB.pdf 
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8 Approval procedures for medicinal products 
This chapter provides information about the marketing approval procedures in the 
EU and USA and describes the types of scientific advice meetings that an applicant 
for a marketing authorization may hold with the relevant regulatory authority (EMA / 
FDA). Regulatory meetings are an important step within the marketing approval 
process. 
 Authorization procedures in the European Union 8.1
Medicinal products may be approved either by the national competent authority of 
the relevant EU-member state (national authorization), or in case of a Union 
approval, by the designated authority of the European Union, the EMA. Both, Article 
3 of Regulation (EC) No 726/2004 and Article 6 of Directive 2001/83/EC specifically 
establish the authorization requirements for medicinal products prior to marketing.  
The European system provides three routes for authorizing medicinal products 
within the EU: [1] the Centralized Procedure (CP), [2] the Decentralized Procedure 
(DCP) and [3] the Mutual-recognition Procedure (MRP). In addition to these three 
routes, the EU-member states offer National Procedures (NP) to authorize a 
medicinal product in only that single EU-member state for which authorization has 
been applied. In the following sections, the principle aspects of the CP, DCP, MRP 
and NP will be briefly described in their principles.   
Prior to authorizing medicinal products, the EMA or the responsible national 
competent authority may provide scientific advice to marketing authorization 
applicants (MAA). An overview of that process is provided. 
 The Centralized Procedure  8.1.1
A marketing authorization holder that has its biotechnology-derived product 
approved under the Centralized Procedure (CP) is allowed to market its medicinal 
product in all EU-member states by holding one EU-marketing authorization. The 
intention of the Centralized Procedure is it to make novel, innovative and high-grade 
technology medicinal products to treat rare, serious, life-threatening or chronic 
diseases, available to all citizens of the European Union. The Centralized Procedure 
is legally established in Regulation (EC) No 726/2004. Regulation (EC) No 726/2004 
provides information on the applicability of the Centralized Procedure and states that 
medicinal products listed in the Annex of the Regulation must be authorized by the 
European Commission through the Centralized Procedure. [118] The referenced 
Appendix details the medicinal products for which the Centralized Procedure is 
mandatory. Regarding biotechnology-derived products the Appendix states in item 
one: 
“1. Medicinal products developed by means of one of the following biotechnological 
processes:  
                                               
 [118] Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 3; 
OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
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— recombinant DNA technology,  
— controlled expression of genes coding for biologically active proteins in 
prokaryotes and eukaryotes including transformed mammalian cells,  
— hybridoma and monoclonal antibody methods.”
 [118]
  
In Article 3(2) and 3(3) of the Regulation (EC) No 726/2004 are the types and 
conditions of medicinal products where the Centralized Procedure may be an 
alternative to other available authorization procedures. As stated there, the 
Centralized Procedure is optional for other cutting-edge medicinal products (new 
active substances) substantiating a significant innovation or such which are of 
interest for patients at the EU level. [118] 
Prior to submission of the application, the applicant is requested to inform the EMA 
of the intended filing date by providing a pre-submission request form and a letter of 
intent to submit an application at least seven month before the submission is 
planned. To apply for a marketing approval under the Centralized Procedure, the 
applicant submits a single application dossier to the EMA that must contain all 
documents and data as specified in Directive 2001/83/EC Articles 8(3), 10, 10a, 10b 
or 11 and Annex I. [119]  [120] If the applied biological or biosimilar product contains or 
consists of genetically modified organisms additional data requirements as defined 
in Directive 2001/18/EC must be addressed as well. The submitted application file of 
the applied medicinal product is reviewed and scientifically assessed by members of 
the EMA´s Committee Medicinal Products for Human Use (CHMP) for medicinal 
products. The tasks of the CHMP are established in Article 5 of the Regulation (EC) 
No 726/2004. The EMA´s Biologics Working Party (BWP) is involved in the 
assessment process as an expert group for evaluation of quality and safety aspects 
of biotechnology-derived products.  
The review and assessment process consist of several steps and is managed by 
CHMP members of two EU-member states which function as experts for the 
assessment, namely the Rapporteur and the Co-Rapporteur. The assessment shall 
be performed within a defined timeframe of 210 days and ends with a CHMP 
scientific recommendation regarding the products adequacy for authorization. The 
scientific recommendation is then forwarded to the European Commission. If the 
CHMP recommendation is positive, the CHMP proposes that the applied medicinal 
product be approved by the European Commission. The European Commission 
may adopt the CHMP proposal by following the Decision Making Procedure for the 
Adoption of Commission Decisions and a single marketing authorization is issued to 
the applicant which authorizes the applicant to market the medicinal product in all 
EU-member states. After the medicinal product has received approval for the EU- 
market, a European Public Assessment Report (EPAR) is published by the EMA on 
the EMA website. The EPAR is an executive summary and contains an overview of 
the medicinal product and why it was approved by Centralized Procedure.  
                                               
 [118] 
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 3; 
OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
 [119] 
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 4; 
OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
 [120] 
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 6; 
OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
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In cases where the CHMP opinion would result in not recommending the medicinal 
product, procedures for re-examination of CHMP opinions are available. The legal 
basis for re-examination of CHMP opinion in Centralized Procedures is established 
in Regulation (EC) No 726/2004. [121] 
There are special cases within the Centralized Procedure that are not described in 
further detail within this dissertation; specifically, [1] the conditional marketing 
approval as defined in Article 14(7) of the Regulation (EC) No 726/2004, [2] the 
marketing approval under exceptional circumstances as defined in Article 14(8), [3] 
the accelerated assessment procedure as defined in Article 14(9), and [4] the 
marketing approval that is subject to certain conditions as defined in Article 9(4) b, c, 
ca, cb, cc of the mentioned Regulation.  
 The Decentralized Procedure 8.1.2
The legal basis for the Decentralized Procedure is established in Article 28 of 
Directive 2001/83/EC. The DCP is used when the medicinal product in question is 
not approved in any EU-member state and it is desired to obtain approval in more 
than one EU-member state. The DCP cannot be used when approval is required via 
the Centralized Procedure. The basic principle of the DCP is that the NCA(s) of the 
concerned member state(s) (CMS) where the medicinal product is intended to 
achieve the approval recognizes the [1] draft scientific assessment report to an 
application, [2] draft summary of product characteristics (SmPC), and [3] labeling 
and package insert as prepared and proposed by the NCA of the reference member 
state (RMS). [122] This principle is called “mutual recognition”.  
The outcomes of the process are national marketing authorizations issued by the 
desired member states. The marketing approval is valid for five years and may be 
renewed after that time. [123] Through the variation system legally based on 
Regulation (EC) No 1234/2008 the issued marketing authorizations are maintained 
and their harmonization is further ensured. [124] 
 The Mutual Recognition Procedure 8.1.3
The legal basis of the Mutual Recognition Procedure (MRP) is established in Article 
28 of Directive 2001/83/EC. The MRP is used when the medicinal product in 
question is already approved in an EU member state via national authorization and it 
is desired to obtain approval in additional EU member state(s). The MRP cannot be 
used when approval is required via the Centralized Procedure. When the MRP is 
used, the country which previously approved the medicinal product via the national 
authorization is automatically the reference member state (RMS). Like in the DCP, 
                                               
 [121] 
Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 9(2); 
Article 62(1); OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; 
http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
 [122] 
Notice to Applicants, Procedures for Marketing Authorisation CHAPTER 2, Mutual Recognition; Revision 5, 
February 2007; http://ec.europa.eu/health/files/eudralex/vol-2/a/vol2a_chap2_2007-02_en.pdf 
 [123] Directive 2001/83/EC of 6 November 2001, Article 24; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [124] 
Commission Regulation (EC) No 1234/2008 of 24 November 2008, OJ L 334, 12.12.2008, p. 7, 
Consolidated version 04.08.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2008_1234_cons_2012-11-02/reg_2008_1234_cons_2012-11-02_en.pdf 
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the MRP relies on the principle of the mutual recognition. In this case, each involved 
CMS relies on the existing marketing authorization and updated scientific 
assessment report from the RMS.  
The marketing approval is valid for five years and may be renewed after that time. 
[123] Through the variation system legally based on Regulation (EC) No 1234/2008, 
the issued marketing authorizations are maintained and their harmonization is 
further ensured. [124] 
 National authorization procedures 8.1.4
Every EU-member state has defined a national authorization procedure (NP) in its 
national law. Under the NP, the responsible national competent authority evaluates 
and determines if the applied medicinal product meets the requirements with 
regards to quality, efficacy and safety and therefore if it is eligible to be marketed. 
Typically, the NP is available for medicinal products that have not been approved in 
any other EU-member state as long as the medicinal product is not required to be 
approved via the Centralized Procedure. The NP is applicable only to market the 
medicinal product in question solely in the country applied for. In Germany, the 
national procedure is established in §§ 21-24 of the German Drug Law (AMG).  
 Approval procedures for biological and biosimilar products 8.1.5
The applicable authorization procedure for biological products 
Biological products considered in this work are mentioned in Article 3(1) of 
Regulation (EC) No 726/2004 and defined in point 1 of its Annex. [26] These 
biological products must be authorized through the Centralized Procedure. For 
these products, a “full application” as described in Article 8(3) of Directive 
2001/83/EC must be submitted. [125] 
Applicable authorization procedures for biosimilar products 
The legal basis for biosimilar product applications is established in Regulation (EC) 
726/2004. [120] Application data requirements are established in Article 10(4) of 
Directive 2001/83/EC which provides a shortened application type for certain 
                                               
 [123] Directive 2001/83/EC of 6 November 2001, Article 24; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [124] 
Commission Regulation (EC) No 1234/2008 of 24  November 2008, OJ L 334, 12.12.2008, p. 7, 
Consolidated version 04.08.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2008_1234_cons_2012-11-02/reg_2008_1234_cons_2012-11-02_en.pdf 
 [26] Regulation (EC) No 726/2004 Article 3(1) and Point 1 of the Annex; OJ L 136, 30.4.2004, p. 1, Consolidated 
version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
 [125] 1.6 What will be the legal basis for my application?; 2017; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000167.jsp&mid
=WC0b01ac0580b18196 
 [120] Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 6; 
OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf 
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biosimilar products. [126] However, the abridged application defined in Article 10(4) of 
the Directive is frequently insufficient for biosimilar products due to the products’ 
characteristics and complexity. In addition, the bibliographic applications defined in 
Article 10a of Directive 2001/83/EC is also frequently insufficient. [127]  [128] Therefore, 
it may be required to submit a full application in accordance with Article 8(3) of 
Directive 2001/83/EC. [84] 
For biosimilar products considered in this work the Centralized Procedure must be 
used because Article 3(1) of Regulation (EC) No 726/2004 and point 1 of the Annex 
of the mentioned Regulation applies. Further, a full application according to Article 
8(3) of the Directive 2001/83/EC must be submitted. [127] 
 Format and content of an application dossier  8.1.6
Like other authorization procedures (e.g., MRP, DCP, and National Procedure) the 
application dossier for the Centralized Procedure must be compiled in the ICH 
format standard for common technical documents (CTD). The ICH CTD-standard 
defines the application dossier format and structure that shall be used for presenting 
the data and information on the quality, safety and efficacy of the applied medicinal 
product.  
The harmonized format shall be used from all three ICH-regions, but it does not 
provide any information about the content (e.g., required studies and data that need 
to be generated) of an application dossier. The content of an application dossier 
may vary between countries or regions due to country or region specific 
requirements as well as applicants´ priorities or preferences (e.g., CTD Module 3 
section 3.2.R Regional information). [129] Articles 8 and 10 of Directive 2001/83/EC, 
and Article 6 of Regulation (EC) No 726/2004 serve as the legal basis for the CTD-
format requirement. The applicable ICH-guidelines about Quality (Q), Safety (S) and 
Efficacy (E) provide detailed requirements regarding dossier content information. 
Since 1st of July 2003, the CTD-format is applicable to all application dossier 
documents submitted for marketing authorization, as well as for variations 
applications, extension applications, follow-up measures and renewals. [129] The CTD 
format consists of five modules as listed and explained below. Module 1 contains 
administrative and regional or country specific information as defined by the 
European Commission and the EU-member states regulatory authorities; thus the 
                                               
 [126] Directive 2001/83/EC of 6 November 2001, Article 10(4); OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [127] CMDh Questions & Answers Biologicals, Question 3; Doc. Ref.: CMDh/269/2012, Rev.1, July 2016; 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_269_2012_R
ev1_2016_07_clean.pdf 
 [128] Guide to EU Pharmaceutical Regulatory Law, Sally Shorthose, Bird & Bird LLP; 2011; ISBN 978-90-411-
3658-9 
 [84] Directive 2001/83/EC of 6 November 2001; Article 8; Article 8(i); OJL 311, 28.11.2001, p.67, Consolidated 
Version 16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [127] CMDh Questions & Answers Biologicals, Question 3; Doc. Ref.: CMDh/269/2012, Rev.1, July 2016; 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_269_2012_R
ev1_2016_07_clean.pdf 
 [129] Volume 2B Notice to Applicants Medicinal products for human use, Presentation and format of the dossier 
Common Technical Document (CTD); May 2008; http://ec.europa.eu/health/files/eudralex/vol-
2/b/update_200805/ctd_05-2008_en.pdf 
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provided information may vary. The structure that is defined in Module 2-5 is used in 
and applicable to all ICH regions and furthermore, it is applied in certain countries 
that have adopted the ICH CTD-format (e.g., Swiss, Canada, and Australia).  
 Module 1 is not considered as portion of the CTD. However, for electronic 
submissions, Module 1 is considered as full portion in the e-CTD format [130] 
 Module 2: Serves as general introduction of the applied biological product 
and also contains summaries and overviews to quality, non-clinical and 
clinical information prepared by persons with relevant professional expertise 
 Module 3: Contains specific data to and documentation of Chemical, 
Pharmaceutical and Biological information. 
 Module 4: Contains detailed reports for non-clinical studies 
 Module 5: Contains detailed reports for clinical studies 
The Parts I to IV of Annex I of the Directive 2001/83/EC define further pre-
authorization requirements to be addressed in the application dossier for medicinal 
products. Part I of Annex I also contains specific requirements for biological 
medicinal products and EudraLex Notice to Applicants Volume 2B provides further 
guidance for each requirement that is to be addressed in a biological medicinal 
products dossier. For biological and biosimilar products mandatory for the 
Centralized Procedure, an active substance master file (ASMF) as mentioned in 
Part I Module 3, Point 3.2(8), of Annex I of the Directive is not applicable. [127] For 
more information please refer to Appendix 5 of the EMA guidance document on 
ASMF. [131] Furthermore, the European Pharmacopoeia monographs 01/2005:1468 
products of fermentation are not applicable. [64] 
Please see Appendix G for a visualized explanation of the CTD format and to 
Appendix H for information on the EU-Dossier requirements for biosimilar products 
versus biological originator products. 
 The biosimilar product application – The time point of submission and 8.1.7
market access  
The EU has regulated the point in time when a biosimilar product application is 
allowed to be submitted and when a biosimilar product is allowed to be marketed.  
Directive 2001/83/EC and Regulation (EC) No 726/2004 specify a data protection 
period for the reference product of eight years. [132]  [133] According to that, a 
biosimilar product may be marketed after the market exclusivity of the reference 
                                               
 [130] 
ICH eCTD Specification V 3.2., Electronic Common Technical Document Specification; July 2008; 
http://estri.ich.org/eCTD/eCTD_Specification_v3_2_2.pdf 
 [127] CMDh Questions & Answers Biologicals, Question 3; Doc. Ref.: CMDh/269/2012, Rev.1, July 2016; 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_269_2012_R
ev1_2016_07_clean.pdf 
 [131] 
Guideline on Active Substance Master File Procedure; CHMP/QWP/227/02 Rev 3/Corr; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129994.pdf 
 [64] Vorlesung „Biotechnisch hergestellte Arzneimittel“, Unterlagen zum Weiterbildenden Studiengang „Master 
of Drug Regulatory Affairs“; Folie 43 von 183; Brake, Frau Dr. Brigitte; May 2012 
 [132] 
Directive 2001/83/EC of 6 November 2001, Article 10(1); OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [133] Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, Article 
14(11); OJL 136, 30.04.2004, p.1, Consolidated version 05.06.2013; 
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
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product, which is 10 years after the marketing authorization was issued, has been 
elapsed. This data protection period may be extended for one further year to a 
maximum of 11 years when new indications for the biological innovator product are 
obtained within the first eight years of the market exclusivity period. [133] 
Article 89 of Regulation (EC) No 726/2004 defines exemptions of the periods 
defined in Article 14(11) and Article 90 is limiting the year of additional protection to 
those reference products whose initial application was submitted after 20 November 
2005. [134] 
 Meeting regulatory authorities  8.1.8
The regulatory basis for providing scientific advice is established in Regulation (EC) 
No 726/2004, and in Regulation (EC) No 141/2000 for orphan medicinal products. 
[135]  [136] Although the scientific advice is not binding for authorities or applicants, and 
despite of the existence of many specific scientific guidance’s that are published by 
the EMA to advice applicants, scientific advice is an important step in obtaining the 
desired approval for marketing biotechnology-derived products. Therefore, advice 
should be requested from the authorities (e.g., EMA or NCA).  
Scientific advice may be obtained in the pre-authorization phase (e.g., during 
development phase), or in the post-authorization phase of a biotechnology-derived 
product. The scientific advice may cover topics that need to be addressed within the 
specific periods of the lifespan of a biotechnology-derived product, especially when 
no product-specific guidance document is available (e.g., CHMP guidance 
documents).  
Another important meeting which is encouraged by the EMA in view of intended 
marketing applications is the pre-submission meeting which should be performed 
about seven month before planned MAA submission. The goal is to enable the 
applicant to verify that the application intended for submission meets the relevant 
legal and regulatory requirements. [134] 
                                               
 [134] 
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure, 1.8. 
What is the period of protection for my medicinal product?; EMA/339324/2007; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/W
C500004069.pdf 
 [135] 
Regulation (EC) No 726/2004 of the Parliament and of the Council of 31 March 2004, Article 56(3), Article 
57(1)(n); OJ L 136, 30.4.2004, p. 1, Consolidated version 05.06.2013; 
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
 [136] Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999, Article 
6; OJ L 18, 22.1.2000, p. 1, Consolidated version 07.08.2009; 
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-
07/reg_2000_141_cons-2009-07_en.pdf 
 [134] European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure, 1.8. 
What is the period of protection for my medicinal product?; EMA/339324/2007; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/W
C500004069.pdf 
 - Page 54 of 215 - 
APPROVAL PROCEDURES … 
 
 Approval procedures in the USA 8.2
Prior to placing a biotechnology-derived product it must be approved by the 
responsible competent authority, the FDA. [137] 
The US-legislation provides three primary types of applications in order to request 
approval of medicinal products for the US-market; specifically: [1] the New Drug 
Application (NDA), [2] the Abbreviated New Drug Application (ANDA) and [3] the 
Biologics License Application (BLA). Additionally, under the PHS Act, product 
application procedures are provided for biosimilar or interchangeable biosimilar 
products. In the following sections, the NDA, the ANDA, the BLA and, as a subtype 
the biosimilar application will be briefly described. Prior to authorization of medicinal 
products, the FDA may provide options or meetings to discuss open issues with the 
marketing authorization applicants. An overview of that process is also provided. 
 The New Drug Application  8.2.1
The New Drug Application legal basis is established in the FD&C Act which is 
further defined by the FDA in 21 CFR 314. [7] Under the New Drug Application, all 
chemical and, biotechnology-derived products not covered under the PHS Act, are 
reviewed and approved by the FDA on the basis of the submitted full or partial 
application dossier. 21 CFR 314.50 provides information on the content and format 
of the NDA which must also contain all clinical data required by 21 CFR 312. 
According to the FDA review timeframes established in 21 CFR 314.100(a), CDER 
is requested to review and decide on the application within the 180 days "initial 
review cycle" after the NDA has been filed. [138] If necessary the 180 day timeframe 
may be extended. [139] 
 The Abbreviated New Drug Application  8.2.2
The Abbreviated New Drug Application legal basis is established in the FD&C Act 
which is further defined by the FDA in 21 CFR 314 subpart C. [7] Under the 
Abbreviated New Drug Application, all generic chemically-synthesized and generic 
biological products not covered under the PHS Act, will be reviewed and approved 
by the FDA´ CDER´s Office of Generic Drugs. The ANDA process is a shortened 
application process when compared to the NDA process in whereby data on safety 
and efficacy will normally not be required. In addition, generic medicinal products 
applied for using the ANDA process are not required to comply with the 
requirements defined in rules of 21 CFR Part 314. [140] 21 CFR 314.92 provides 
information on the suitability of the ANDA process.  
                                               
 [137] 
21 USC 355: New drugs; 21 USC §355(a); April 2015; 
http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim 
 [7] 
Food and Drugs, Parts 200 - 499, PART 314; April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-title21-
vol5/pdf/CFR-2014-title21-vol5-chapI.pdf 
 [138] 
21 CFR 314.100(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-
vol5-chapI-subchapD.pdf 
 [139] 
21 CFR 314.60; 21 CFR 314.96; April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-
2014-title21-vol5-chapI-subchapD.pdf 
 [140] 
21 CFR Part 314.50(c), (d)(2), (4), (5), (6) and (f); April 2014; https://www.gpo.gov/fdsys/pkg/CFR-2014-
title21-vol5/pdf/CFR-2014-title21-vol5-chapI.pdf 
 - Page 55 of 215 - 
APPROVAL PROCEDURES … 
 
As opposed to the NDA, the ANDA does not require any preclinical and clinical data 
to demonstrate safety and effectiveness of the generic drug product. However, it is 
necessary to demonstrate that the generic drug product is bioequivalent to the 
original drug product through bioequivalence studies. [141] 
According to the FDA´ review timeframes established in the CFR the CDER´s Office 
of Generic Drugs is requested to review and decide on the application within the 180 
days "initial review cycle" after the NDA has been filed. [138] If necessary, the 180 
day timeframe may be extended. [139] 
 The Biologics License Application  8.2.3
In the USA, biological products that are subject to the provisions of the Public Health 
Service Act become licensed through the standard Biologics License Application as 
defined in section 351(a) of the PHS Act. Biosimilar products that can demonstrate a 
high similarity to an already FDA licensed biological reference innovator product, or 
those that can be shown to be interchangeable with the reference product become 
licensed through an abbreviated pathway of the Biologics License Application as 
defined in section 351(k) of the PHS Act. The FDA regulations for marketing 
approval of these biological medicinal products are laid down in the 21 CFR Part 
601.2, information to the licensing and filing procedures of the BLA are provided 
there. Like NDA applications, BLA applications must contain all clinical data as 
defined in 21 CFR 312.  
The standard BLA procedure according to section 351(a) of the PHS Act is a 
licensure process in which the application file of a biological innovator product is 
submitted to the CBER or CDER department of the FDA. The application file is 
reviewed and scientifically assessed by the responsible FDA departments using a 
five phase process with the goals as described below: [142] 
 Phase 1:  Determination of filing the application and planning the review 
   phase 
 Phase 2:  Review of the application phase: 
 Phase 3:  Advisory committee meeting phase 
 Phase 4:  Action phase 
 Phase 5:  Post-action phase 
The FDA has a timeframe of 180 days that starts with the date the application is filed 
to perform the “initial review cycle” and to notify the applicant of the review outcome. 
[138] The review timeframe is based on the Prescription Drug User Fee Act (PDUFA) 
from 1992 which defines that the FDA receives user fees from companies producing 
                                               
 [141]
 Abbreviated New Drug Application (ANDA): Generics; September 2014; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalAp
plications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm 
 [138] 
21 CFR 314.100(a); April 2014;  http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-
vol5-chapI-subchapD.pdf 
 [139] 
21 CFR 314.60; 21 CFR 314.96; April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-
2014-title21-vol5-chapI-subchapD.pdf 
 [142] 
Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA 
Products; April 2005; http://www.fda.gov/downloads/Drugs/.../Guidances/ucm079748.pdf 
 [138] 21 CFR 314.100(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-
vol5-chapI-subchapD.pdf 
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certain medicinal products. For biotechnology-derived products user fees are 
required. [143] Based on the PDUFA, certain review performance goals are defined 
for the FDA, and these goals are valid within the current PDFUA five year 
authorization period. The FDA´s review performance goals are applicable for the 
review of all user fee billable biotechnology-derived products. The current goals 
specify that the review and approval decision process shall not take more than ten 
month for standard review and not more than ten month for a priority review 
decision. [144]  [145] 
If the FDA denies the biologics license because the company or product does not 
meet the requirements established for biologics licensing the applicant may request 
public hearing with the FDA to hear the grounds for denial. [146]  [147] 
8.2.3.1 The 351(k) applications (section 351(k) of the PHS Act) 
In order to create a licensure pathway for products biosimilar to or interchangeable 
with a FDA licensed biological reference product, the foresaid section 351(a) was 
amended with “subsection (k)” that allows an abbreviated approval pathway based 
on less product -specific preclinical and clinical data than required in a standard BLA 
procedure. [148]  [149] Within the biosimilar application dossier, comparable analytical-, 
non-clinical-, and clinical study data must be submitted that demonstrates the 
biosimilarity of the applied biosimilar product to the chosen biological innovator 
products. [150] It is up to the FDA to decide, if all studies are required and to what 
extent. However, the five phase´ review process and the time allowed for reviewing 
the application documents remains the same as for a standard BLA as defined in 
section 351(a) of the PHS Act due to the similar complexity of the submitted 
documents. [151] 
To speed up the review and approval process for certain innovative medicinal 
products, especially of those drugs intended to treat serious diseases, the FDA has 
created four unique approaches that shall only be listed and not discussed in further 
detail here; specifically: [1] the Priority Review, in which the FDA aims to achieve an 
                                               
 [143] 
CDER Therapeutic Biologic Product; September 2015; 
http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM164641.pdf 
 [144] 
PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 through 2017; 2013; 
http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf 
 [145] 
PDUFA V: Fiscal Years 2013 – 2017; 
https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm272170.htm 
 [146] 
21 CFR 601.4(b); April 2016; https://www.gpo.gov/fdsys/pkg/CFR-2016-title21-vol7/pdf/CFR-2016-title21-
vol7-chapI-subchapF.pdf 
 
[147] 
21 CFR 12.21(b); April 2016; 
 
https://www.gpo.gov/fdsys/pkg/CFR-2016-title21-vol1/pdf/CFR-2016-title21-
vol1.pdf 
 
[148] 
42 USC 262(k);
 
December 2016; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [149] 
FDA Webinar - FDA’s Overview of the Regulatory Guidance for the Development and Approval of Biosimilar 
Products in the US; December 2014; 
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM428732.pdf 
 [150] 
Biologic License Application (BLA) Checklist;
 
Troutman Sanders LLP; October 2015;
 
http://www.troutmansanders.com/files/FileControl/c38042c0-a860-4179-8a50-12c1170d84fd/7483b893-
e478-44a4-8fed-f49aa917d8cf/Presentation/File/Biologic%20License%20Application%20Checklist.pdf 
 [151] 
Federal register/Vol.80, No.22 / Tuesday, February 03, 2015 / Notices; http://www.gpo.gov/fdsys/pkg/FR-
2015-02-03/pdf/2015-02025.pdf 
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application result within six month, [2] the Breakthrough Therapy, in which the FDA 
aims to accelerate the review of applications for medicinal products demonstrating 
significant improvement compared to current used therapies, [3] the Accelerated 
Approval, that allows the drug approval based on surrogate endpoints particularly for 
new medicinal products for the treatment of serious diseases; and [4] the Fast Track 
procedure, in which the FDA starts to relieve a successful application in the 
development stage of the drug intended for application specifically new medicinal 
products for the treatment of serious diseases are considered and to accelerate their 
review. [152] 
 Approval procedures for biological and biosimilar products 8.2.4
Applicable approval procedures for biological products 
The biological medicinal products considered in this work are covered by the Public 
Service Health Act. They are defined by the FDA as “specified biological products”. 
[5] These biological products must be authorized through the Biologics License 
Application (BLA) as established in 42 U.S.C. 262(a).  
Applicable approval procedures for biosimilar products 
The biosimilar products considered in this work are covered by the Public Service 
Health Act, and they are biosimilar to the biological products called “specified 
biological products”. [5] For these biosimilar products the “section 351(k) application” 
applies. [150] 
 Format and content of a Biologics License Application  8.2.5
The ICH CTD-dossier format and structure used for Modules 2-5 is the same in all 
three ICH regions.  
With respect to the contents of Module 1, the FDA has issued a Draft Guidance for 
Industry which provides further information on how to organize Biologics License 
Applications and gives information on the archival structure of all Modules and 
required quantity of copies. [153] Further, 21 CFR 601.2 details the administrative 
documents and specifics of a BLA. 
With regard to abbreviated BLA´s for biosimilar products the United States Code 
defines information that such biosimilar applications must include: [154] 
                                               
 [152] 
Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review; September 2014; 
http://www.fda.gov/ForPatients/Approvals/Fast/default.htm 
 [5] 21 CFR §601.2(a); April 2015; https://www.gpo.gov/fdsys/pkg/CFR-2015-title21-vol7/pdf/CFR-2015-title21-
vol7-part601.pdf 
 [150] 
Biologic License Application (BLA) Checklist;
 
Troutman Sanders LLP; October 2015;
 
http://www.troutmansanders.com/files/FileControl/c38042c0-a860-4179-8a50-12c1170d84fd/7483b893-
e478-44a4-8fed-f49aa917d8cf/Presentation/File/Biologic%20License%20Application%20Checklist.pdf 
 [153] Submitting Marketing Applications According to the ICH-CTD Format —General Considerations; Draft 
guidance, August 2001; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073308.pdf 
 [154] 
42 USC §262(k)(2)(A)(i);
 
October 2015, 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF&edition=prelim 
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 Data derived from analytical studies, animal studies, and clinical studies that 
are eligible to demonstrate a high biosimilarity of the applied product to one 
reference product and information that are adequate to show safety, purity, 
and potency in the applied conditions of use; [155] 
 Data that show the same mechanism of action as in the reference product is 
utilized; 
 Evidence that the conditions of use as proposed in the labeling have been 
approved for the reference product; 
 Data that show that the route of administration, the dosage form and the 
strength is the same as for the reference product; 
 Data that show that the facilities involved in manufacturing, processing and 
packaging of the biosimilar product meet the defined applicable standards.  
Please refer to Appendix I for information showing the content shares between a 
BLA dossier and an abbreviated BLA dossier.  
Furthermore, it is required that a “section k” application shall contain FDA 
information about the safety, purity and potency of the reference product and that 
this information shall be publicly available. [156] Also, information demonstrating that 
the biosimilar product complies with the standards that allow the FDA to determine 
interchangeability of the biosimilar product shall be submitted. [157] The information 
submitted to determine interchangeability must demonstrate biosimilarity to the 
reference product and, in addition, demonstrates that the same clinical result as the 
reference product in any given patient produces can be archived and for chronically 
use and with regard to alternating or switching the biosimilar product with the 
reference product, the risk of safety and reduced efficacy shall not being greater 
than using the reference product without alternation or switch. [158] 
Additionally, the FDA guidance document on quality considerations for biosimilarity 
states that a complete CMC section for the proposed biosimilar product is required 
as well as animal studies (including the assessment of toxicity) and clinical studies 
(including the assessment of immunogenicity and pharmacokinetics and/or 
pharmacodynamics) in addition to comparative analytical studies. [159] The FDA 
guidance document on scientific considerations for biosimilarity the FDA states that 
                                               
 [155] 
42 USC §262(k)(5)(A);
 
October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF&edition=prelim 
 [156] 
42 USC §262(k)(2)(A)(iii); October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [157] 
42 USC §262(k)(2)(B);
 
October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [158] 
42 USC §262(k)(2)(B)(4); October 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-
title42-section262&num=0&edition=prelim 
 [159] Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
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during the application review the totality of the data and information submitted in the 
application will be considered. [160] 
 The biosimilar product application – The time point of submission and 8.2.6
market access  
In the USA the title 42 of the United States Code defines the effective date of a 
biosimilar application approval. [161] The marketing approval of the biosimilar product 
is effective not earlier than 12 years after the date of first licensure of the reference 
product. Further, an application for licensure of biological products as biosimilar or 
interchangeable may not earlier submitted to the FDA than 4 years after the date of 
first licensure of the reference product. [161] 
 Meeting regulatory authorities 8.2.7
The regulatory basis for performing meetings between FDA and sponsors is 
established in various US-laws and acts, e.g., in the Prescription Drug User Fee Act 
of 1992 (PDUFA) for biological products and new chemical entities; in the Biosimilar 
User Fee Act of 2012 (BsUFA) for biosimilar products or in the Generic Drug User 
Fee Amendments (GDUFA) of 2012 for generics drugs. [162] Furthermore, CFR 
regulations detail various types of meetings like the Pre-IND meeting, the End-of 
Phase 1 meeting, or the End-of Phase 2 meeting. 
The FDA encourages sponsors to utilize the available meeting opportunities 
because they play a critical role within the regulatory process. In regards to 
biosimilar products, the FDA expects the applicant to discuss plans for the biosimilar 
product development program and the intended approaches early with the FDA to 
ensure that there is adequate support with scientific justifications and facilitation of 
the biosimilar development. [163] The FDA has issued various guidance documents 
on the different types of meetings that are available with the purpose establishing 
uniform procedures in order to conduct effective, well-documented and well-
managed meetings scheduled in a timely manner. [164] 
Typically, three different types of meetings can be requested with the FDA for 
biological products: [1] Type A meeting, [2] Type B meeting and [3] Type C meeting: 
                                               
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015;http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291
128.pdf 
 [161] 
42 USC §262(k)(7)(A), 42 USC §262(k)(7)(B); October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [162] 
Industry Meeting Type; December 2014; 
http://www.fda.gov/drugs/developmentapprovalprocess/formssubmissionrequirements/electronicsubmission
s/datastandardsmanualmonographs/ucm071774.htm 
 [163] 
Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants; Guidance for 
Industry, November 2015; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm345649.pdf 
 [164] 
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products; Draft guidance for 
Industry, March 2015, Revision 2; 
http://www.fda.gov/downloads/Drugs/GuidanceCompliance%20RegulatoryInformation/Guidances/UCM4374
31 
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1. Type A meeting: Used for development programs that have either become 
stuck and where the sponsor needs information on how to proceed, or where 
serious safety issues need to be discussed [164] 
2. Type B meeting: Used to review the progress of the drug development [164] 
3. Type C meeting: Used to discuss and clarify sponsor questions regarding 
site designs, development, or the medicinal product in general that may not 
be covered under Type A or B meetings [164] 
Specifically for biosimilar products for which a biosimilar BLA according to section 
351(k) PHSA applies, five different types of meetings are available for request with 
the FDA: [1] Biosimilar Initial Advisory Meeting (BIAM); [2] Biosimilar Product 
Development Type 1 Meeting (BPD); [3] Biosimilar Product Development Type 2 
Meeting; [4] Biosimilar Product Development Type 3 Meeting; and [5] Biosimilar 
Product Development Type 4 Meeting. [163] 
1. Biosimilar Initial Advisory Meeting (BIAM): Used to assess and to discuss if 
the biosimilar product intended for application under section 351(k) of the 
PHS Act is eligible for this specific licensure procedure by evaluating 
preliminary comparative analytical similarity data.  
2. Biosimilar Product Development Type 1 Meeting (BPD): Used for biosimilar 
development programs that have either become stuck and where the 
sponsor need information on how to proceed, or where serious safety 
issues need to be discussed.  
3. Biosimilar Product Development Type 2 Meeting (BPD): Used to discuss 
particular study related questions or to request specific advice on a current 
product development program. 
4. Biosimilar Product Development Type 3 Meeting (BPD): Used to request 
advice for a current product development program on the basis of in-depth 
review of data (e.g., study reports), to receive advice on biosimilarity to the 
referenced biological innovator product and to gather information if and 
which further studies are required. 
5. Biosimilar Product Development Type 4 Meeting (BPD): Used to discuss a 
biosimilar biological product application under section 351(k) of the PHS 
Act or supplements regarding its content and format. 
                                               
 [164] Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products; Draft guidance for 
Industry, March 2015, Revision 2; 
http://www.fda.gov/downloads/Drugs/GuidanceCompliance%20RegulatoryInformation/Guidances/UCM4374
31 
 [163] 
Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants; Guidance for 
Industry, November 2015; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm345649.pdf 
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9 The main legislation for biotechnology-derived products  
This chapter identifies and presents the main legislation for biotechnology-derived 
products in the EU and the USA and significant overall safety relevant regulatory 
standards established therein.  
 Directive 2001/83/EC and Regulation (EC) No 726/2004 9.1
Directive 2001/83/EC establishes many pre-and post-authorization-, and overall 
safety relevant regulatory standards that apply to all medicinal products intended for 
human use in the EU. The most important safety relevant regulatory requirements 
are presented in Appendix J. Please note, provisions that are only applicable to 
specific medicinal drugs (e.g., homeopathic drugs, radio-nucleotides, etc.), or 
circumstances and specific provisions regarding the different MRP and DCP 
authorization procedures are excluded from the examination. 
Regulation (EC) No 726/2004 establishes many pre-and post-authorization- as well 
as overall safety relevant regulatory standards that apply to all medicinal products 
intended for human use and that have to be authorized centrally by using the 
Centralized Procedure. The most important safety relevant regulatory requirements 
are presented in Appendix K.  
In analyzing the information provided in Appendix J and K, the following safety 
relevant regulatory requirements were identified as significant and applicable to all 
medicinal products:  
 General marketing authorization requirement prior to marketing; 
 Regulatory approval pathway requirements; 
 Renewal requirement; 
 Manufacturing authorization requirement; 
 Pharmacovigilance- and general reporting requirements (via Eudravigilance 
database) (e.g., Periodic Safety Update Reports (PSURs), Individual Case 
Safety Reports (ICSRs));  
 Postmarketing monitoring and surveillance requirements; additional 
monitoring programs (e.g., black triangle labeling); 
 Incident reporting requirements (e.g., (Suspected Unexpected) Serious 
Adverse Reaction ((SU)SARs));  
 Labeling requirements (e.g., INN, brand name); 
 Post-Authorization-Safety-Studies (PASS) or Post-Authorization-Efficacy-
Studies (PAES); 
 Post-authorization measures (PAMs); e.g., Follow-Up Measures (FUMs) or 
Specific Obligations (SOs), Appendix II condition (ANX), additional 
pharmacovigilance activity in the Risk-Management Plan (MEA), legally 
binding measure (LEG) and recommendation (REC); 
 Risk management / European Risk Management Strategy (ERMS); 
 Good Manufacturing Practice (GMP) and inspections (self- and announced 
and unannounced authority inspections);  
 Summary of Product Characteristics (SmPc) and labeling / Product 
information; 
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 Falsified medicinal products / authorization or licensure requirement for 
wholesale, distribution, import and manufacturing; 
 Variation system; 
 Drug shortage pre-notification requirement (at least two month before 
permanent or temporary cessation occurs followed by disruption of supply 
the authority has to be notified). 
In reviewing the information for biosimilar products that is provided in Directive 
2001/83/EC and Regulation (EC) No 726/2004, it is observed that very limited 
legislative information is provided that specifically applies to biotechnology-derived 
biosimilar products e.g., determination of interchangeability, substitution of biological 
products with biosimilar products.  
 21 CFR 600 - 680 9.2
21 CFR Parts 600-680 establishes many pre-and post-authorization- as well as 
safety relevant regulatory standards that apply to all biotechnology-derived products 
under the PHS Act and intended for human use. The most significant safety relevant 
regulatory requirements applicable for biological products and biosimilar products 
that are established in relevant regulations are presented in Appendix L. Specific 
provisions only applicable to specific medicinal drugs (e.g., blood and plasma 
products) are exempted from the following examination. 
In analyzing the information provided in Appendix L the following safety relevant 
regulatory requirements were identified as significant:  
 General marketing licensure requirement prior to marketing; 
 Requirements to the Regulatory approval pathway; 
 Reporting of product deviations (quality issues); 
 Distribution reports to FDA on half-yearly frequency; 
 Pharmacovigilance system and postmarketing monitoring and surveillance 
(IND incidence reporting and general postmarketing drug safety issues 
reporting e.g., types of adverse experiences such serious (unexpected) 
adverse experiences; follow-up reports, medication error reports – reporting 
via MedWatch database; Periodic Adverse Experience Reports; Alert reports 
based on scientific literature; Individual Case Safety Reports (ICSRs); and 
“Sentinel System”; [165]  [166] 
 Prompt review of adverse experiences required; 
 Labeling and naming requirements (e.g., official nonproprietary name 
(WHO/USAN, established name); 
 Postmarketing safety studies requirement; 
 Post-authorization measures (approved BLA annual reports); 
 Risk management (Risk evaluation and Mitigiation strategies (REMS)); 
 Current Good Manufacturing Practice (GMP);  
                                               
 [165] Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines; Draft 
Guidance for Industry; March 2001; 
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory%20Information/G
uidances/Vaccines/ucm092257.pdf 
 
[166] 
The sentinel initiative; July 2010; 
http://www.fda.gov/downloads/Safety/FDAsSentinelInitiative/UCM233360.pdf 
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 FDA Inspections with or without prior notice to verify compliance of cGMP 
requirements (Inspection frequency once every two years); 
 Change system (comparable to the EU Variation system); 
 Drug shortage pre-notification requirement (to notify FDA six month priorly) 
in case of discontinuance or potential interruption in the production of life-
saving drugs; and 
 Establishment registration and annual registration renewal. 
 Comparison of the overall safety relevant regulatory 9.3
requirements established by legislation 
The legislation from the EU and the USA is very similar in their overall safety 
relevant regulatory requirements and no major differences between the regions 
were identified. However, the FDA requires stricter reporting and processing than 
that required in the EU. Examples of the stricter requirements include submission of 
distribution reports to the FDA on a half-yearly basis, reporting of biological product 
deviations within 45 calendar days (quality issues) inspections performed every two 
years, and the requirement to perform a prompt review of adverse experiences. 
Furthermore, in the USA the establishment registration must be renewed annually 
which is not required by EU-law.  
An additional difference concerns the regulation of drug shortage. While the FDA 
requires a notification of six month prior to a discontinuance or interruption in 
product manufacturing that could lead to a significant disruption of drug product 
availability, a notification of only two month is required within the EEA and only if the 
product ceases to be made available on the market either, temporarily or 
permanently. In an EMA reflection paper on drug supply shortages, the EMA 
indicates that the national competent authorities of the EU-member states and 
responsible institutions of the European Union are aware of the safety issue caused 
by drug shortage. [167] 
Another difference is that while the EU requires a minimum of one qualified person 
to perform certain safety-related tasks (e.g., batch compliance), the FDA does not 
require that position. Furthermore, the EU has implemented the black triangle 
labeling that represents extended monitoring of new and high-risk products; a 
comparable instrument is not implemented in the USA.  
Overall, the regulatory requirements established by EU legislation provide the 
manufacturers with more individual responsibility (e.g., they are responsible to watch 
their distributors) than the US-legislation. The main legal document for medicinal 
products, the Directive 2001/83/EC, need to be transposed into national law by the 
EU-member states while the United States Code applies without transposing into 
national law. The U.S.C. is interpreted and implemented by the FDA. In 
consequence, the EU-member states have more freedom regarding the 
implementation of EU legislation established in Directives. The US-legislation 
provides the FDA with more authority and power than the EU legislation to the EMA. 
For example, the FDA may order a recall of hazardous products and is allowed to 
                                               
 [167] 
Reflection paper on medicinal product supply shortages caused by manufacturing/Good Manufacturing 
Practice Compliance problems; EMA/590745/2012; November 2012; 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/11/WC500135113.pdf 
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promptly suspend biologics licenses and therefore the FDA may react more 
promptly and with stricter consequences for the pharmaceutical manufacturer, 
supplier or importer. 
 Pharmacovigilance – Significant activities to ensure the 9.4
safety of biotechnology-derived products 
Pharmacovigilance is considered an important instrument to monitor and evaluate 
marketed medicinal products in both, the EU and USA. In the recent past 
pharmacovigilance requirements were amended and the importance of market 
surveillance has been highlighted. Routine pharmacovigilance activities that apply to 
all marketing authorization holders include periodic reporting and monitoring 
requirements such as postmarketing safety reporting, adverse event / medication 
error reporting and literature monitoring. Postmarketing studies have a significant 
role within and after the marketing approval of biotechnology-derived products. 
Many of these products are intended to treat chronic diseases and therefore the 
duration of treatment is long term. Further, it is known that rare safety risks such as 
serious immune reactions induced by biotechnology-derived products may not be 
observed during the pre-approval clinical program. As the market share of 
biotechnology-derived products has increased in the past years, the focus and 
importance of comprehensive postmarketing- and monitoring instruments has also 
been increased.  
Since 2007, postmarketing studies and clinical trials may be required by the FDA to 
further evaluate safety and efficacy of certain medicinal products after they have 
been approved for the US- market. This expanded authority for the FDA was 
implemented on September 27, 2007 when the Food and Drug Administration 
Amendments Act (FDAAA) was signed into law by the President and a new section 
505(o) was added to section 901 of Title IX of FDAAA. Section 505(o) is relevant to 
all prescription drugs approved under the FD&C Act, as well as for biological 
products approved under the PHS Act. [168] By the amended section 505(o)(3), the 
FDA is now authorized to require postmarketing studies and clinical trials for 
applicable medicinal products. Post-approval studies or post-approval clinical trials 
are intended to: [1] evaluate known serious risks related to the product use; [2] 
evaluate any signs of serious risk related to the product use; and [3] to identify any 
potential unexpected serious risks when indicated on the basis of available 
information. [168] In the FDA guidance document about the implementation of 
amended Section 505(o)(3) FD&C Act, the FDA states the conditions that allow the 
agency the request of postmarketing studies. [169]  
 
According to that information, postmarketing studies can be requested when:  
 Scientific data lead the FDA to the decision to request a postmarketing study 
or clinical trial 
                                               
 [168] 
21 USC § 505(o); March 2016; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-
section355&num=0&edition=prelim 
 [169] 
Postmarketing Studies and Clinical Trials -Implementation of Section 505(o)(3) of the Federal Food, Drug, 
and Cosmetic Act; Guidance for Industry; April 2011; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm172001.pdf 
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 The FDA has determined that adverse reporting and pharmacovigilance 
system or a planned postmarketing study will not adequately address the 
assessment of known serious risk and signals related to product use or the 
identification of unexpected serious risk when such potential is indicated by 
data [169] 
By the same section, the FDA is authorized to require periodic reports on the status 
of a required postmarketing study or -clinical trial. This legal requirement is further 
detailed in 21 CFR 601.70 that requires annual progress reports of a postmarketing 
study. The reporting requirements for biological products refers to both study types, 
postmarketing studies and clinical trials required on the basis of section 505(o) and 
also to agreed studies, the so called postmarketing commitments, which are 
required due to their approval basis according to 21 CFR 600.41. Further, section 
505(o)(4) authorizes the FDA to request safety labeling changes to marketed drugs 
and section 505(p) requires the compliance with the approved risk evaluation and 
mitigation strategy (REMS).  
In the EU, Directive 2001/83/EC and Regulation (EC) No. 726/2004 were amended 
in 2010 to extend the pharmacovigilance requirements and to include [1] the 
conduct of postmarketing studies; [2] the need of a risk management system and –
plan; and [3] to add additional monitoring requirements. [170]  [171] The amended 
legislation is called “pharmacovigilance legislation”, and came into effect in July 
2012. That pharmacovigilance legislation was implemented through Regulation No 
520/2012. [172] The pharmacovigilance legislation was complemented with the 
purpose to further improve the patient safety in 2012. [173]  [174]  
One significant requirement of the new pharmacovigilance legislation is the 
postmarketing instrument of post-approval studies which is established in Article 21a 
of the amended Directive 2001/83/EC. [175] 
Post-authorization safety- and efficacy studies may be a condition of the marketing 
approval. Significant goals of the PASS or PAES are to detect, quantify, investigate 
or exclude potential safety risks such as safety after long-term treatment, and to 
confirm the safety or efficacy profile of a biotechnology-derived product or to 
evaluate the effectiveness of risk-minimization actions. [170] 
                                               
 [169] Postmarketing Studies and Clinical Trials -Implementation of Section 505(o)(3) of the Federal Food, Drug, 
and Cosmetic Act; Guidance for Industry; April 2011; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm172001.pdf 
 [170] 
Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010; L 348/74 
Official Journal of the European Union 31.12.2010; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2010_84/dir_2010_84_en.pdf 
 [171] 
Regulation (EU) No 1235/2010 of the European Parliament and of the Council; L 348/1 Official Journal of 
the European Union; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf 
 [172] 
Commission Implementing Regulation (EU) No 520/2012 of 19 June 2012; L 159/5 Official Journal of the 
European Union 20.06.2012; http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF 
 [173] 
Regulation (EU) No 1027/2012 European Parliament and the Council of 25 October 2012; L 316/38, Official 
Journal of the European Union, 14.11.2012; http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:316:0038:0040:EN:PDF 
 [174] 
Directive 2012/26/EU of the European Parliament and the Council of 25 October 2012; L 299/1 Official 
Journal of the European Union, 27.10.2012; http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:299:0001:0004:EN:PDF 
 [175] 
Directive 2001/83/EC of the European Parliament and the Council of 6 November 2001 on the Community 
code relating to medicinal products for human use; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
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Beside the PASS and PAES requirements, the pharmacovigilance legislation also 
introduces the concept of additional monitoring presented by a black symbol 
(triangle) in the package leaflet. The black symbol is established by Article 23 of 
Regulation (EC) No 726/2004 and is intended for products containing novel active 
substances and biotechnology-derived products authorized after 1st of January 
2011; and which are included in the list required by Article 23(1) of the Regulation. 
The black symbol represents that these products are subject to additional monitoring 
and makes users (e.g., patients and physicians) aware of this specific condition. A 
further instrument to facilitate pharmacovigilance activities is the risk management 
plan (RMP) which is required by Article 8(3) of Directive 2001/83/EC. Since March 
2014, the summaries of RMPs are published for centrally authorized medicines on 
the EMA website in order to improve transparency. [176] To support the EU-
pharmacovigilance legislation and the safety monitoring, the “Good 
Pharmacovigilance Practices” (GVP) were developed. The GVP are a huge set of 
documents separated into 12 single modules and will replace the pharmacovigilance 
guidelines established in Article 106 of Directive 2001/83/EC. [177] 
Overall, appropriate activities to monitor and further confirm the safety and efficacy 
of biotechnology-derived products are available in both regions but their application 
is handled differently and on a case by case basis. [178] Possible reasons for the 
different handling include: [1] different scientific assessment standards evaluating 
the need for further safety data and risk measures; [2] different marketing 
experiences and available surveillance data for the product in question and/or [3] 
different points in time when relevant laws were enacted. For example, in the USA 
the postmarketing studies and postmarketing clinical trials requirement including risk 
evaluation and mitigation strategies (REMS) and new pharmacovigilance system 
requirement was added to the US law in 2007 by section 901 of the FDAAA. The 
European counterpart, the postmarketing safety and efficacy trials requirement 
including the risk management system / -plan- and new pharmacovigilance system 
was implemented into Directive 2001/83/EC by Directive 2010/84/EU in 2010. 
 
                                               
 [176] 
Risk-management plans; European Medicines March 2016; 
Agencyhttp://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_
000360.jsp&mid=WC0b01ac058067a113 
 [177] 
Good pharmacovigilance practices; September 2016; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345
.jsp&mid=WC0b01ac058058f32c 
 [178] 
FDA Approval letter of Actemra; BLA No 125276; January 2010; 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000Approv.pdf 
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10 Implementation of the regulatory requirements  
Typically, the regulatory and safety relevant requirements applicable to medicinal 
products are highly complex and of a similar nature in both regions, the EU and 
USA. However, differences exist in the density and implementation of legislation. 
Within this chapter, the density of regulation (regulatory burden) in both regions is 
analyzed. 
 The density of regulation and the implementation of EU 10.1
legislation 
The key players within the structure and framework of the European regulatory 
environment are: [1] the European Commission which develops the EU legislation; 
[2] the EU-member states, which transform and implement indirect binding 
legislation into national law and, which also have the overall responsibility of 
securing the implementation of EU legislation at national level; [3] the EMA and, if 
applicable, the HMA which develop regulatory and scientific guidance documents to 
assist the performance of the implemented regulatory requirements; and [4] the ICH 
organization that develops widely recognized guidelines. Also, the requirements 
defined in the ICH guidelines often are incorporated into the EU legislation as well 
as in national laws. [83] 
On the EU level, the acts proposed by the European Commission become legal 
through their adoption by the ordinary legislative procedure (formerly known as co-
decision procedure). Once the legal act is enacted, it is the responsibility of all levels 
(european, federal and local) to implement the EU legislation within the the EU-
member states.  
Figure 3 shows the density of regulation for medicinal products, implementation 
structures and relations within the European Union.  
                                               
 [83] "Transnationalisierung der Arzneimittelregulierung: Der Einfluss der ICH-Guidelines auf das deutsche 
Arzneimittelzulassungsrecht"; September 2010, Volume 28, Issue 9, Engelke, K. MedR (2010) 28: 619. 
doi:10.1007/s00350-010-2743-9; http://link.springer.com/article/10.1007%2Fs00350-010-2743-9#page-1 
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Figure 3 Density of regulation, implementation structures and relations within the EU 
 
Due the fact that within the European Union the needs of all member states must be 
considered and national sovereignty of each EU-member state respected and kept, 
it is not possible to release very detailed strict legally binding requirements EU 
widely and to regulate the legal requirements of all EU-member states uniformly and 
identically. Therefore, all EU-member states are legally obligated to transform the 
EU-requirements established in Directives into national law. Differences between 
the EU-member states in interpretation and implementation of the EU-requirements 
may occur which may result in legal variations and inconsistencies.  
The transformation of the indirect binding requirements of any relevant Directives 
into national law that in turn is nationally implemented as national law, ordinances or 
other national types of legal documents may increase the regulatory burden and 
range of regulatory requirements within and between the EU-member states. 
Another aspect is that between the EU-member states, the implementation structure 
may vary leading to differences in implementation responsibilities (e.g., 
implementation at federal level or local level). This may also lead to differences in 
the density of regulation that can occur within a given EU-member state. 
In order to minimize the legal inconsistencies between the EU-member states when 
interpreting the EU legislation, and to further explain and detail the EU legislation, 
the European Medicines Agency (EMA) on behalf of the European Commission is 
preparing and publishing “quasi binding” regulatory and scientific guideline 
documents with the purpose of facilitating a consistent scientific level in regards to 
the approval of medicinal products and defined safety standards. 
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In summary, the regulatory burden in the European Union is very high, 
comprehensive and complex in its nature due to the number of parties involved in 
passing, detailing and implementing EU legislation. In addition, the range of subjects 
covered by various legal acts is very broad with the result that the sector concerning 
medicinal products is well regulated. 
The density of regulation for biosimilar products is basically the same as for the 
biologic innovator products. The requirements for biosimilar products were 
implemented into Directive 2001/83/EC in 2004 with Directive 2004/27/EC, and the 
overall requirements and safety standards defined in Directive 2001/83/EC and 
Regulation 726/2004/EC apply to biosimilar products as well. [179] To date, there are 
few overall and diverse product specific EMA scientific guidance documents 
available for biological and biosimilar products. The first significant overarching 
similar products guidance document, revised in 2014 was published in 2005. [30] So 
far, the European Union plays a pioneering role concerning the regulation of 
biosimilar products which, however, is still in an early stage. It is anticipated that 
more guidance documents will become available over time that address the needs 
of marketing authorization applicants and manufacturers of biosimilar products. 
 The density of regulation and the implementation of US 10.2
legislation  
The key players within the structure and frame of the USA regulatory environment 
are: [1] the US congress, that passes federal laws and statutes; and [2] the 
government agencies within the executive, legislative and judicial branches of the 
Federal government, which for medicinal products is the FDA (executive branch) 
which interprets, details and implements the federal laws by establishing rules and 
issuing relevant guidance documents. Figure 4 shows the density of regulation and 
the implementation structure of the US law.  
 
                                               
 [179] 
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, L 136/34, Official 
Journal of the European Union, 30.04.2004; http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/dir_2004_27/dir_2004_27_en.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
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Figure 4 Density of regulation, implementation structures and relations in USA law 
 
Compared to the EU, the transformation of the United States law into national law is 
not necessary due to the different political structure. The US law passed by the US 
government is interpreted and further detailed in rules and regulations (e.g., Code of 
federal regulation) by the responsible agencies (e.g., the FDA for medicinal 
products). In general, states are bound to follow US law. However, there is nothing 
to stop any state from writing a law that contradicts US law in which case the 
Federal government must sue in court to overturn the state law. So, it is possible, 
although unlikely, that a state law contradicts the US law or regulation. Like the EU, 
relevant regulatory and scientific guidance documents are developed and published 
by the responsible agencies (e.g., the FDA for regulation of medicinal products) but 
these are not called “quasi binding” and are of a recommendatory nature, except for 
those sections where specific regulations are cited and the requirements of the 
regulations are reiterated. 
Due to the fewer number of parties involved in implementing laws and the simpler 
implementation structure, the density of regulation in the USA is less intense than in 
the EU. The FDA´ CFR regulations are less complex than the EU legislation and 
national laws, but they are similar in their comprehensive nature as they cover a 
broad range of subjects in the sector concerning medicinal products. Therefore, this 
sector is regulated in the USA in a comparable intensity and manner as in the EU, 
but with fewer FDA guidance documents compared to that of the EMA guidance.  
The density of regulation for biosimilar products is basically the same as for the 
innovator biological products.  
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To date, the FDA has published seven FDA guidance documents relevant for 
biosimilar products. [180] The first three guidance documents were drafted by the 
FDA in February 2012. It is anticipated that over time more guidance documents will 
become available. 
                                               
 [180] 
Biosimilars; June 2015; 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm 
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11 The ICH guidelines for biotechnology-derived products 
The purpose of this chapter is to introduce the types of ICH guideline documents 
relevant for biotechnology-derived products. The ICH guideline documents address 
the following topics: [1] quality; [2] safety; [3] efficacy and [4] multidisciplinary items 
but only in the quality and safety topics, guidance specifically for biotechnology-
derived products is available.  
 The ICH quality guideline documents 11.1
The main purpose of the quality guideline documents is to address the information 
and content of “Chemistry, Manufacturing and Control”, also known as CMC. The 
CMC information has to be provided in Module 3 of the application dossier for a 
biotechnology-derived product. The following guideline documents for 
biotechnology-derived products are available: 
 ICH Q5A (R1) “Viral safety evaluation of biotechnology products derived 
from cell lines of human or animal origin” [181]  
 ICH Q5B “Analysis of the expression construct in cell lines used for 
production of r-DNA derived protein products” [182]  
 ICH Q5C “Stability testing of biotechnological/biological products” [183]  
 ICH Q5D “Derivation and characterisation of cell substrates used for 
production of biotechnological/biological products” [184]  
 ICH Q5E “Comparability of biotechnological/biological products” [185]  
 ICH Q6B “Test procedures and acceptance criteria for biotechnological / 
biological products” [186]  
In addition, the following guideline documents describe strategic approaches to 
assist in complying with the CMC: 
                                               
 [181] Viral Safety Evaluation of Biotechnology Products derived from cell lines of human or animal Origin, 
Q5A(R1); September 1999; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__
Guideline.pdf 
 [182] 
Quality of Biotechnological Products: Analysis of the Expression construct in cells used for production of R-
DNA  derived Protein products, Q5B; November 1995; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5B/Step4/Q5B_Guideline.
pdf 
 [183] 
Stability testing of Biotechnological / Biological Products; Q5C; November 1995; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.
pdf 
 [184] 
Derivation and Characterisation of cell substrates used for production of biotechnological / biological  
products; Q5D; July 1997; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.
pdf 
 [185] 
Comparability of biotechnological / biological products subject to changes in their manufacturing process; 
Q5E; November 2004; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.
pdf 
 [186] 
Specifications: Test procedures and acceptance criteria for biotechnological / biological products; Q6B; 
March 1999; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.
pdf 
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 ICH Q7 “Good Manufacturing Practise guide for active pharmaceutical 
ingredients” [187] 
 ICH Q8 (R2) “Pharmaceutical development” [188] 
 ICH Q9 “Quality Risk Management” [189] 
 ICH Q10 “Pharmaceutical Quality System” [190] 
 ICH Q11 “Development and manufacture of drug substances (chemical 
entities and biotechnological / biological entities)” [191]. 
 The ICH safety guideline documents  11.2
The main purpose of the ICH safety guideline documents is to detect and identify 
any potential risks related to the drug substance or –product. Currently, one 
guideline document is available that addresses preclinical specifics of 
biotechnology-derived products.  
 ICH S6 (R1) “Preclinical safety evaluation of biotechnology-derived 
pharmaceuticals” [192]  
                                               
 [187] 
Good Manufacturing Practice guide for active pharmaceutical ingredients; Q7; November 2000; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf 
 
[188] 
Pharmaceutical development; Q8(R)2; August 2009; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guid
eline.pdf 
 
[189] 
Quality Risk Management; Q9; November 2005; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf 
 
[190] 
Pharmaceutical Quality System; Q10; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.
pdf 
 [191] 
Development and Manufacturer of Drug Substances; Q11; May 2012; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf 
 [192] 
Preclinical safety evaluation of biotechnology-derived pharmaceuticals, S6(R1); July 1997; 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guidel
ine.pdf 
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12 Analysis of EMA scientific guidance documents  
Within this chapter, the most significant EMA scientific guidance documents for 
biological innovator products applicable for mAbs as well as EMA scientific guidance 
documents for biosimilar products will be identified and analyzed with respect to the 
categories of standards impacting the safety of biotechnology-derived products. The 
EMA guidance documents were analyzed in order to assess how far the following 
categories of safety standards are addressed:  
 Overall regulatory requirements  
 Non-clinical considerations 
 Clinical considerations. 
 Quality considerations related to safety. 
Various scientific EMA guidance documents for biotechnology-derived products are 
available on the EMA homepage. All available documents are categorized into 
individual sections as listed below:  
 Quality 
 Biologicals 
 Non-clinical 
 Clinical efficacy and safety 
 Clinical pharmacology and pharmacokinetics 
 Multidisciplinary 
 ICH guidelines.  
The documents in section “Biologicals” were reviewed for relevant guidance 
documents for biological innovator products. The documents in the 
“Multidisciplinary” section were reviewed for relevant guidance documents available 
for biosimilar products.  
 The EMA scientific guidance documents for biological 12.1
innovator products with main focus on mAbs  
In the “Biologicals” section, guidance documents are available for active substances 
and for finished products. The scientific guidance documents provided for active 
substances cover the following topics:  
 Manufacture, characterization and control of the active substance 
 Specifications 
 Comparability and biosimilarity 
 Plasma-derived medicinal products 
 Plasma master file 
 Vaccines 
 Stability 
The guidance documents in the mentioned topics are product class specific and 
address for example gene therapy products, allergen products. Three scientific 
guidance documents within the active substances guidance section were identified 
that may be applicable for biotechnology-derived monoclonal antibodies. These are: 
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1. The “Guideline on development, production, characterisation and 
specifications for monoclonal antibodies and related products” in which 
quality aspects for mAbs to support a marketing authorization application is 
discussed. [193] 
2. The guideline “Production and quality control of medicinal products derived 
by recombinant DNA-technology” 3AB1a which provides information related 
to the data collection and submission in order to support marketing 
authorization applications. [194] 
3. The “Guideline on process validation for the manufacture of biotechnology-
derived active substances and data to be provided in the regulatory 
submission” which provides advice to the data requirements for process 
characterization and verification in manufacturing in order to support 
marketing authorization applications. [195] 
All three documents are intended to support marketing applications by providing 
advice to the data collection and compilation. This shall not be discussed in further 
due to the lack of relevance to the defined safety categories.  
The scientific guidance documents provided for finished products cover the following 
topics: 
 Pharmaceutical development 
 Product information 
 Adventitious agents safety evaluation viral safety 
 Transmissible spongiform encephalopathy (TSE) (animal and human) 
 Investigational medicinal products 
 Genetically modified organisms (GMOs) 
 Specifications 
The available documents are very specific and for different product classes. Most of 
the guidance documents cover drug products such as plasma derived medicinal 
products or vaccines.  
Five scientific documents were identified which may apply to biological innovator 
monoclonal antibody products, whereby the first three mentioned documents which 
are also applicable to biosimilar products. 
1. The “Guideline on the requirements for quality documentation concerning 
biological investigational medicinal products in clinical trials” [92] 
2. The “Guideline on virus safety evaluation of biotechnological investigational 
medicinal products” [93] 
                                               
 [193] Guideline on development, production, characterisation and specifications for monoclonal antibodies and 
related products; EMA/CHMP/BWP/532517/2008; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211640.pdf 
 [194] 
Production and Quality control of medicinal products derived by recombinant technology; 3AB1A; December 
1994; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003433.pdf 
 
[195] 
Guideline on process validation for the manufacture of biotechnology-derived active substances and data to 
be provided in the regulatory submission; EMA/CHMP/BWP/187338/2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/04/WC500205447.pdf 
 
[92] 
Guideline on the requirements for quality documentation concerning biological investigational medicinal 
products in clinical trials; EMA/CHMP/BWP/534898/2008; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127370.pdf 
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3. The “Note for guidance minimising the risk of transmitting animal spongiform 
encephalopathy agents via human and veterinary medicinal products” [196]  
4. The “Guideline on the use of bovine serum in the manufacture of human 
biological medicinal products” [197]  
5. The “Guideline on the use of porcine trypsin used in the manufacture of 
human biological medicinal products” [198]  
The guidance document in the first item discusses the requirements and information 
that need to be provided in the documentation of clinical trials with biological 
investigational products. This shall not be discussed in further due to the lack of 
relevance to the defined safety categories. 
The guidance document in the second item addresses the viral safety of IMPs 
during clinical development and provides advice with respect to a clinical trial 
application. This shall not be discussed in further due to the lack of relevance to the 
defined scope and safety categories. 
The guidance document in the third item addresses the issue of transmitting animal 
spongiform encephalitis (TSE). The guidance document provides general 
information on the TSE issue and provides recommendations on minimizing the risk 
for TSE. The document addresses neither clinical safety and non-clinical safety 
requirements, nor quality related safety considerations. 
The guidance documents in the fourth and fifth item are applicable to biotechnology-
derived products that use animal-derived materials in the manufacturing. Generally, 
manufacturers of recombinant proteins and mAbs should seek the use of non-
animal derived materials (e.g., transgenic plant-derived trypsin, recombinant human 
transferrin derived from yeast or transgenic rice, etc.). The documents do not 
address clinical safety or non-clinical safety requirements nor quality safety relevant 
considerations and therefore shall not be further discussed.  
Overall, no scientific guidance document was found in the “Biologicals” section that 
discusses one of the four defined categories of safety standards.  
  
                                                                                                                                     
 
[93] 
Guideline on Virus Safety Evaluation of biotechnological investigational medicinal products; Doc. Ref. 
EMEA/CHMP/BWP/398498/2005, 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf 
 [196] 
Note for guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via 
Human and Veterinary Medicinal Products; EMA/410/01 rev. 3, C73/1 Official Journal of the European 
Union, 05.03.2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf 
 [197] 
Guideline on the use of bovine serum in the manufacture of human biological medicinal products; 
EMA/CHMP/BWP/457920/2012 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500143930.pdf 
 
[198] 
Guideline on the use of porcine trypsin used in the manufacture of human biological medicinal products; 
EMA/CHMP/BWP/814397/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162147.pdf 
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 The EMA scientific guidance documents for biosimilar 12.2
products with main focus on mAbs 
Most of the current scientific guidance documents for biosimilar products are found 
in the “Multidisciplinary” section. The biosimilar guidance documents on the EMA 
website are categorized into the following sections:  
1. Overarching biosimilar guidance documents, applicable to all biosimilar 
products 
2. Product-specific biosimilar guidance documents  
3. Other guidance documents relevant for biosimilar products and biological 
innovator products  
Table 1 shows the applicable scientific guidance documents for biosimilar products 
and the categories of safety standards addressed. 
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Table 1 EMA biosimilar products guidance documents and categories of safety standards 
Title of guidance document Category of safety standard 
Overarching biosimilar products guidance documents 
“Guideline on similar biological medicinal 
products” [30]  
 
Authors short title: Similar products 
guidance document 
Overall safety-relevant regulatory 
requirements 
“Guideline on similar biological medicinal 
products containing biotechnology-derived 
proteins as active substance: non-clinical 
and clinical issues” [57]. 
 
Authors short title: Similar products - non 
clinical and clinical issues guidance 
document 
Non-clinical safety and clinical safety 
requirements, Overall safety-relevant 
regulatory requirements 
“Guideline on similar biological medicinal 
products containing biotechnology-derived 
proteins as active substance: quality 
issues” [199] 
 
Authors short title: Similar products - 
quality issues guidance document 
Overall safety-relevant regulatory and 
quality requirements  
Product-specific biosimilar products guidance documents 
“Guideline on similar biological medicinal 
products containing monoclonal 
antibodies: non-clinical and clinical 
issues” [200]  
 
Authors short title: Similar products mAb 
guidance document 
Non-clinical safety and clinical safety 
requirements, Overall safety-relevant 
regulatory requirements 
Beside of the biosimilar guidance documents presented in Table 1 several product 
class specific documents such as for products containing recombinant follicle-
stimulating hormone or interferon beta, etc., are available for biosimilar products.  
                                               
 [30] Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[199] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: quality issues (revision 1); EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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In addition, the following documents are relevant for biotechnology-derived products 
and may address the analyzed categories of safety standards. These documents 
will be considered in the comparison chapter as necessary: 
 “EMA Procedural advice for users of the Centralised Procedure for Similar 
Biological Medicinal Products applications” [201]  
 “Labeling and naming (INN): WHO Guidelines on the Use of INNs for 
Pharmaceutical Substances (1997)” [202]  
 “Biological Qualifier- An INN Proposal, Programme on International 
Nonproprietary Names (INN)” [203] 
 “Immunogenicity assessment of monoclonal antibodies intended for in vivo 
clinical use” [204] 
 “Guideline Immunogenicity assessment of biotechnology-derived therapeutic 
proteins”
 [61]
 
 
                                               
 [201] 
EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [202] 
Guidelines on the use of international nonpropriertary names (INNs) for pharmaceutical substances; WHO 
Pharm S/NOM 1570; http://apps.who.int/iris/bitstream/10665/63779/1/WHO_PHARM_S_NOM_1570.pdf 
 [203] 
Biological Qualifier -An INN Proposal; INN Working Doc. 14.342, Rev. Final October 2015;  
http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf?ua=1 
 [204] 
Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use; 
EMA/CHMP/BMWP/86289/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf 
 [61] 
Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
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13 Analysis of publicly available FDA guidance documents  
Within this chapter, the most significant and publicly available FDA guidance 
documents for biological innovator products, especially for mAb products, and 
biosimilar products will be analyzed with respect to the categories of safety 
standards. 
The FDA´s relevant publicly available guidance information can be found on the 
FDA website under section “Vaccines, Blood & Biologics”. [205] Following guidance 
documents, compliance and regulatory information for “Biologics” are provided 
there:  
 Biologics Rules (e.g., Federal Register Notices) 
 Biologics Guidances  
 Other Recommendations for Biologics Manufacturers (e.g., Points to 
consider and Memoranda) 
 Biologics Procedures (FDA SOPPS (FDA Standard Operating Procedures 
and Policies)) for transparency purpose 
 Biologics Establishment Registration (for Blood products, Human cells, 
tissue und cellular based products) 
 Compliance Actions (Biologics)  
 Biologics Post-Market Activities (e.g., Postmarketing clinical trials). 
Additionally, some of the FDA guidance documents applicable for biotechnology-
derived products are available in the “Drugs” section on the FDA website.  
CDER publishes a list of all new and withdrawn guidance documents each year. [206] 
The adopted ICH-guidelines and some clinical trial guidance documents may be 
found in the “General” section under “Jointly issued or Agency-level guidance”. [207] 
 The FDA guidance documents for biological innovator 13.1
products with main focus on mAbs  
The “General Biologics Guidance” section in “Vaccines, Blood & Biologics” contains 
guidance to topics like:  [208] 
 Administrative 
 Adverse Events and Product Deviation Guidances 
 Application Submissions Guidance 
 Biosimilars Guidances 
                                               
 [205] 
Guidance, Compliance & Regulatory Information (Biologics); June 2015; 
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm 
 [206] 
Guidances (Drugs); April 2015; 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
 [207] 
Biologics Guidances; July 2015; 
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.
htm 
 
[208] 
General Biologics Guidances; April 2015; 
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Gener
al/default.htm 
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 Clinical Guidances 
 CMC and GMP Guidances 
 Devices 
 Generics 
 Labeling and Promotion. 
All guidance documents available within these topics were reviewed for applicability 
to mAb products and the four categories of safety standards. One guidance 
document was identified:  
 “Guidance for Industry for the submission of chemistry, manufacturing and 
controls information for a therapeutic recombinant DNA-derived product or a 
monoclonal antibody product for in vivo use”. [209] 
This guidance document provides general information on the submission content of 
mAb products. It does not provide information to the defined categories of safety 
standards.  
In addition, the section “Other recommendations for Biologics Manufacturers” 
provides Points to Consider (PTC) documents. [210] Here, the “Points to Consider in 
the Manufacture and Testing of Monoclonal Antibody Products for Human Use” from 
February, 1997 is available. [211] As the PTC´s have neither regulation nor guideline 
status it will not be further discussed. However, applicants of monoclonal antibody 
products, namely immunoglobulin’s, may find some helpful information. 
Two guidance documents were identified in the “Drugs” section of the FDA website: 
[212] 
 Guidance for Industry “Nonproprietary Naming of Biological Products”. [213] 
This guidance document establishes the overall safety relevant regulatory 
requirements for the naming of biological products and applies to biological 
innovators and biosimilar products. It will be discussed in further detail in later 
chapters.  
 Guidance for Industry: “Immunogenicity Assessment for Therapeutic Protein 
Products, August 2014” [60] 
                                               
 [209] For the Submission of chemistry, manufacturing, and controls information for a therapeutic recombinant 
DNA-derived product or a monoclonal antibody product for in-vivo use, Guidance for Industry; August 1996; 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidan
ces/General/UCM173477.pdf 
 [210] 
Other Recommendations for Biologics Manufacturers; June 2010; 
https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherRecommend
ationsforManufacturers/default.htm 
 [211] 
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, 
28.02.1997; 
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/OtherR
ecommendationsforManufacturers/UCM153182.pdf 
 [212] 
Guidances (Drugs), April 2017; 
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm 
 [213] 
Guidance for Industry Nonproprietary Naming of Biological Products, Guidance for Industry; January 2017; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.
pdf 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
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This guidance document applies to biological innovator and biosimilar products and 
informs about immune reactions to and consequences of therapeutic protein 
products, dependencies and relations of product- and patient-specific factors and 
provides risk mitigation strategies in the clinical phase of development. This 
guidance will be further discussed in later chapters.  
The other biological products guidance documents provided in the sections 
“Vaccines, Blood & Biologics” and “Drugs” on the FDA´s homepage are very specific 
and address special topics like administrative and procedural questions, certain 
products, diseases and general questions.  
 The FDA guidance documents for biosimilar products  13.2
Both, the “Vaccines, Blood & Biologics” and the “Drugs” section provide the same 
publicly available FDA guidance documents for biosimilar products.  
Table 2 lists the biosimilar product guidance documents and their classification into 
the four categories of safety standards.  
Table 2 FDA biosimiliar products guidance documents and categories of safety standards  
Title of guidance document Category of safety standard 
“Scientific Considerations in Demonstrating 
Biosimilarity to a Reference Product” [160] 
 
Authors short title: Scientific considerations 
guidance document 
Overall safety-relevant regulatory 
requirements 
“Quality Considerations in Demonstrating 
Biosimilarity of a Therapeutic Protein Product 
to a Reference Product“ [159] 
 
Authors short title: Quality considerations 
guidance document 
Overall safety-relevant regulatory 
and quality requirements 
Non-clinical safety considerations  
Clinical safety considerations  
“Clinical Pharmacology Data to Support a 
Demonstration of Biosimilarity to a Reference 
Product” [214] 
 
Authors short title: Clinical Pharmacology 
Non-clinical safety considerations 
Clinical safety considerations 
                                               
 [160] Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry, April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 [214] 
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Guidance 
for Industry; December 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.
pdf 
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guidance document  
“Biosimilars: Questions and Answers 
Regarding Implementation of the Biologics 
Price Competition and Innovation Act of 2009 
Guidance for Industry” [215] 
 
Authors short title: Biosimilar products 
guidance Q&A document 
Overall safety-relevant regulatory 
requirements 
“Biosimilars: Additional Questions and 
Answers Regarding Implementation of the 
Biologics Price Competition and Innovation Act 
of 2009” [104]  
 
Authors short title: Biosimilar products 
guidance additional Q&A document  
Overall safety-relevant regulatory 
requirements 
In addition, the following documents are relevant for biotechnology-derived products 
and may address the analyzed categories of safety standards. These documents 
will be considered in the comparison chapter as necessary: 
  “Nonproprietary Naming of Biological Products” [213] 
 “Reference Product Exclusivity for Biological Products Filed Under Section 
351(a) of the PHS Act” [216] 
 “Labeling for Biosimilar Products” [217]  
                                               
 [215] Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [104] 
Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price 
Competition and Innovation Act of 2009, Question Q II.3.; Draft Guidance, Revision 1, May 2015; 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdf 
 [213] 
Guidance for Industry Nonproprietary Naming of Biological Products, Guidance for Industry; January 2017; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.
pdf 
 [216] 
Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act, Draft 
guidance, August 2014; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.p
df 
 
[217] 
Labeling for Biosimilar Products, Draft guidance, March 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM493439.
pdf 
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14 Analysis and comparison of the identified EMA and FDA 
guidance documents  
This chapter compares and discusses the identified categories of safety standards 
for biosimilar products provided in the applicable EMA and FDA guidance 
documents.  
 Analysis of the overall safety relevant regulatory 14.1
requirements  
The following text analyzes significant overall safety relevant regulatory 
requirements of the USA and Europe that may influence the safety of biosimilar 
products and summarizes them in an overall summary. 
Biological product definition and the applicable approval pathways  
The Part I of Annex I of Directive 2001/83/EC and the EMA procedural advice 
document for biosimilar products describe a biological product as a “…product that 
contains a biological substance”, whereby the biological substance comes from a 
biological source. [201] Thus, diverse medicinal products such as recombinant 
proteins, monoclonal antibodies, products produced or extracted from human blood 
or plasma, or immunological and advanced therapy products are biological products. 
Such products require a combination of physico-chemical and biological testing to 
characterize the products properly and a well-controlled production process to 
determine product quality.  
In the context of the biotechnology-derived products discussed, it is observed that 
monoclonal antibodies and recombinant proteins are defined as biological medicinal 
products. Article 3(1) of Regulation (EC) No 726/2004 establishes the mandatory 
scope of the Centralized Procedure requirement. According to that article, medicinal 
products that use the biotechnological processes described in the Annex of 
Regulation (EC) No 726/2004 in their development must use the Centralized 
Procedure as the applicable approval pathway.  
The FDA describes the term biological product on their website as products that are 
“…generally derived from living material--human, animal, or microorganism-- are 
complex in structure, and thus are usually not fully characterized”. [218] Within the 
US-legislation, monoclonal antibodies and recombinant protein products are 
                                               
 [201] 
EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [218] 
Frequently Asked Questions About Therapeutic Biological Products, Question 1. What is a biological 
product?; July 2015; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalAp
plications/TherapeuticBiologicApplications/ucm113522.htm 
 - Page 85 of 215 - 
ANALYSIS AND COMPARISON OF GUIDANCE DOCUMENTS … 
 
covered by the Public Service Health Act and are defined by the FDA regulations 
“specified biological products”. [27] 
In the context of the biotechnology-derived products discussed, monoclonal 
antibodies and recombinant proteins are considered as “specified biological 
products” in the US regulation. This is in contrast to the EU definition which 
considers these products as “biological medicinal products”.  
Compared to the EU approval pathway, the Biologics License Application 
established in 21 CFR § 601.2(a) is the applicable licensure pathway. Of interest is 
the exclusion requirement in 21 CFR § 601.2(c)(1) which applies only to the 
“specified biological products”. The exclusion requirement establishes the non-
applicability of the sections §§ 600.10(b) and (c), 600.11, 600.12, 600.13, 610.53, 
and 610.62 of this chapter. [219] 
Biosimilarity 
Within the EU region, the EMA similar products guidance document considers the 
term “biosimilar” for biological products that contain “…a version of the active 
substance” of an EU authorized biological innovator product (reference product). [30] 
Similiarity to the authorized biological innovator product shall be demonstrated 
through extensive comparability testing “…in terms of quality characteristics, 
biological activity, safety and efficacy”. [30] 
In the US regulations, Section 351(i)(2) of the PHS Act provides the regulatory basis 
and legal definition of the term “biosimilar” in reference to a biological product. 
Following that definition, the term “biosimilar” refers to a biological product that is 
“…highly similar to the reference product notwithstanding minor differences in 
clinically inactive components;” and further clarifies the term “highly similar” by 
stating, that there are “…no clinically meaningful differences between the biological 
product and the reference product in terms of the safety, purity, and potency of the 
product.” [32] 
Both regions, the EU and USA, refer to a reference product and require 
demonstration of a similar product safety.  
  
                                               
 [27] 21 CFR §601.2(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol7/pdf/CFR-2014-title21-
vol7-part601.pdf 
 [219] 
21 CFR § 601.2(c)(1), April 2016; https://www.gpo.gov/fdsys/pkg/CFR-2016-title21-vol7/pdf/CFR-2016-
title21-vol7.pdf 

 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [32] 
42 USC §262 (i)(1), 42 USC §262 (i)(2)(A),(B); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:262%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section262%29&f=treesort&edition=prelim&num=0&jumpTo=true 
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Reference product  
Within the EU, the reference product must be a biological innovator product, 
authorized in the EEA by a Member State or by the EU-Commission on the basis of 
a full dossier as established in Article 8 of Directive 2001/83. [84]  [201] It is required to 
use one, and only one single reference product throughout the comparability 
program. [30] However, the comparison of the biosimilar product with a biological 
innovator product not authorized in the EEA may be acceptable for certain clinical 
studies and for in-vivo non-clinical studies provided, that the non-EEA authorized 
reference product was approved by a regulatory authority using a similar level of 
scientific and regulatory standards as the EMA applies. As detailed in the EMA´s 
similar products guidance and the EMA advice document for users of the 
Centralized Procedure, the applicant must present comparative bridging data, e.g., 
structural and functional data from analytical studies, data from clinical PK and/or 
PD bridging studies. [201] These data must show that the non-EEA authorized 
biological innovator product represents an EEA-authorized biological comparator 
product and the proposed biosimilar product. [30]  [201] Although the final determination 
of the adequacy of bridging data will be made during application review, the EMA 
recommends discussing such an approach, if intended, with them upfront. [201] 
Like the EU legislation, PHS Act requires that the reference product, against which a 
biosimilar product is evaluated, shall be a single biological innovator product which 
is FDA licensed under subsection 351(a) PHS. [220]  [221] Similar to the EU regulatory 
requirements, the FDA scientific considerations guidance document, and the 
biosimilar products guidance Q&A document allow the use of certain comparative 
animal or clinical data generated with a non-U.S.-licensed product to support a 
biosimilarity demonstration. [160]  [215] However, the following additional requirements 
are also specified “…at least one clinical pharmacokinetic (PK) study and, if 
appropriate, at least one pharmacodynamic (PD) study, [...] must include an 
adequate comparison of the proposed biosimilar product directly with the U.S.-
licensed reference product….” [215] If such study is not needed, this shall be 
scientifically justified.  
                                               
 [84] Directive 2001/83/EC of 6 November 2001; Article 8; Article 8(i); OJL 311, 28.11.2001, p.67, Consolidated 
Version 16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [201] 
EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [220] 
42 USC § 262(i)(4); April 2015; April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-
title42-section262&num=0&edition=prelim 
 [221] 
Information for Consumers (Biosimilars), August 2015; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalAp
plications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 
[215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
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With regard to suitable bridging data, it is required that this information can 
“…scientifically justify the relevance of these comparative data to an assessment of 
biosimilarity…” and further, that this data shall establish an appropriate brigde to the 
U.S.-licensed reference product. [215] Such bridging data shall include “…data from 
analytical studies […] that directly compare all three products […], and is likely to 
also include bridging clinical PK and/or PD study data for all three products….” [215] 
But in regard to product interchangeability, the biosimilar products guidance Q&A 
document states that it is “…unlikely that clinical comparisons with a non-U.S.-
licensed product would be an adequate basis to support the additional criteria 
required for a determination of interchangeability with the U.S.-licensed reference 
product.” [215] 
Like the EMA, the FDA requires the non-US licensed comparator product to have 
been licensed under similar regulatory and scientific standards as US regulatory 
standards. The FDA´ biosimilar products guidance Q&A document provides very 
detailed information on the use of a non-licensed comparator product and necessary 
bridging data. The FDA encourages sponsors to discuss such an approach during 
the development program. [160] 
Interchangeability  
The PHS Act defines the additional standard of “interchangeability” for a biosimilar 
product. Interchangeability refers to the medical practice of changing one 
biotechnology-derived medicinal product for another biotechnology-derived product 
that is equal, in a given clinical setting on the initiative or with the agreement of the 
prescriber. A centralized approach is applied to determine the interchangeability of 
such product with the FDA. [222] 
To meet that standard, an interchangeable biosimilar product is expected to 
generate the same clinical outcome as the reference product in any given patient. 
For a product that is administered more than once, it is required that the safety risk 
is not increased nor the efficacy is reduced due to alternating or switching when 
compared to the repeated use of the reference product without alternating or 
switching. This means that the interchangeable biosimilar product can be substituted 
for the reference product without any additional or higher risks. [223] 
                                               
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 
[222] 
42 USC §262(k)(3); April 2015, http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-
section262&num=0&edition=prelim 
 [223] 
42 USC §262(i)(3), April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-
section262&num=0&edition=prelim 
 - Page 88 of 215 - 
ANALYSIS AND COMPARISON OF GUIDANCE DOCUMENTS … 
 
42 U.S.C §262(k)(2)(B) defines the requirement of providing information to the FDA 
that demonstrates that the biosimilar product complies with the standards in order to 
allow the FDA to determine the interchangeability of a biosimilar product. [224] 
The FDA´ biosimilar products guidance Q&A document specifies the requirements 
and further explains the term interchangeability. [215] According to the information 
provided, the applicant must demonstrate product biosimilarity and, in addition, 
demonstrate that the proposed interchangeable biosimilar product “…can be 
expected to produce the same clinical result as the reference product in any given 
patient…” and further, it is to demonstrate that “…the risk in terms of safety or 
diminished efficacy of alternating or switching between the use of the biological 
product and the reference product is not greater than the risk of using the reference 
product without such alternation or switch…” if the interchangeable product is 
administered multiple times to an individual. [215] 
Once a biosimilar product has received interchangeability status, it may 
automatically be substituted for the original biological innovator product by the 
retailing pharmacist, assuming that the applicable US state provision has enforced 
the US federal law on biosimilar automatic substitution. [223]  [225] Automatic 
substitution refers to the practice whereby a pharmacist is obliged to dispense one 
medicine instead of another equivalent and interchangeable medicine due to 
national or local requirements. Following sample demonstrates different 
requirements to the automatic substitution in the different US-states. In one state, 
the physician can deny automatic substitution by adding information to the 
prescription, e.g., in California the information “brand medically necessary” or 
“dispense as written”. Alternatively, in Arizona the physician must be notified about a 
substitution. In other states the pharmacy just switches the original biological 
product against the interchangeable biosimilar product without informing the 
physician e.g., in Florida provided the biosimilar product has been determined 
interchangeable by the FDA. [226] The differences in the approach on automatic 
substitution requirements is justified by various factors like traceability and 
identification issues of the substitutes, pharmacovigilance hurdles, safety / efficacy 
aspects (e.g., Immunogenicity concerns) or patients-associations. 
Unlike the US regulations, the possibility of interchangeability is not reviewed during 
the approval review process with the European regulatory authority (EMA) and the 
topic is also not discussed by the EMA due to the lack of authority regarding this 
question. The EMA states in their procedural advice document for biosimilar 
                                               
 [224] 
42 USC §262(k)(2)(B), April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-
section262&num=0&edition=prelim 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [223] 
42 USC §262(i)(3), April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-
section262&num=0&edition=prelim 
 [225] 
US state legislation on biosimilars substitution; Generics and Biosimilars Initiative Journal (GaBI Journal), 
2013; 2(3):155-6; DOI: 10.5639/gabij.2013.0203.040; http://gabi-journal.net/us-state-legislation-on-
biosimilars-substitution.html 
 
[226] 
State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars, September 
2016; http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-
substitution-of-biosimilars.aspx 
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products, those decisions regarding product interchangeability and substitution are 
in the responsibility of the national competent authorities. [201] Thus, the criteria and 
decision on product interchangeability and automatic substitution rest with the EU-
member states. While some EU-member states (e.g., France) allow a restricted 
biosimilar substitution, many EU-member states (e.g., Norway, Spain) have 
introduced laws against it. [227] The decentralized approach on interchangeability and 
automatic substitution is justified by various factors like traceability and identification 
issues of the substitutes, pharmacovigilance hurdles and safety / efficacy aspects 
(e.g., Immunogenicity concerns) and is based on the missing EU legislation 
addressing the interchangeability topic. 
Exclusivity and data protection periods 
A similar biological product application may be submitted after the exclusivity 
periods established by the BPCI Act and explained in the “Background” information 
of the FDA´ biosimilar products guidance Q&A document. [215] According to that 
guidance information, there is a 12-year exclusivity period for the reference product 
starting from the date of first licensure. During this period the “…approval of a 351(k) 
application referencing that product may not be made effective..:” [161] 
Further, a 4-year exclusivity period is defined from “…the date of first licensure of 
the reference product, during which a 351(k) application referencing that product 
may not be submitted…” [161] 
Also, for the first biosimilar product determined to be interchangeable with the 
reference product for any condition of use, an exclusivity period is established by the 
BPCI Act. [215] During this period “…a second or subsequent biological product may 
not be determined interchangeable with that reference product…” and typically, the 
duration of this period takes one year. [228] 
Within the EEA, a similar biological product application may be submitted through 
the Centralized Procedure after the applicable period of data exclusivity and 
protection period ends which depends on the approval procedure that was used for 
the reference product. The EMA procedural advice guidance document describes a 
10-year or eight year protection period for a centrally authorized reference product 
and a “…6/10-year protection period, depending on the Member State which has 
granted the marketing authorisation or 8-year protection period,…” for a nationally 
                                               
 [201] EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [227] 
Legislations on biosimilar interchangeability in the US and EU – developments far from visibility, June 2015; 
http://www.gabionline.net/Sponsored-Articles/Legislations-on-biosimilar-interchangeability-in-the-US-and-
EU-developments-far-from-visibility 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [161] 
42 USC §262(k)(7)(A), 42 USC §262(k)(7)(B); October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [228] 
42 USC 262(k)(6), July 2016; 
http://uscode.house.gov/view.xhtml?req=(title:42%20section:262%20edition:prelim)%20OR%20(granuleid:U
SC-prelim-title42-section262)&f=treesort&edition=prelim&num=0&jumpTo=true 
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authorized reference product. [201] If the reference product is also authorized in 
member states with a 10 year protection period, then this period must have been 
expired before the biosimilar product application can be processed via the 
Centralized Procedure. [201] In the case, the marketing authorization holder applies 
and receives authorization for new indications during the first eight years of those 10 
years and these indications show a significant clinical benefit in comparison with 
existing therapies, then the 10-year protection period is extended to 11 years 
maximum. Similarly to the USA, the protection period starts with the date of 
notification of the marketing authorization decision to the applicant. Since the 
concept of interchangeability is not defined in the EU regulations, no exclusivity 
period for interchangeable biosimilar products is provided in the EU. 
While the protection period is typically 10 years in the EU with a maximum of 11 
years, the product exclusivity period for the referenced innovator is 12 years in the 
USA. After expiry of the relevant periods a biosimilar product can be placed on the 
market when approval has been granted.  
Drug Master File 
In both, the USA and the EEA, the Drug Master File (DMF) document is not 
accepted for the authorization application of a biosimilar product. [131]  [159]. 
Naming and labeling  
The international nonproprietary name (INN) for an active substance must be 
requested from the World Health Organization (WHO) by the innovator of the active 
substance or the marketing authorization applicant. The WHO, then designates a 
generally accessible and non-protected INN. National and / or international 
legislation requires the use of INNs in many uses like labeling, advertising and 
promotion, literature, etc. The INN is intended to clearly identify active substances 
with uniform designations in order to promote drug safety and pharmacovigilance 
systems at an international level. [229] The US naming system, called United States 
Adopted Names (USAN) is the American counterpart of the INN system and almost 
always adopts the INN so that both systems very similar. Due to the general product 
complexity of and structural differences, even in highly similar biotechnology-derived 
products, the INN system may be challenging for biosimilar and interchangeable 
products.  
42 USC §262(a)(1)(B)(i) requires a proper name as defined in 21 CFR 600.3(k) for 
biological products. The use of the INN system and the USAN system seems 
inappropriate for biosimilar products for the US- market and its specific requirements 
                                               
 [201] EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [131] 
Guideline on Active Substance Master File Procedure, CHMP/QWP/227/02 Rev 3/Corr; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129994.pdf 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry; April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 [229] 
Guidance on INN; http://www.who.int/medicines/services/inn/innguidance/en/ 
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as it contains some disadvantages, such as lack of consistency, predictability, and 
uniqueness (e.g., the name “interferon beta-1α” applies to several products in the 
US- market). [230] In order to ensure a well-functioning pharmacovigilance and 
tracking system, a clear identification of all biological products and differentiation 
between interchangeable and non-interchangeable biosimilar products is necessary 
to avoid unintentional substitution; therefore shared nonproprietary names are not 
appropriate. [230] 
To improve the naming situation, the FDA distributed a draft guidance document for 
the nonproprietary naming of biological products in August 2015, which was 
finalized in early 2017. [213] In that document, the FDA proposes the use of a FDA 
designated nonproprietary name. This FDA designated name is a so called proper 
name consisting of a shared core name (which again is the component shared 
among a biological innovator product and the related biological and biosimilar or 
interchangeable products as part of the proper names of those products) plus a 
FDA-designed product unique suffix. This suffix consists of four letters which enable 
to distinguish between biological innovator products, biosimilar products and related 
biological products (e.g., innovator product name replicamab-cznm; biosimilar 
product name replicamab-hixf) licensed under the PHS Act. [213] For biological 
innovator products, the FDA adopted core name for the active substance which was 
designated by the USAN Council is intended to be used when available. For 
biosimilar, interchangeable and related biological products, the core name will be 
the same as the core name identified in the proper name of the applicable 
previously FDA licensed biological innovator product. The positioning of the identifier 
as a suffix shall ease grouping in electronic databases and promote identification 
and localization of biological products with the same core name. 
Initially for interchangeable biosimilar products, the FDA was gathering public input 
on two options: [1] the proper name should also include an individual suffix; or [2] 
the proper name should share the same suffix as its reference product (e.g., the 
proper name of the reference product as well as the interchangeable biosimilar 
product could be replicamab-cznm). Now, in the finalized guidance document, the 
FDA considers applying a similar naming policy as biosimilar products have and will 
use the same approach of that of a core name and a suffix included in the proper 
name, but the FDA is still searching for the appropriate suffix format for 
interchangeable products. [213] 
With regard to the prescription information, on the FDA website, the FDA informs 
healthcare professionals about prescription requirements for interchangeable and 
non-interchangeable biosimilar products. According to that information, there is no 
difference in prescribing biosimilar and / or interchangeable products and any other 
medicinal products, which means, that either the proprietary name or the 
nonproprietary name may be documented on the prescription. It is Important to note 
that due to the fact that a biosimilar might be approved for fewer indications and 
conditions of use than its reference product is licensed, the healthcare professional 
                                               
 [230] “Nomenclature of New Biosimilars Will Be Highly Controversial”, Ronald A. Rader; June 2011; 
https://www.ftc.gov/system/files/documents/public_comments/2014/02/00013-88587.pdf 
 [213] 
Guidance for Industry Nonproprietary Naming of Biological Products, Guidance for Industry; January 2017; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.
pdf 
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must always check the product labeling (prescribing information) to avoid 
prescription errors. [231] In principle, interchangeable biosimilar products may be 
automatically substituted at the pharmacy without the co-determination of a 
healthcare professional, if not otherwise regulated by state law.  
In order to assist applicants in addressing labeling specifics of biosimilar products 
for submission purpose, the FDA has issued recommendations to industry in a 
labeling guidance document which provides information to the content of the 
prescribing information (package insert). The guidance document recommends, 
among other things, a “Biosimilarity Statement” in the “Highlights of Prescribing 
Information” section which provides information to the relationship of the biosimilar 
product to its reference product. [217] However, the labeling of interchangeable 
biological products is not considered in this guidance.  
Within the EEA, according to Article 1(21) of Directive 2001/83/EC medicinal 
products to be authorized in the EEA shall provide a common name. Ideally the 
name shall be the INN, but if such does not exist, the usual common name may be 
used. For biosimilar products, the applicant may either apply the INN used for the 
reference biological product or may request a new INN from the WHO if no suitable 
INN is available. [201] 
Similar to the FDA and upon requests of international drug regulatory authorities in 
the past years, the WHO has realized that the naming situation for biological 
products needs to be improved to ensure clear product identification and traceability. 
Thus, the WHO started examining different solutions in 2012 and issued a five page 
final document for INN proposal of biological products in October 2015. [203] The INN 
proposal document envisages a biological qualifier (BQ) code that is specifically 
assigned by the WHO to all biotechnology-derived substances having or eligible to 
have INNs. The BQ is intended to improve the prescription and dispensing of 
biological substances to aid in pharmacovigilance and to support the overall transfer 
of prescriptions. It is planned to apply the mechanism retrospectively. The biological 
qualifier is a four letter random alphabetic code that will be added as unique 
identification code to the INN. It is used in conjunction with the INN but will remain 
independent from the INN. [203] The BQ scheme may be used voluntarily by any 
regulatory authority and would be recognized worldwide. The INN proposal 
document does not explain if and how the BQ is eligible to distinguish between 
biological and biosimilar products and between substitutable (interchangeable) and 
non-substitutable (non-interchangeable) biosimilar products in order to avoid 
unintentional substitution. 
                                               
 [231] 
Information for Healthcare Professionals (Biosimilars), August 2015; 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalAp
plications/TherapeuticBiologicApplications/Biosimilars/ucm241719.htm 
 
[217] 
Labeling for Biosimilar Products, Draft guidance, March 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM493439.
pdf 
 [201] 
EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf 
 [203] 
Biological Qualifier -An INN Proposal; INN Working Doc. 14.342, Rev. Final October 2015; 
http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf?ua=1 
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With regard to the prescription of biological innovator products, the requirement 
defined in Article 1(21) of Directive 2001/83/EC which is the INN requirement, is 
slightly modified by the Directive 2012/52/EU in order to implement the requirements 
of Directive 2011/24/EU. [232] The modification is described in the Annex of Directive 
2012/52/EU and defines that a prescribed biological product shall be identified, 
amongst other information, with the brand name instead of the INN on the medical 
prescription. [233] The identification by brand name is not required for other medicinal 
products. However, no information related to biosimilar product is provided in the 
mentioned Directive. There is no EMA guidance document comparable to the FDA´s 
labeling guidance for biosimilar products available in the EU. 
While the INN system works well for classic generic drugs (e.g., chemically-
synthesized substances), it does not work well for complex biological, biosimilar 
products and interchangeable products due to lacking a clear identification and 
traceability which may negatively impact drug safety and pharmacovigilance. [230] 
However, to this date, biosimilar products are marketed under the same INN as the 
innovator biological product in the EEA. 
Container Closure System  
According to the FDA biosimilar products guidance Q&A document, the FDA may 
accept slight deviations in the design of a delivery device, (e.g., the use of an auto-
injector device instead of a vial), or container closure system between the compared 
products. [215] This is accepted by the FDA when the following conditions are met: [1] 
it must be demonstrated that the varying delivery device or container closure system 
is compatible with the final product formulation, and this may include performance 
testing and a human factors study and other studies such as extractable/leachable 
studies and stability studies; [2] the design difference may not result in clinically 
meaningful difference with respect to the products safety, purity, and potency; and 
[3] the design difference may not result in a different route of administration or 
dosage form or condition of use for which the reference product is not approved. [215] 
The FDA also accepts a different formulation of the biosimiliar product than the 
reference product owns. Here, the applicant must demonstrate that the proposed 
biosimilar product is highly similar to the reference product and no clinically 
meaningful differences with respect to the products safety, purity, and potency exist. 
If the proposed product is a proposed interchangeable product, the FDA regulations 
are stricter. In such cases, the FDA also reviews if the differences between the 
biosimilar and the reference product influence any critical design attributes, product 
                                               
 [232] Directive 2011/24/EU, Article 11(2); L88/45, Official Journal of the European Union, 04.04.2011 http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32011L0024&from=DE 
 [233] 
Commission Implementing Directive 2012/52/EU, Annex of Directive 2012/52/EU, L 356/68, Official Journal 
of the European Union, 22.12.2012; 
http://ec.europa.eu/health/cross_border_care/docs/impl_directive_presciptions_2012_en.pdf 
 [230] 
“Nomenclature of New Biosimilars Will Be Highly Controversial”, Ronald A. Rader; June 2011; 
https://www.ftc.gov/system/files/documents/public_comments/2014/02/00013-88587.pdf 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
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performance, etc., or require additional use instructions. Thus, the FDA may require 
additional performance data for the delivery device or container closure system. [215] 
The FDA guidance document about immunogenicity assessment for protein 
products should be considered specifically for monoclonal antibodies and other 
complex protein therapeutic products. [60] It recommends maintaining detailed raw 
material data of the container closure system and further, to perform an extensive 
extractables and leachables laboratory assessment in order to evaluate the 
attributes of the system and possible interactions that could lead to degradation of 
the product structures. [60] It should be noted that the tests described in the United 
States Pharmacopeia “Elastomeric Closures for Injections” do not address the 
specifics of storage containers used for products like monoclonal antibodies under 
real-time conditions. Therefore, additional testing for leachables under stress- and 
under real time storage conditions should be performed for each product and its 
storage container. [60] 
Similar to the accommodation in the FDA Q&A guidance document the EMA´s 
similar products- quality guidance document also provides the possibility of using a 
different container or closure system than the reference product uses; provided that 
its potential impact on the biosimilar´s product safety and efficacy is appropriately 
justified. [199] In contrast to the FDA guidance document the EMA document does 
not further detail the topic or requires any additional data. For any used active 
substance formulation of the biosimilar product, the applicant shall demonstrate their 
eligibility regarding stability, compatibility, activity, strength and integrity. The 
applicant shall consider the common requirements that apply for testing a 
formulation.  
Pediatric assessment 
US legislation defines that a biosimilar product not holding the interchangeable 
status is considered as a “new active ingredient” in terms of the Pediatric Research 
Equity Act (PREA). [234] Therefore, a pediatric assessment is required unless waived 
or deferred. [235] Biosimilar products determined to be interchangeable with its 
reference product are excluded from the pediatric assessment requirement, as such 
products are not considered to have a “new active ingredient”. However, PREA 
requirements must be fulfilled when an applicant applies for licensure without 
                                               
 [215] Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
 
[199] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: quality issues (revision 1); EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf 
 [234] 
21 USC §355c (a)(1); 21 USC §355c (l)(1),(2), April 2015; 
http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355c&num=0&edition=prelim 
 [235] 
21 USC §355c(a)(3),(4), April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-
section355c&num=0&edition=prelim 
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providing interchangeability status even if it intends to amplify the licensure at a later 
date with the interchangeability status. [215] 
According to the current EU pediatric legislation Regulation (EC) No 1901/2006, the 
requirement to submit a pediatric investigation plan does not apply, to biosimilar 
products because the approval basis for such products is the demonstration of 
comparability. [236] This is in contrast to the US legislation requiring a pediatric 
assessment for biosimilar products without interchangeability status, and this is 
despite the fact that biosimilar products in EU are considered as “new active 
substance”. [237] 
Pharmacovigilance and post-approval safety monitoring considerations  
The FDA considers a robust post-approval safety monitoring program and risk 
evaluation and mitigation strategies as defined under the Federal Food, Drug, and 
Cosmetic Act as crucial to ensure the safety and efficacy of biotechnology-derived 
products. For this purpose, it is important to monitor the safety or effectiveness 
related to the reference product and its product class, the proposed biosimilar 
product itself and its specific indications and patient groups as well as any other 
international clinical use of the proposed biosimilar product. The safety monitoring 
program should be designed in a way that a differentiation between adverse events 
of reference and proposed product is possible, including any side effects not 
previously observed with the reference product. [160] 
Sponsors are encouraged to discuss their intended post-approval safety monitoring 
program with the responsible FDA review division in order to satisfy product specific 
aspects. Information on the intended pharmacovigilance activities including risk 
management relevant information should be properly described and detailed, and 
must be provided together with risk management information to the FDA with the 
application file. Sponsors should also consider in their planning the possibility of 
additional post-approval surveillance, clinical studies or – trials, required to further 
assess rare safety risks such as serious immune reactions as it might be possible 
that rare safety risks may not be observed during the pre-approval clinical program. 
[60] 
Similarly to the FDA, the EMA also focuses on post-approval safety monitoring 
programs and continued benefit-risk assessment to ensure the safety and efficacy of 
biotechnology-derived products. Like the US legislation, a pharmacovigilance 
                                               
 [215] Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [236] 
Regulation (EC) No 1901/2006, "Wheras" section (11); L 378/1, Official Journal of the European Union, 
27.12.2006; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf 
 [237] 
VOLUME 2A Procedures for marketing authorisation Chapter 1 Marketing Authorisation, Annex I, Definition 
of a new active Substance; Revision 5, July 2015; 
http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-2/a/vol2a_chap1_201507.pdf 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
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system and a product specific risk management plan is required in accordance with 
the current EU legislation and guidelines on good pharmacovigilance practices. The 
risk management plan should consider and address identified and potential risks, 
e.g., immunogenicity, related to the use of the reference product within the post-
approval phase and should also take into account any specific safety monitoring 
requirements required for the reference product or product class. The risk 
management plan, which details the intended risk management system of the 
proposed biosimilar product, must be provided together with information on all 
intended pharmacovigilance activities to the EMA with the application file. More 
information on the risk management plan can be found in the EMA Q&A to risk 
management guidance document. [238] 
The safety monitoring program should be designed in a way that a clear 
identification by brand name and batch number of the pertained product and 
regarding its manufacturing is possible in case of any suspected adverse reactions. 
Of significant importance is the comparison of the type, severity and frequency of 
the known adverse reactions of the biosimilar product and the reference product. 
Like the US, applicants should consider the possibility of additionally required post-
approval surveillance; clinical studies or - trials such as post-authorization safety 
studies (PASS) or post-authorization efficacy studies (PAES), required to further 
assess rare safety risks or efficacy and should take into account participation in 
running pharmaco-epidemiological studies conducted for the reference product. [57] 
Monoclonal antibodies (EEA) 
The basic approach for monoclonal antibodies is similar to that of biosimilar 
products that are not mAbs; namely, to amend routine pharmacovigilance activities 
with more proactive activities depending on the product. Thus, the applicant should 
provide information addressing his considerations on how to study the safety of the 
product in future with the application file. These considerations may address, for 
example: [1] (long term-) safety data in indications / conditions of use that have been 
extrapolated; [2] activities to gain additional immunogenicity data; and [3] monitoring 
of rare and serious adverse events documented and anticipated for the reference 
product. [200] Furthermore, it is recommended to monitor the developments 
regarding the automatic substitution of potentially interchangeable biosimilar mAb 
products at a national level. Such considerations should be part of the risk 
management plan.  
Quantity and type of scientific guidance documents for biosimilar products 
Currently, there are seven FDA guidance documents for biosimilar products which 
were first released as final or draft in 2014 and 2015. Two guidance documents 
address procedural issues; three of them address [1] scientific / overall regulatory 
                                               
 [238] Questions and answers on the risk management plan (RMP) summary, EMA/156738/2014, 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/05/WC500166101.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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issues, [2] quality considerations and [3] clinical pharmacological data. There is 
currently no product-class specific biosimilar product guidance available; for 
example, there is no mAb specific guidance. Two FDA guidance documents answer 
specific questions to biosimilar products (Q&A documents).  
In contrast to the FDA, the EMA published the first biosimilar product scientific 
guidance documents in 2005/2006 and as of today there are several overall and 
different product-class specific documents (e.g., for somatropin, erythropoietins, or 
recombinant granulocyte-colony stimulating factor, etc.) developed and published. 
[239] 
Three EMA scientific guidance documents for biosimilar products are available 
which address: [1] overall issues; [2] non-clinical and clinical requirements; and [3] 
quality considerations. All three documents are very similar in content to the FDA 
overall guidance documents for biosimilar products. Only one EMA product-specific 
guidance document for biosimilar mAbs is available which addresses non-clinical 
safety -and clinical safety issues. However, one further document is also relevant for 
biosimilar products and this addresses the immunogenicity assessment of mAbs. In 
contrast to the FDA, the EMA has not developed a guidance document yet, which 
specifically addresses the topic of clinical pharmacological data for biosimilar 
products.  
 Overall summary of overall safety relevant regulatory 14.2
requirements 
The following text summarizes the most significant safety relevant items mentioned 
above and outlines the identified differences between regulatory recommendations 
and legal provisions of both regions.  
The overall definition of biological medicinal products is very similar. Both regions 
refer to the biological and living source of such products, and recognize the resulting 
product complexity and structure. In consequence, the thorough structural and 
functional characterization requires a higher testing effort than for chemically-
synthesized products. However, the USA and the EU recognize that the 
characterization of biological medicinal products usually stays incomplete. 
In the EEA, monoclonal antibody -and recombinant protein products are considered 
as biological medicinal products; however, these types of biological products are 
defined as “specified biological products” in the US-regulations. [27] In the USA, 
certain requirements are not applicable for “specified biological products” and these 
requirements can be waived in the Biologics License Application dossier. [219] 
In the EEA, the Centralized Procedure is the applicable authorization pathway for 
biotechnology-derived products defined in the Annex of Regulation (EC) No 
                                               
 
[239] 
Multidisciplinary: biosimilar, December 2016; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=
WC0b01ac058002958c 
 [27] 
21 CFR §601.2(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol7/pdf/CFR-2014-title21-
vol7-part601.pdf 
 [219] 
21 CFR § 601.2(c)(1), April 2016; https://www.gpo.gov/fdsys/pkg/CFR-2016-title21-vol7/pdf/CFR-2016-
title21-vol7.pdf 
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726/2004. In the USA, the applicable approval pathway for most biotechnology-
derived products is the Biologics License Application. Both approval pathways 
require a comprehensive and full drug dossier including clinical data that must be 
submitted to the regulatory authority.  
In contrast to the EEA, the generation of clinical data in the USA occurs in the 
centralized regulatory framework of an investigational new drug application and 
therefore is an inherent part of the application and review process with the FDA. [113] 
Thus, the FDA is involved in and familiar with the drug product at a very early stage 
of drug development. This differs from the process in the EEA where the approval 
process starts at a later stage with the submission of the dossier. This is because in 
the EU the generation of clinical data is neither a part of the application process, nor 
is there a centralized regulatory approach for clinical studies applied. Until the date 
of application of the clinical trials Regulation EU No 536/2014 clinical trials are 
decentralized regulated at a national level under Directive 2001/20/EC. [87] However, 
clinical trial data are reviewed by the EMA as well during the standard application 
review.  
Both, the EEA and USA refer to the similarity to a reference product when defining 
the term “biosimilar”. While in the EEA, similarity to the reference product in quality-, 
biological-, safety- and efficacy related matters shall be established, the USA 
regulations require establishing a high similarity to the reference product in safety, 
purity and potency related matters. Furthermore, in the USA, the meaning of “highly 
similar” is explained with the absence of “clinically meaningful differences”. [30]  [32] In 
this aspect the USA definition for the term “biosimilar” is more detailed and more 
stringent than that of the EEA.  
The approval procedures for biosimilar products are only slightly different in the 
compared regions. Like for biological products, the Centralized Procedure is the 
mandatory approval pathway also for most of biosimilar products in the EEA. In the 
USA regulation, the approval pathway under 42 USC § 262(a) of the Biologics 
License Application was amended with subsection (k) which provides an 
abbreviated approval procedure for biosimilar products. Regarding the abbreviated 
dossier content (e.g., required testing and data), theoretically it could be less in 
volume with the approval procedure provided under 42 USC § 262(k); however, the 
FDA will determine the dossier content on a case-by-case basis. It should be noted 
that due to the small quantity of biosimilar products approved so far and 
corresponding minimal experience, it is not possible to provide more detailed 
information regarding the content and volume of a biosimilar product application 
dossier.  
                                               
 [113] Code of Federal Regulations (Annual Edition 2014), 21 CFR 312.2(a); 21 CFR 312.2(b); 
http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5-part312.pdf 
 [87] 
Clinical trials - Regulation EU No 536/2014; General information section, European Commission, 
Directorate-General for Health and Food Safety, December 2016; https://ec.europa.eu/health/human-
use/clinical-trials/regulation_en 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 
[32] 
42 USC §262 (i)(1), 42 USC §262 (i)(2)(A),(B); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:262%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section262%29&f=treesort&edition=prelim&num=0&jumpTo=true 
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In the EEA, an abridged application procedure established with Article 10(4) of 
Directive 2001/83/EC for biosimilar products is also available. [126] However, within 
the EEA, biosimilar products such as recombinant monoclonal antibodies require a 
full application dossier in accordance with Article 8(3) of Directive 2001/83/EC. [84] In 
summary, an abbreviated procedure for biosimilar products is available in both 
regions. If, and how the procedure can be applied, depends on the proposed 
biosimilar products and its comparability to the reference product and need to be 
determined on a case-by-case basis.  
There are no significant differences between the regions regarding the requirements 
of the reference product and to the use of a non-EEA / non-US licensed comparator 
product. Both, the EMA and the FDA allow the use of a non-EEA / non-US licensed 
comparator product to conduct certain non-clinical studies, but encourage the 
applicant to discuss such an approach upfront with them. Furthermore, the non-EEA 
/ non-US comparator product must be authorized by a regulatory authority applying 
a similar regulatory and scientific level as the EMA and FDA applies. When using a 
non-EEA / non-US comparator, reliable bridging data involving all three products 
(proposed biosimilar product, EEA- or US- reference product, and non-EEA or non-
US comparator product) must be provided. The similar approach to the use of a 
non-EEA / non-US comparator product has the advantage that the development 
program for the proposed biosimilar product may be used for both, the EU 
authorization and the US filing; however, such bridging data may adulterate safety 
relevant data (e.g., thru potential bias). Specifically the FDA Q&A guidance 
document discusses the topic of using a third-party comparator product and 
providing more detailed information than the relevant EMA guidance documents. [215] 
In contrast to the EU legislation, the US-American federal law provides the 
possibility to provide a biosimilar product with an interchangeable status which 
allows an approved interchangeable biosimilar product to get substituted at the 
pharmacy level. [223] However, it remains at state level to enforce the federal law on 
automatic substitution in the individual US states. The US states may add specific 
requirements to the US law on automatic substitution when enforcing the US law at 
state level. Further, there is nothing to stop any state from writing a state law that 
contradicts US law. Determining a biosimilar product as interchangeable within in 
EEA region is at a national level. Further, the EMA has neither the authority to 
determine a biosimilar product to be interchangeable / substitutable, nor are there 
appropriate regulation / legislation in place at the Union level. The lack of a 
centralized and EU-regulated determination on interchangeability and automatic 
substitution leads to individual national solutions which negatively impact 
                                               
 [126] Directive 2001/83/EC of 6 November 2001, Article 10(4); OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [84] 
Directive 2001/83/EC of 6 November 2001; Article 8; Article 8(i); OJ L 311, 28.11.2001, p. 67, Consolidated 
version 16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [223] 
42 USC §262(i)(3), April 2015; http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-
section262&num=0&edition=prelim 
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pharmacovigilance activities through the lack of proper and clear biosimilar product 
identification and traceability / tracking systems.  
Regarding the prescriptions information for biosimilar products and interchangeable 
biosimilar products, neither the EMA nor the FDA provides a final solution here. 
Directive 2012/52/EU requires the brand name instead of INN for biological 
products, however no information to biosimilar products is provided. In the US, no 
difference between medicinal products and biosimilar products is made regarding to 
the prescription information. Either the proprietary name or nonproprietary name 
shall be provided on the prescription. To avoid prescription errors, to improve 
traceability, and to facilitate pharmacovigilance activities information to biosimilar 
products and interchangeability should be described properly in prescriptions.  
While the exclusivity period in the US-market is 12 years, it is typically 10 years with 
the EEA with the Centralized Procedure. [161]  [201] This allows biosimilar products to 
be available for patients two years earlier in the EEA than in the US; however, there 
is also two years less market and pharmacovigilance experience with the reference 
product.  
The naming and labeling of biosimilar products, especially for interchangeable 
products, is still an open item in both regions that need to be addressed. While the 
FDA is already working on the remaining issues regarding interchangeable 
products; the WHO just published a solution on the naming of biological products. 
And, while the FDA has issued a guidance document about the labeling of biosimilar 
products, a similar guidance document is not available in the EEA. 
The use of a different container- / closure- or delivery device system than the 
reference product owns is allowed for biosimilar products in the EEA if the impacts 
to the product are properly justified. The EMA guidance document does not provide 
any further information, especially to additional testing’s (e.g., leachable profile). In 
contrast to the EMA, the FDA accepts only minor deviations and these only if certain 
conditions are met. For interchangeable products the FDA regulations are even 
more thorough. The FDA guidance document provides detailed information on the 
topic including additional testing and informs about the non-applicability of the US 
Pharmacopeia “Elastomeric Closures for Injections”. With adequate testing, a 
different formulation than the reference product uses can be used for the biosimilar 
product in both regions.  
Unlike the requirements in the FDA regulation, biosimilar products are waived from 
pediatric assessment requirement in the EEA.  
Basically, there are no significant differences in pharmacovigilance system related 
matters and regulatory recommendations between the two regions; however 
compared to the FDA counterpartying guidance document, the EMA provides very 
detailed information on what needs to be addressed in the RMP regarding 
                                               
 [161] 42 USC §262(k)(7)(A), 42 USC §262(k)(7)(B); October 2015; 
http://uscode.house.gov/view.xhtml?path=/prelim@title42/chapter6A/subchapter2/partF/subpart1&edition=pr
elim 
 [201] 
EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products 
applications; EMA/940451/2011; 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/W
C500125166.pdf
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immunogenicity. [61] For mAbs the relevant EMA guidance document recommends 
monitoring the developments regarding the substitution of potentially 
interchangeable biosimilar mAb products at a national level and recommends 
addressing this in the risk management plan as well. The FDA encourages the 
applicants to discuss the intended pharmacovigilance system with the agency.  
Overall, it is of note, that the amount and scope of regulation is very similar as the 
same topics are covered by the relevant guidance documents. There exist some 
differences in the overall safety relevant regulatory requirements between the two 
regulatory regions although most items are addressed similarly. The unresolved 
issues of biosimilar product identification, traceability, labeling and naming, and the 
prescription information of interchangeable biosimilar products may impact the 
safety of such biosimilar products in the EU and the USA. Different regulatory 
requirements regarding the reference container closure system and the extent of 
accepted deviations and different testing requirements (e.g., leachables testing) in 
the two regions may result in different product safety. The use of a non-EU / non-US 
comparator product may impact the biosimilar product safety in both regions since 
the bridging data that enable the comparison of all three products involved, may 
pose a risk of potential bias which could produce incorrect safety data.  
Regarding the quantity and type of scientific guidance documents for biosimilar 
products published by the FDA and the EMA, it is observed, that the FDA has 
impacted development in this sector by delaying the provision of scientific guidance 
documents. However, the FDA guidance documents that are available now are very 
similar to the EMA guidance documents in overall content and type. Nevertheless, 
both the EMA and the FDA should continue developing overall and product-class 
specific scientific documents to topics like: [1] quality considerations for mAbs; [2] 
clinical trials and PASS with biosimilar products; [3] extrapolation of safety, efficacy 
and immunogenicity data across indications; [4] comparability of biosimilar products 
after a change in the manufacturing process, etc. 
 Analysis of the non-clinical safety considerations  14.3
USA 
The FDA scientific considerations guidance document addresses non-clinical safety 
considerations such as non-clinical testing strategies, general approaches and 
clinical safety considerations. [160] The FDA quality considerations guidance 
document also addresses non-clinical safety requirements and testing but does not 
address clinical safety requirements. [159] 
                                               
 [61] Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry; April 2015; 
 - Page 102 of 215 - 
ANALYSIS AND COMPARISON OF GUIDANCE DOCUMENTS … 
 
The FDA uses the “Totality-of-the-Evidence” approach to assess the demonstration 
of biosimilarity. This approach is described in great detail in the scientific guidance 
documents. Also described in detail is the development of data necessary to 
facilitate a demonstration of biosimilarity with a focus on the structural 
characterization of the product. The guidance documents also provide information 
on quality considerations for non-clinical tests, especially to comparative analytical 
studies by providing information to physicochemical characterization, functional 
activities, receptor binding and immunochemical properties, impurities, tests on the 
finished drug product and stability testing. [159] 
The FDA recommends a stepwise approach to developing the data needed to 
demonstrate biosimilarity. The goal is to establish comparable data that demonstrate 
that there are no clinically meaningful differences between the proposed biosimilar 
product and the reference product regarding safety, purity, and potency. Thus, the 
sponsor should evaluate the extent of residual uncertainties regarding biosimilarity 
after each step and should address these uncertainties in the next step. [160] The 
stepwise testing approach facilitates a target-oriented approach to non-clinical and 
clinical studies.  
The FDA reserves the right to determine the type, amount and necessity of non-
clinical and clinical testing, including immunogenicity data on a case by case basis 
necessary to sufficiently demonstrate biosimilarity. The FDA also encourages the 
sponsors to discuss their planned biosimilar development program early with the 
FDA.  
Extensive and robust structural and functional characterization of the products to be 
compared is the first step of the approach. For this comprehensive product 
characterization, suitable in-vivo and in-vitro studies according to the latest 
technology should be used to qualitatively and quantitatively detect differences in 
characteristics of the compared products. [160] It should be demonstrated within the 
structural and functional characterization that the expression construct of the 
comparators are highly similar in encoding with basically the same primary amino 
acid sequence except for minor modifications (e.g., N- or C-terminal truncations). 
Additionally, the [1] primary- (e.g., amino sequence), [2] secondary-, tertiary-, and 
quaternary structures; [3] post-translational modifications (e.g., glycosylation); [4] 
biological activities; [5] any other variations; and [6] intentional chemical 
modifications (e.g., pegylation) of the comparative products should be physico-
chemically evaluated and compared. [160] The physicochemical and biological 
characterization of the two compared products should be performed with an 
appropriate number of multiple lots to see the lot-by-lot variability. Both, lots 
intended for clinical study purpose and lots of the proposed product intended to be 
                                                                                                                                     
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry; April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry; April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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marketed should be used for comparability demonstration with the reference 
product. [160] The analysis should also include evaluation of excipients, purity, 
impurities (e.g., process and product related), and stability of the final formulation of 
the proposed product and the reference product. If one of the compared products 
cannot be characterized in a sufficient manner, a change of the approval pathway 
should be discussed with the agency.  
The analytical structural and functional comparison should be followed by steps [2] 
animal data investigating toxicity; [3] comparative clinical human PK- and PD 
studies; [4] clinical immunogenicity; and finally in case of any residual uncertainties 
regarding biosimilarity [5] targeted comparative clinical studies to gather additional 
clinical data in safety and effectiveness. [160] 
Outcomes from animal toxicity studies are more suitable to support a comparative 
safety evaluation than to demonstrate biosimilarity. The safety of the proposed 
product may be supported with comparative animal toxicity testing data (including 
animal pathology, histopathology, PD / PK- and immunogenicity studies) prior to the 
initiation of human clinical studies in such cases where the outcome of the previous 
steps (structural and functional characterization) was not sufficiently meaningful and 
where safety concerns of the proposed biosimilar product remain. [160] Limited animal 
toxicity data (if a relevant animal model is available) may be adequate to facilitate 
initial clinical use assuming comparative structural and functional data have 
adequately demonstrated analytical similarity between the two products [160]. The 
FDA scientific considerations guidance document refers to the ICH guideline 
document for industry S6 (R1) regarding the design of animal toxicology studies and 
limitations of such studies. [160] Sponsors are encouraged to discuss their intended 
development plans, including any plans and justifications regarding animal toxicity 
studies at an early date with the FDA.  
Safety data generated from animal toxicity studies are not necessary when clinical 
data (e.g., from non-US- markets) are available. If a relevant animal species for the 
proposed product is not available, animal toxicity studies are not adequate to gather 
pharmacologically relevant data. [160] Instead, additional comparative in-vitro studies 
using human cells or tissues shall be performed to obtain data on potential clinical 
effects. When the data that were generated during the structural and functional 
characterization demonstrate high similarity between the two products, reference 
product and biosimilar product, then, non-clinical safety pharmacology, reproductive 
and developmental toxicity and carcinogenicity studies are not required. [160] 
With respect to the use of animal PK- and PD- measures, the scientific 
consideration guidance indicates that a comparative single-dose animal study using 
PK and PD measures could support a demonstration of biosimilarity. However, the 
use of such study will not make human PK- and PD studies unnecessary.  
Animal immunogenicity studies are not adequate to detect potential immune 
reactions to protein products in human individuals. Nevertheless, differences in 
manufacturing between the compared products may lead to varied immunogenicity 
                                               
 [160] Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry; April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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and therefore anti-protein antibody response measurements in animals could 
provide helpful information. Also, differences noticed during immunogenicity 
assessments in animals may point to potential differences in structure or function 
not captured in the previous testing but relevant to human safety. [160] 
EEA 
There are three relevant EMA guidance documents: [1] similar products guidance 
document, [2] similar products – non clinical and clinical issues guidance document, 
and [3] similar products- quality guidance document. [30]  [57]  [199] These EMA 
guidance documents address general approaches, non-clinical safety 
considerations as well as clinical safety topics, including immunogenicity.  
The product specific EMA guidance document on biosimilar mABs to non-clinical 
and clinical issues is also relevant as this document address requirements for 
biosimilar monoclonal antibodies. [200] 
Like the FDA, the EMA considers the full and complete set of comparative data in 
the assessment of the demonstration of biosimilarity. The goal of the comparability 
program is to establish similarity to the reference product concerning quality 
attributes, biological activity, safety and efficacy based on extensive and 
comparative testing data. [30] 
In developing the non-clinical comparative data needed, the EMA also recommends 
the use of a stepwise testing approach. The process begins with extensive and 
robust structural and functional testing and includes characterizing the 
physicochemical and biological product properties using the latest state of the art 
orthogonal analytical methods and testing in-vitro- and in-vivo. The comparative 
physicochemical and biological characterization of the compared products should be 
performed with an appropriate quantity of batches intended for clinical use and 
commercialization. The outcome of the physicochemical characterization should 
provide data for example to: [1] the primary and higher order structures of the tested 
product; [2] the target amino acid sequence; [3] the N- and C-terminal amino acid 
sequences and SH groups; or [4] any post-translational modifications; and as well 
as [5] any variations related to the used expression system, etc. [199] 
The outcome of the biological assessment under use of biological assays should 
provide data to the biological activity. In addition, the purity and impurity profiles of 
the compared products should be investigated.  
                                               
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry; April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[199] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: quality issues (revision 1); EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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Then, depending on the level of evidence achieved in the structural and functional 
characterization, subsequent non-clinical and clinical studies are necessary to be 
conducted. The amount of these studies may be more or less extensive. The goal of 
the in-vitro studies is to gather data that allow the analysis of the concentration – 
activity / binding relationship of the two products at the pharmacological target(s). [57] 
It should be noted that in-vitro assays are considered more suitable for non-clinical 
comparability testing than animal studies due to their higher sensitivity and 
specificity.  
After evaluation of the in-vitro study results, and depending on the extent of 
evidence these data have provided, the need for in-vivo studies in a species 
relevant animal model should be determined. If a species relevant model does not 
exist, the applicant may generate the necessary data in human studies. Typically, an 
in-vivo animal study is not necessary when data from the previous steps [1] product 
property characterization and non-clinical in vitro studies, and [2] determining the 
need for in-vivo studies, are adequate and without any identified issues. [57] 
Safety data generated from standard repeated dose toxicity studies in non-human 
primates, and toxicity studies in non-relevant species are not recommended. Non-
clinical safety pharmacology, reproductive and developmental toxicity and 
carcinogenicity studies are not necessary, and local tolerance studies are normally 
not required assuming no unknown or not well known excipients are involved with 
the intended route of administration. Generally, a flexible approach should be 
applied for safety studies. 
Immunogenicity assessment is considered an integral part of the comparability 
program. However, animal immunogenicity studies are not adequate to detect 
potential immune reactions to protein products in human individuals. Nevertheless, 
such study data may help in interpreting in-vivo animal data and thus blood samples 
should be taken and stored.  
If the outcome of the biosimilar comparability program cannot demonstrate 
biosimilarity with the reference product, the applicant should consider the alternative 
approval pathway of a full marketing authorization application.  
Non-clinical specifics for similar monoclonal antibodies (EEA) 
The guidance on non-clinical and clinical issues of monoclonal antibodies also 
recommends a stepwise approach to be applied to non-clinical testing. The extent 
and nature of non-clinical and clinical studies may vary depending on the outcome 
of the previous characterizations testing. [200] The selection of the in-vitro and in-vivo 
studies to be conducted varies from case to case, but the process should begin with 
investigating the specifics on binding or function within a comparative in-vitro testing. 
The EMA guidance document describes the testing in three steps: 
                                               
 [57] Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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1. Step 1 provides information on the assays that should be included in the in-
vitro non-clinical study; such as assays assessing immunological functions 
(e.g., product binding affinity to the intended target and receptors), induction 
of Fab- and Fc-associated effector functions. An assessment of ADCC and 
CDC is not needed when the concerned mAbs are directed against non-
membrane bound targets. [200] 
2. Step 2 provides information that shall help determining the need for in-vivo-
studies that includes considerations of any unidentified quality attributes of 
the reference product (e.g., new post-translational modification structure), 
different quantity of quality attributes between the comparators, or varying 
formulations (e.g., application of excipients typically not used for mAbs). [200] 
3. Step 3 provides the same information on in-vivo testing as the overall 
document similar products – non clinical and clinical issues guidance. If 
further in-vivo testing is necessary, a relevant animal model should be 
identified as toxicological data gathered from non-human primates are 
typically not useful.  
 Overall summary to non-clinical safety considerations 14.4
The following text summarizes the most significant safety items mentioned in the 
scientific recommendations to the non-clinical safety requirements of both the USA 
and the EU.  
In both regions, the EU and the USA, extensive comparability testing using sensitive 
equipment and according to the latest technology is necessary to characterize 
physicochemical and biological product properties in order to demonstrate 
biosimilarity of the proposed biosimilar product to the chosen reference product. In 
order to allow a structured and well comparative testing program and generation of 
comparative data, a stepwise approach is generally recommended from both 
regulatory authorities. For the evaluation of the non-clinical data, the same totality of 
comparability data approach is used which is also used to evaluate the biosimilarity 
between the compared products.  
Animal toxicity testing and animal immunogenicity studies are usually not 
recommended and considered as useful. Non-clinical safety pharmacology, 
reproductive and developmental toxicity and carcinogenicity studies are typically not 
required. However, both the USA and the EU recognize that animal immunogenicity 
data could be helpful in interpretation of animal in-vivo studies or in evaluation of 
differences in production processes.  
Overall the scope of regulation is very similar as the same topics are covered by the 
relevant guidance documents. It is noted, that the FDA scientific considerations 
guidance document provides more detailed information with respect to the totality-
of-evidence approach and structural analysis than the EMA guidance documents. 
The FDA guidance documents are also more clearly arranged than their EMA 
counterparts. Further, while detailed information on the structural product 
                                               
 [200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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characterization is provided together with other relevant information in the 
mentioned FDA scientific considerations guidance document, the EMA splits the 
information into two documents, in the similar products – quality guidance document 
and the similar products – non clinical and clinical issues guidance document. In 
contrast to the EEA, there is no product-specific FDA guidance document that 
addresses the non-clinical and clinical specifics of biosimilar monoclonal antibodies.  
 Analysis of the clinical safety requirements  14.5
Various scientific guidance documents on clinical safety requirements are available 
in the USA and the EU. 
USA 
The FDA addresses clinical safety considerations with the scientific considerations 
guidance document, the clinical pharmacology guidance document and 
immunogenicity assessment guidance document. [160]  [214]  [60] 
For clinical safety evaluation, the FDA recommends a stepwise and progressive 
approach. The first step begins with comparative human PK- and PD- measures 
along with clinical immunogenicity assessment. This is followed by additional 
comparative clinical studies, such as clinical safety; or clinical efficacy studies, when 
needed due to address residual uncertainties about biosimilarity. [214] 
Comparative clinical human pharmacology studies (PK/PD) including 
immunogenicity assessment, represent a critical part of demonstrating biosimilarity, 
and typically, the FDA expects the results of such studies to properly demonstrate 
biosimilarity. If the outcomes of the comparative human PK- / PD- studies show a 
meaningful correlation between PK- / PD-results and clinical effectiveness, 
comparative efficacy studies may be skipped. [160] 
The selected PK- and PD-parameters, including their selection criteria should be 
predefined. Also, the selected PK- and PD-study population shall be scientifically 
justified; this also applies to the selected study dose and chosen route of 
administration. Furthermore, the selection of PD- parameters should be orientated 
on: [1] the relevance to clinical outcomes; [2] the ability to ensure appropriate 
precision; and [3] the necessary sensitivity to detect clinically meaningful 
differences. [160] The FDA recommends a crossover designed study for PD- studies 
for products with a short half-life (e.g., < five days). A parallel study design is 
recommended for products with a long half-life (e.g., > five days). [160] 
The FDA´s clinical pharmacology guidance document addresses questions that a 
sponsor may have regarding the design and use of clinical pharmacology studies. 
                                               
 [160] Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [214] 
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Guidance 
for Industry; Guidance for Industry, December 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.
pdf 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
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The guidance provides detailed information on three concepts that need to be 
considered in the use of clinical pharmacology studies: [1] exposure and response 
evaluation; [2] assessment of remaining uncertainty; and [3] suppositions about 
analytical quality and similarity. It further discusses adequate bio-analytical methods 
used for PK- and PD-assessments and general and specific assay considerations. 
[214] The guidance document provides very detailed information to critical study 
design issues such as study population, dose selection, route of administration, PK- 
and PD- measures, sampling strategy, etc. In certain cases it is desirable to 
increase the sensitivity for detecting differences. This may be desired e.g., when a 
product can only be administered to patients and if the approved dose results in 
nonlinear PK or exceeds the dose needed for maximal PD- effect. In such a case, 
the FDA provides the possibility of the selection of an alternative dosing scheme, 
e.g., a single dose for a chronic indication or a lower dose than the approved 
dose, provided that their appropriateness is scientifically justified and submitted to 
the FDA. [214] The FDA encourages the sponsors to discuss the clinical 
pharmacology development plan upfront with them.  
Immunogenicity assessment  
All three FDA guidance documents mentioned above address the clinical 
immunogenicity assessment topic in some way. Clinical immunogenicity 
assessment is considered a key element in the demonstration of biosimiltarity. To 
assess and mitigate immunogenicity, a risk-based approach should be applied. [60] 
In consequence, one comparative clinical study investigating immunogenicity is 
expected by the FDA at a minimum since non-clinical immunogenicity testing in 
animals is of low predictive value due to different immune responses in human and 
animal immune systems. [160] Furthermore, additional pre- and / or post-approval 
surveillance or studies may be considered to further assess immunogenicity. A 
comparative parallel designed study (e.g., a head -to-head study) in subjects that 
have not been previously exposed to the (reference-) product but for whom the 
product is indicated is recommended to evaluate clinical PK- and PD- similarity 
including immunogenicity assessment. The FDA expects the sponsors to proactively 
define and discuss the clinical immune response criteria by defining significant 
clinical incidents for each type of potential immune reaction (e.g., anaphylaxis, 
neutralizing antibody formation) using established criteria where available. The 
length of the follow-up period shall be described in detail and depends on several 
factors like: [1] the time duration for the generation of immune reactions and clinical 
sequelae; [2] the time duration until disappearance of the immune reactions and 
clinical sequelae following interrupting therapy; and [3] the length of administration. 
                                               
 [214] 
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Guidance 
for Industry; Guidance for Industry, December 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.
pdf 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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For chronically administered products a follow-up period of at least one year is 
recommended. [160] 
The FDA also allows for the possibility to extrapolate immunogenicity findings for 
one condition of use to other conditions of use. In order to do this, the sponsor 
should use an adequately sensitive study population and treatment scheme in order 
to prognosticate distinctions in immune reactions between the compared products 
across the indications. [160] Each additional indication that is sought through 
extrapolation should be scientifically justified. [215] 
The FDA immunogenicity assessment guidance document applies to biological 
products and biosimilar products. The document describes clinical consequences of 
and the immunogenicity influencing patient- and product specific factors in great 
detail. [60] It also provides recommendations to address these issues and outlines a 
risk-based approach in order to evaluate and mitigate the risk of unwanted immune 
reactions in the clinical phase. Further, it outlines that assays used in routine lot 
release and stability testing should be validated.  
With regard to the risk mitigation the FDA document provides information on the 
evaluation of clinical relevant immune reactions that includes:  
1. Assays for anti-drug antibody 
Sensitive assays for anti-drug antibody (ADA) should be developed and 
levels of protein product in the sample should be assessed at the same time; 
[60] 
2. Sampling considerations 
For product-specific antibody testing collecting baseline samples is 
recommended and the anticipated intended use of the protein product should 
be considered in determining the post-baseline sampling frequency and 
period. During the initial phase of use a more frequent sampling is 
recommended for new, chronically administered products and a less 
frequent sampling after ongoing use. The duration of repeat sampling 
periods should be sufficient to determine the type of immune reaction (e.g., 
persistent, neutralizing, or linked with clinical long-term complications). In 
order to define the clinical relevance of anti-drug antibodies unscheduled 
sampling, initiated by suspected immune related adverse events, should be 
performed supplementing the pre-specified sampling schedule. Blood 
samples should be taken and banked for future testing; [60] 
3. Dosing 
Regarding the dosing, the FDA recommends a conservative approach for 
first-in-human-trials with graded dosing between individuals and dosing 
                                               
 [160] Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
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cohorts. Further, sufficient time intervals among dosing cohorts and among 
individuals within a dosing cohort as well as prespecified dose escalation 
criteria is recommended; [60] 
4. Adverse events 
In high-risk situations, the FDA recommends more intensive monitoring, such 
as investigating the development of unwanted antibodies through real-time 
assessments prior additional dosing. Further, if clinically relevant immune 
responses are detected, these should be investigated and the underlying 
mechanisms and contributing factors identified; [60] 
5. Comparative immunogenicity studies 
The FDA recommends preparing a justification including predefined criteria 
that rationale the extent on differences in incidence or severity of immune 
reactions considered unacceptable for the safety of the biotechnology-
derived product; [60] 
6. Postmarketing monitoring of product safety  
Postmarketing safety monitoring should be robust and be adjusted to the 
specifics of the biotechnology-derived product. Therefore, the FDA 
recommends discussing the intended postmarketing safety monitoring 
approach with the FDA. Further postmarketing clinical studies may be 
required to assess rare, but potentially serious side effects, which were not 
detected during pre-approval clinical testing because of an inappropriate 
study size. [60] 
The Appendix A of the FDA immunogenicity assessment guidance document 
provides information to: the [1] Diagnosis of Anaphylaxis; [2] Cytokine Release 
Syndrome; [3] Non-Acute Immune Responses; [4] Antibody Responses to 
Therapeutic Protein Products; [5] Utility of Animal Studies; and [6] Comparative 
Immunogenicity Studies in great detail. [60] 
There is no specific FDA guidance document for monoclonal antibodies that 
addresses immunogenicity assessment, non-clinical issues or clinical issues. 
However, in the clinical pharmacology guidance document and the immunogenicity 
assessment guidance document, certain aspects specific to mAbs are considered in 
a manner similar to the EMA guidance document on mAbs. [214]  [60] 
Comparative clinical studies 
Comparative clinical studies will be necessary when after the outcomes of the 
previous steps structural / functional characterization, animal testing, human PK- / 
PD- data, and clinical immunogenicity assessment still uncertainties remain about 
clinically meaningful differences between the compared products or when specific 
                                               
 [60] Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry, August 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
 [214] 
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Guidance 
for Industry; December 2016; 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.
pdf 
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aspects and prior experiences related to the safety or efficacy of the reference 
product or its product class require additional clinical study data. [160] 
To conduct a comparative clinical study, a comparative equivalence trial design with 
symmetric inferiority and superiority margins would be typical to establish the 
necessary statistical evidence. [160] The chosen study endpoints should be capable 
of determining clinically meaningful differences between the two compared products. 
The study duration, study population and study sample size should be sufficient to 
allow the detection of clinically meaningful differences between the compared 
products, including any relevant safety signals (e.g., immune responses). If this is 
not possible within a single comparative study, any safety and immunogenicity 
related signals may be investigated in a separate study. [160] 
Overall, all study related key factors (e.g., design, population, endpoints, size, 
margins, etc.) should be scientifically justified and discussed with the FDA prior to 
study initiation. Ideally, clinical trial data should be generated with biosimilar 
products derived from the commercial manufacturing process.  
If the biosimilar product in the application fulfills the regulatory requirements under 
section 351(k) of the PHS Act, the FDA provides the possibility to extrapolate clinical 
data across indications. This means that safety, purity, and potency information for 
one or more additional indications for which the reference product is approved may 
be extrapolated to and applied for the proposed biosimilar product. [160] The 
prerequisite is that the applicant of the biosimilar product demonstrates biosimilarity 
of its product to the reference product in one condition of use for which the reference 
product is licensed. However, each indication that is sought additionally must be 
scientifically justified, and one indication must be studied that provides clearance for 
successive extrapolation of clinical data to other indications. Therefore, the FDA 
recommends studying an indication sensitive enough to detect clinically meaningful 
differences between the compared products. [215] Factors that need to be considered 
and scientifically justified in order to extrapolate such data include information about 
the proposed biosimilar product with respect to: [1] the mode of action in each 
additional indication; [2] PK/PD-data; [3] Immunogenicity data; [4] possible 
differences in toxicity for the additional indications; and [5] other factors that could 
influence safety or efficacy. [160] 
EEA 
The EMA addresses general approaches, clinical considerations (e.g., 
pharmacokinetic, pharmacodynamic, and efficacy studies) and clinical safety topics 
including immunogenicity of biosimilar products in the EMA´ scientific guidance 
                                               
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
[160]
 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
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document on similar products – non clinical and clinical issues. [57] The product 
specific document similar products mAb guidance addresses the mentioned 
requirements for monoclonal antibodies. [200] 
There are no scientific guidance documents that specifically address the 
immunogenicity assessment for biosimilar products available. The available EMA 
guidance document on immunogenicity assessment and the guidance document on 
the immunogenicity assessment of monoclonal antibodies address the 
immunogenicity topic of biological products. [61]  [204] These guidance documents 
apply for biological products but are applicable to biosimilar products as well. 
Like the FDA, the EMA recommends that clinical evaluation be performed in a 
stepwise approach that begins with pharmacokinetics (PK) and, if needed, 
pharmacodynamic (PD) studies. Next, clinical efficacy and safety trial(s) should be 
performed, or if necessary, confirmatory PK / PD trials. Ideally, clinical study data 
should be generated with biosimilar products derived from the commercial 
manufacturing process.  
Comparative pharmacology studies typically represent an essential role in 
demonstrating biosimilarity, and data should normally being provided. [57] The 
selected PK- parameters should be predefined and their limits scientifically justified. 
It is possible to skip a pivotal PK- study in the target population if previous in-vitro 
study data have demonstrated comparable product-target(s) interaction, and 
continuing PK- data are gathered during further studies (e.g., safety-, efficacy-, or 
PD- studies). [57] The EMA recommends a single dose cross-over study be 
performed including a complete pharmacokinetic characterization and data of the 
late elimination phase in a sensitive population (e.g., populations with fewer human 
factors that might cause variations between individuals). A parallel group design is 
recommended for products with a long half-life and / or high incidence of immune 
reactions. PK- studies should be used to collect immunogenicity data through anti-
drug antibody measurements.  
The choice of PD- markers used in PD- studies depend on their ability to 
demonstrate the intended clinical result. PD-measures should be performed 
together with PK- studies where possible. In some cases, the results of comparative 
PK-/PD- measures may be adequate to demonstrate clinical comparability between 
the compared products when certain requirements are met such as:  
                                               
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
 [61] 
Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
 [204] 
Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use; 
EMA/CHMP/BMWP/86289/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; ; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
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[1] PD- marker is a widely recognized surrogate marker that can be correlated to 
patient results;  
[2] PD- markers are adequate to demonstrate pharmacological action of the active 
substance and a clear relationship of dose-response or concentration-response. If 
so, a clinical efficacy study may be waived provided that the results of a single or 
multiple dose-exposure-response study at two dose levels minimum provide 
sufficient data;  
[3] Previous testing steps provide strong and robust data in such a manner that 
biosimilarity can be well demonstrated. In such cases a confirmatory clinical trial 
may be skipped. [57] 
Efficacy studies may be necessary in order to confirm similar clinical performance 
between the compared products, when surrogate markers are not available. The 
comparative efficacy study design should be a randomized equivalence parallel 
group trial design, ideally double-blind with the use of efficacy endpoints and in an 
adequately sized patient group, or in models sensitive enough to identify safety- and 
efficacy related discrepancies. A non-inferiority trial design could be used with 
proper justification. Product-class-specific EMA guidance provide information on 
efficacy endpoints; otherwise, sensitive clinical models and study conditions should 
be used in order to detect safety and efficacy issues. Typically, pre-defined and 
justified comparable margins are needed to establish statistical and clinical 
evidences. The relevant ICH- and EMA guidance documents should be consulted to 
help choosing comparable margins.  
A confirmatory clinical study may be unnecessary in cases where the data from the 
structural and functional characterization as well as data from the PK- and/or PD-
profile are able to clearly demonstrate similar efficacy and safety, providing that the 
impurity- and excipients profiles are acceptable. [30]  [57] The EMA should be involved 
if the sponsor determines that a confirmatory clinical study is not necessary. 
Clinical safety adverse reactions between the compared products should be 
monitored and quantified in type, severity and frequency. This includes adverse 
reactions already known and described for the reference product. Immunogenicity is 
the most significant issue to consider in clinical safety. Immunogenicity studies 
should be comparative in nature, and their duration should be determined on a 
case-by-case basis. The length of the follow-up period depends on several factors 
like length of administration and types of unwanted immune reactions known from 
the reference product. The follow-up period should be justified accordingly. A follow-
up period of at least one year is required in the pre-authorization phase for 
chronically administered products, but a shorter period (e.g., 6 month) might be 
possible with adequate rationale. [57] 
                                               
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; ; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
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Once the biosimilar product has successfully demonstrated biosimilarity in one 
indication of the reference product, it is possible to extrapolate clinical data on safety 
and efficacy to other indications of the reference product if properly justified. [30] 
However, additional data may be required when the relevance of the confirmed 
safety and efficacy data for the indications sought is vague, or when the active 
substance of the reference product: [1] interacts with various receptors that may 
affect the indications; [2] has multiple active sites which may affect various 
indications; or [3] the studied indication is improper for the indications sought in 
question of safety and efficacy. [57] In order to extrapolate immunogenicity data from 
the confirmed indication to other indications of the reference product, the EMA 
requires proper justification and additional data may be needed. [57] It should be 
noted, that after a biosimilar product has received marketing authorization, further 
changes to the manufacturing process of the biosimilar product do not require the 
repeat of biosimilarity demonstration to the reference product according to the 
regulation. [30] 
Clinical specifics for similar monoclonal antibodies (EEA) 
The similar products mAb guidance document also recommends a stepwise 
approach to the clinical testing. [200] A pharmacokinetic study serves as the first step 
in the clinical data development to establish similar efficacy and safety. The study 
population should be homogeneous and sensitive enough to detect any potential 
differences. Therefore, a single dose study in healthy subjects is to prefer due to the 
less variability in PK. The rationale for the choice of the patient population for the 
PK- study shall be documented. The EMA recommends a parallel group design to 
assess pharmacokinetics due to the long half-life of mAbs and the potential 
incidence for immune reactions. A single dose cross-over study with complete 
identification of the PK-profile and data of the late elimination phase is 
recommended for mAbs with short half-life. PK- studies should be used to collect 
immunogenicity data through anti-drug antibody measurements. [200] 
Like other biosimilar products that are not mAbs, the comparability of the PK-profiles 
should have been investigated in the previous non-clinical testing. However, in some 
cases (e.g., when the PK of the mAb is highly variable even in the same indication), 
it may make more sense to investigate the PK in a comparability clinical efficacy trial 
because only that involves enough subjects to demonstrate equivalence of PK. If a 
comparative clinical efficacy trial is intended that includes PK- assessment without 
prior comparative PK- evaluation and human exposure of the biosimilar mAb, this 
should be properly and individually justified, especially when only limited non-clinical 
in vivo data are available. [200] 
Pharmacodynamic parameters may help to establish comparability for some mAb 
products and indications. For the purpose of establishing overall comparability, the 
                                               
 [57] Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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use of multiple PD- markers is preferred. Where no specific PD endpoints are 
available, data of non-clinical PD- assessments such as in-vitro testing data should 
be used accordingly. When PD- markers are intended to be used as pivotal 
evidence to demonstrate comparability, the dose-concentration-response 
relationships or time-response relationships should be investigated as this may 
successfully generate evidence of comparability if the selected doses are within the 
linear part of the dose-response curve. The risk of developing anti- mAb antibodies 
should always be considered. [200] 
Clinical efficacy trials are necessary if the results of the comparative PD- studies 
were not sufficient to demonstrate clinically comparability between the compared 
products. The design of comparative efficacy studies should be a randomized 
equivalence parallel group trial design, ideally double-blind with the use of the 
clinical endpoint (and, if required, any additionally implemented measures) and with 
a clinical model or patient population sufficient in size and sensitive enough to 
identify safety- and efficacy related discrepancies between the two compared 
products. Pediatric clinical studies are typically not required for biosimilar products 
as the goal of the development program is to establish comparability thus, the focus 
in selecting the primary patient population is laid on homogeneity and sensitivity. [200] 
In order to further evaluate the comparability of the clinical safety, the type, severity 
and frequency of the adverse reactions of the comparators should be compared with 
a focus on the adverse reactions previously documented for the reference product. 
Where PD- markers were used as pivotal evidence to demonstrate comparability, 
adequate data should be provided in order to confirm similar clinical safety and 
immunogenicity. The rationale for the length of the follow-up period pre- 
authorization should be documented. 
Because it is nearly impossible to detect rare but serious adverse events like 
progressive multifocal leukencephalopathy within the pre-authorization phase, 
applicants may choose to collect additional safety data post-authorization (e.g., 
through PASS). Such activities need to be discussed and detailed in the risk 
management plan (RMP) submitted with the product application. The RMP should 
also provide information on how to evaluate and monitor clinical safety in re-
treatment conditions (e.g., chronically administered mAbs).  
For immunogenicity assessment purpose, a systematic and comparative evaluation 
of immunogenicity is required to identify possible clinical consequences (e.g., loss of 
efficacy). In order to detect anti-drug antibody development, the best suitable 
approach in terms of the best population and administered dose (e.g., population 
PK- approach in patients or healthy subjects; inhibition of antibody development in 
high doses) should be explored.  
It is possible to extrapolate clinical data, including immunogenicity data, to other 
indications / conditions of use of the reference mAb, if properly justified and based 
on the results from a successful comparability exercise. However, where PD- 
markers were used to establish pivotal evidence demonstrating comparability, and 
                                               
 [200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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when different mechanisms of action apply to the claimed indications or in case of 
any other existing uncertainties, further data are needed to support extrapolation for 
each indication sought additionally. [200] Appropriate postmarketing activities 
monitoring the clinical safety of the indications to which safety and immunogenicity 
data have been extrapolated should be described in the RMP and provided with the 
application dossier.  
Immunogenicity assessment  
The available EMA guidance document on immunogenicity assessment provides 
guidance on non-clinical and clinical issues. [61] Like the FDA, the EMA considers 
clinical immunogenicity assessment as a key element in the biosimilarity 
demonstration since non-clinical immunogenicity testing is of low predictive value 
due to different immune responses in human and animal immune systems (e.g., 
animal anti-drug antibody response versus to human ADA). For clinical studies, 
immunogenicity assessment should always be considered in order to: [1] detect 
immune reactions, [2] investigate binding and neutralizing ADAs and their 
interactions; and [3] receive PK-and PD data and data on efficacy and safety. 
A risk-based approach should be applied to analyze and mitigate immunogenicity. 
This includes extension and adaption of pre-approval studies if necessary, as well 
as consideration of further studies in the post-approval phase to assess rare 
immunogenicity related events. Similar to the FDA guidance document, the EMA 
guidance document describes in great detail the clinical consequences of and the 
immunogenicity influencing patient- and product specific factors. However, in 
contrast to the FDA guidance document it does not provide any recommendations to 
address the patient- and product specific factors that affect immunogenicity. Also in 
contrast to the structure of the FDA guidance document, the EMA guidance 
document discusses the non-clinical immunogenicity testing in a separate section 
and recommends the application of emerging technologies such as novel in-vivo, in-
vitro and in-silico models to estimate potentials of risk for immunogenicity. [61] 
Clinical and non-clinical comparative immunogenicity testing should be performed 
with biosimilar products derived from the commercial manufacturing process. Blood 
samples should be taken and banked for future testing. The EMA guidance 
document provides further detailed information to the immunogenicity assessment 
testing strategy and development of assays for detecting and measuring clinically 
relevant immune reactions such as: [1] screening assays; [2] assays that confirm the 
presence of antibodies; [3] neutralization assays; and [4] assays for comparative 
immunogenicity. [61] All assays are expected to be fully validated for marketing 
authorization purpose as discussed in the mentioned EMA guidance document.  
For immunogenicity testing, patients should be studied using routine repetitive 
sampling as well as unscheduled sampling that depends on the symptoms in case 
of undesired immune reactions. It is recommended to always collect baseline 
samples. [61] 
                                               
 [61] 
Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
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The sampling plan should be designed in a way to separate patients that develop 
antibodies on a temporarily basis from patients that develop anti-drug antibodies on 
a permanent basis. The length of post-treatment follow-up sampling should be of 
adequate time duration to provide information on the persistence of the immune 
reactions and to detect any suppressed reactions; it should be taken at the earliest 
upon four weeks after the last dose was administered. [61] 
The EMA document recommends more frequent sampling during the initial phase of 
drug administration with a reduced sampling frequency for long-term (e.g., 
chronically administered products) use. For chronically administered products, a 
follow-up period of at least one year is recommended; however, if properly justified, 
a shorter follow-up period is possible. As the development of non-neutralizing 
antibodies may impact pharmacokinetic behavior of the product (e.g., in the 
elimination phase by increasing efficacy due to lengthen the half-life), it is 
recommended to collect PK- data along with the immunogenicity data during repeat 
dose studies to enable the early detection of changes in the PK. The studied target 
population should be sensitive enough to detect any clinically relevant differences in 
immunogenicity, and should be compiled of subjects that have not been previously 
exposed to the (reference-) product but for whom the product is indicated. [61] The 
discussed EMA guidance document does not address extrapolation of 
immunogenicity data whereas the FDA counterpart guidance document does.  
The EMA guidance document on immunogenicity assessment indicates that the 
influence of leachables to immunogenicity (e.g., substances or particles leached-out 
from rubber stoppers or syringes of the container closure or drug delivery device) 
should be considered. [61] It also indicates that considerations should be given to 
substances or particles leached-out during clinical application (e.g., infusion devices 
or accessories) practice. However, leachables are neither explicitly mentioned, nor 
is any data or testing requirements specified in that or in any other relevant EMA 
guidance document for biosimilar products.  
Specifics in immunogenicity assessment of monoclonal antibodies 
The EMA guidance document “Immunogenicity assessment of monoclonal 
antibodies intended for in vivo clinical use” addresses specific immunogenicity 
related issues experienced with mAbs. [204] It recommends a risk-based approach in 
the evaluation and mitigation of immunogenicity and provides risk management 
information. The guidance document amends the information provided in the main 
EMA guidance document on immunogenicity assessment discussed before, by 
discussing difficulties when using screening and confirmatory assays, measuring 
neutralizing capacity of antibodies induced against mAbs, and provides information 
to the risk management of immunogenicity. [61] 
                                               
 [61] 
Guideline on Immunogenicity assessment of biotechnology-derived therapeutic proteins; 
EMEA/CHMP/BMWP/14327/2006 Rev1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500194507.pdf 
 
[204] 
Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use; 
EMA/CHMP/BMWP/86289/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf 
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In contrast to other therapeutic proteins, it is unlikely that antibodies developed 
against therapeutic monoclonal antibodies will induce cross-reactions and 
neutralizing endogenous counterparts (e.g., such with erythropoietin (EPO)). 
Monoclonal antibodies are often considered as alternative therapies and typically 
not used as replacement therapies. The mAb specific EMA guidance document on 
the immunogenicity assessment of monoclonal provides specific advice to antibody 
detection screening assays, and recommends the use of alternative approaches to 
that used for other therapeutic proteins. [204] These recommended approaches work 
without anti-immunoglobulin reagents (e.g., use of a bridging design for Enzyme-
linked immunosorbent assays (ELISAs) or electrochemiluminescence (ECL) assays; 
or use of surface plasmon resonance (SPR) procedure). Anti-immunoglobulin 
reagents cannot be used in mAb antibody detection as they typically bind to the 
mAb itself. However, the alternative approaches may be less sensitive than methods 
more commonly used. The guidance document also discusses the issue of the 
presence of mAbs in samples intended to be analyzed. Here, the relatively high half-
life of mAbs may complicate the identification of antibody responses in samples. To 
solve this issue, the sampling may be timely delayed or the use of specific ECL 
based immunoassays that contain a preparatory antigen-antibody dissociation step 
may be used. [204] Regarding the selection of a positive control serum, which is 
considered important to control sensitivity and specificity of the assay, the use of 
human sera should be preferred. Sera from non-human primates and / or the use of 
an antiidiotypic antisera or mAb may be alternatives to human sera. Antiidiotypic 
means an antibody that binds with the variable region of another antibody, the 
idiotype. Spiking samples may be used in verifying assay specificity. [204] 
The clinical effect that a monoclonal antibody generates can be a summary of 
various mechanisms a mAb uses in combination and in a cumulative or synergistic 
way. If so, the assessment of the neutralizing potential is more difficult and should 
start with rigorous characterization of the biological properties of the mAb in order to 
determine a suitable assay strategy. Overall, competitive ligand binding assays to 
assess neutralization capacity are recommended.  
The following items should be taken into account for risk identification when 
developing the immunogenicity related risk management for mAbs: [1] available and 
unavailable experience to related mAbs (e.g., similar to target class, same 
expression system); [2] mAb structure (e.g., mAb sequences (heterologous, 
humanized, human), glycosylation patterns, production impurities, mode of action 
(e.g., cytolytic, apoptotic) and character of the target molecule (e.g., immune 
suppressing, immune stimulating); [3] clinical considerations (e.g., unwanted 
immune responses and influencing factors). [204] 
During the risk assessment, all identified risks should be assessed within a 
multidisciplinary approach and risks should refer to the relevant comparability 
testing. The overall risk assessment should enable applicants to provide information 
relating to the severity, rate of occurrence and detectability of the risks. The conduct 
of further postmarketing -surveillance, -monitoring or -studies should be considered. 
                                               
 [204] Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use; 
EMA/CHMP/BMWP/86289/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf 
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For risk monitoring purpose, the guideline is very similar to the relevant FDA 
guidance in content. The EMA document requires frequent sampling during all 
phases of development for mAbs with higher risks, but allows a reduced sampling 
frequency for low risk mAbs in later phases of development. In addition, and similar 
to the FDA guidance document, it recommends a real time analysis of samples and 
the simultaneous collection of data regarding the antibody level, PK-/PD- 
parameters as well as efficacy and safety data in case of repeated administration for 
high-risk mAbs. [204] 
 Overall summary of clinical safety requirements 14.6
The following text summarizes the most significant items mentioned above and 
outlines the identified differences between the scientific recommendations for the 
clinical requirements of the two regions.  
A stepwise approach is generally recommended from both regulatory authorities for 
conducting clinical testing. Regarding the testing program, the testing steps and 
their order are the same in both regions. The testing program begins with PK- / PD- 
studies including immunogenicity, followed by efficacy and safety studies and, if 
necessary, confirmatory PK- / PD- trials. The evaluation approach for clinical data is 
the same as that for non-clinical data; the totality of comparability data must 
demonstrate biosimilarity between the compared products. Comparative PK- studies 
that ideally include PD- studies and immunogenicity testing are considered essential 
in both regions to establish biosimilarity. Further, both regions agree that such 
studies should be conducted in a parallel group design for products with a long half-
life, and in cross-over design for products with short half-life. The relevant FDA 
scientific considerations guidance provides more detailed information to the 
definition of short half-life and long half-life. [160] Both regions require that the 
selected PK- parameters should be pre-defined and their limits scientifically justified. 
The same recommendation is given for the choice of PD-markers; these should 
depend on their ability to demonstrate the intended clinical outcome. Both 
authorities, the EMA and the FDA, provide the possibility to skip comparative 
efficacy studies (USA) or confirmatory clinical trials (EEA).  
In contrast to the EMA requirements, the FDA allows in certain cases (e.g., product 
can only be administered to patients) the possibility of the selection of an alternative 
dosing scheme if the appropriateness is scientifically justified. 
Both authorities consider immunogenicity studies as a key element in biosimilarity 
demonstration, and both authorities recommend a risk-based approach. Both 
regions recommend that a study utilizing a comparative parallel-group design (e.g., 
a head – to - head study) be conducted in a sensitive population that have not been 
exposed to the (reference-) product previously but for whom the product is indicated. 
Further, both regions recommend a follow-up period of at least one year for 
chronically administered products although the EMA allows shorter periods (e.g., 6 
                                               
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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month) if the rationale is well documented. Both authorities recognize that the length 
of the follow-up periods for other, non-chronically administered products depends on 
several factors. The FDA expects the sponsors to proactively define the clinical 
immune response criteria (e.g., definition of significant clinical incidents) for each 
type of potential immune reaction. Both authorities recommend sampling be 
conducted more frequently during the initial phase of drug administration while less 
frequent sampling is recommended for long-term use (e.g., chronically administered 
products). The duration of repeat sampling periods should be sufficient enough to 
determine the type of immune reaction (e.g., persistent, neutralizing, or linked with 
clinical long-term complications). Both authorities recommend a real-time-
assessment of samples in certain situations (e.g., high risk situations). The EMA´s 
mAb specific guidance document recommends a reduced sampling frequency for 
low risk mAbs in later phases of development but requires more frequent sampling 
during all phases of development for higher-risk mAbs. No mAb related information 
is provided by the FDA as no mAb specific guidance exists.  
For comparative clinical studies, both regions recommend a randomized 
equivalence parallel group trial design to be conducted in models sensitive and 
sufficiently sized to identify safety- and efficacy related discrepancies respectively to 
detect clinically meaningful differences. While the FDA recommends symmetric 
inferiority and superiority margins to establish the necessary statistical evidence, the 
EMA simply refers to the ICH E9 guideline and the EMA guidance document 
“Guideline on the choice of the non-inferiority margin” in which non-inferiority 
margins are discussed and recommends comparable margins to be statistically and 
clinically pre-specified and justified by using the reference product data. [240] 
Generally and in both regions, the population size studied should be sufficient to 
detect clinically meaningful differences in safety and efficacy between the two 
compared products.  
In both regions, biosimilar products derived from the commercial manufacturing 
process should be used to generate clinical trial data. In addition, assays used to 
generate clinical trial data should be fully validated.  
Both regions allow the possibility to extrapolate safety, efficacy and immunogenicity 
data to other indications / conditions of use. To do this, the EMA requires a scientific 
justification and, in certain cases, additional data. [57] For mAbs the EMA requires 
additional data for each additional sought indication, if the essential data that 
demonstrate comparability are based on pharmacodynamic study data and for the 
indications sought different mechanisms of action or uncertainty exist. [200] 
In contrast, the FDA only requires that there is a scientific justification for each 
additional indication that is sought. The FDA also recommends studying a condition 
                                               
 [240] 
Guideline on the choice of the Non-Inferiority Margin, Doc. Ref. EMEA/CPMP/EWP/2158/99; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
 
[200] 
Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical 
issues; EMA/CHMP/BMWP/403543/2010; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf 
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of use sensitive enough to detect clinically meaningful differences between the 
compared products. [215] 
By regulation, the EEA does not require that biosimilarity demonstration to the 
reference product be repeated when changes are made to the manufacturing 
process of the biosimilar product after the proposed product has received marketing 
authorization. [30] The FDA guidance documents provide no information to this topic.  
For changes in the manufacturing process of biological products, the EMA 
document “Guideline on comparability of biotechnology-derived medicinal products 
after a change in the manufacturing process - non-clinical and clinical issues” 
provides information on non-clinical and clinical testing and defines on the basis of 
time points the extent of clinical studies. [241] A risk-based approach is used to 
determine the need and extent of non-clinical and clinical studies. There is no newly 
released FDA guidance that addresses this topic; however, the FDA document 
“Guidance Concerning Demonstration of Comparability of Human Biological 
Products, Including Therapeutic Biotechnology Products” from 1996; and the FDA 
scientific considerations guidance document refer to the ICH guideline document 
Q5E “Comparability of biotechnological/biological products subject to changes in 
their manufacturing process”. [242]  [160] 
Overall both regions regulations are very similar as the same topics are covered by 
the relevant guidance documents. However, unlike the EMA, the FDA does not 
provide any specific guidance on mAbs. No fundamental differences were identified 
between the two regions which may impact the safety of biosimilar products. 
However, although the extrapolation of clinical safety, efficacy and immunogenicity 
data is possible in both regions, the extrapolation topic is handled differently and 
may influence the safety of biosimilar products in the USA due to the lack of the 
additional data requirement when extrapolating data.  
 Analysis of the quality considerations  14.7
Both regulatory regions have issued a scientific document discussing product 
comparability under a quality point of view. These documents are the EMA similar 
                                               
 [215] 
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and 
Innovation Act of 2009, April 2015, Guidance for Industry; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.p
df 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 [241] 
Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing 
process - non-clinical and clinical issues; EMEA/CHMP/BMWP/101695/2006; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf 
 [242] 
Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived 
Products; April 1996, last update: July 6, 2005; 
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm 
 [160] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; Guidance for Industry, April 
2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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products – quality issues guidance document and the FDA´ quality considerations 
guidance document and these will be compared in this section. [199]  [159] 
USA  
Because quality attributes may be used when designing the comparability program, 
comparative analytical and similarity data should be available at early stage of 
development and should be submitted to the FDA, ideally: [1] pre-IND; [2] together 
with the IND-submission; or [3] when providing data from initial clinical studies (e.g., 
PK/PD testing). [159] In general, the FDA recommends the use of state-of-the-art 
technologies, assays and orthogonal methods which should include knowledge 
about their limitations. For analytical studies, an appropriate quantity of multiple lots 
of the reference product as well as the proposed biosimilar product should be used 
to determine the variability within product lots (product consistency). Also to facilitate 
the setting of product consistency acceptance criteria, it is recommended that lots 
used in analytical similarity studies should be identifiable and lot expiration dates 
should be documented along with the testing time point and time point when the lots 
were used in other studies. [159] 
Within the comparative physicochemical and functional testing, quality attributes 
should be set in order to identify and quantify the product in order to define its 
safety, purity, and potency. The structure (e.g., heterogeneity) and function of a 
biological product may be influenced by a number of circumstances, such as protein 
modifications (e.g., posttranslational, deliberate) during cell culture, during 
manufacturing processes and/or during product storage.  
When the analytical characterization has observed qualitative or quantitative 
differences in product quality attributes, these may be further assessed using a 
fingerprint-like analysis that is eligible to analyze numerous products attributes. [159] 
Important factors that should be considered in the comparability program include:  
1. Type of expression system  
The type of expression system that is used for the biosimilar product may 
vary (e.g., in host cell and expression construct) which may impact the 
process- and product-related substances, impurities, and contaminants or 
may lead to any protein modifications. Therefore, any differences between 
the expression systems should be kept to a minimum; [159] 
2. Manufacturing processes 
The manufacturing processes should be consistent, well controlled and run 
under a quality- and risk-management. If changes to the manufacturing 
                                               
 
[199] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: quality issues (revision 1); EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry, April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 [159] Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry, April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
 - Page 123 of 215 - 
ANALYSIS AND COMPARISON OF GUIDANCE DOCUMENTS … 
 
process occur after analytical testing or clinical studies, the pre- and post-
change comparability of the biosimilar product should be demonstrated. 
This may require additional analytical testing depending on the extent and 
nature of the process change; [159] 
3. Physicochemical properties 
The testing applied to assess the physicochemical properties of the 
products should be sensitive and specific enough to provide significant data 
in order to demonstrate biosimilarity and to detect potential differences in 
quality attributes of the compared products; [159] 
4. Functional assays 
Potential assay limitations should be considered as well as the limited 
appropriateness of in-vitro bioactivity assays; [159] 
5. Receptor binding and immunochemical properties 
Receptor binding and immunochemical properties of the biosimilar product 
should be analyzed when these characteristics are part of the activity of the 
biosimilar product. Different analytical test methods are available to 
investigate the kinetics and thermodynamics of binding and results may 
provide additional information to the higher order structure and functional 
activity of the biosimilar product; [159] 
6. Impurities 
The FDA recognizes that process-related impurities (e.g., resulting from 
cell-substrates) vary between manufacturing processes. However; if 
differences in the impurity profiles of the compared products are observed, 
they should be assessed side-by side in a risk-based manner. The 
differences and the potential impact to the product safety should be 
discussed and supported with relevant data. Analytical procedures used 
should be validated and eligible for identification, detection and 
quantification of impurities. Furthermore, critical raw materials should be 
reviewed; and virus removal / inactivation as part of the manufacturing 
process should be tested and confirmed; [159] 
7. Reference product and reference standards 
The FDA recommends providing information on the extraction steps in 
cases where the drug substance has been extracted from the reference 
product for analytical similarity testing purpose. Also, information on the 
impact of the extraction to the quality attributes should be included. Publicly 
available, well-established reference standards for the protein (e.g., 
international standard for calibration of potency) should be used in the 
physicochemical and/or functional testing. However, the use of reference 
standards does not make product-individual comparative testing 
unnecessary in the demonstration of biosimilarity and does not replace the 
reference product. [159] A qualified in-house reference standard should be 
used in manufacturing- and product control (see ICH Q6B);  
                                               
 [159] Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry, April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
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8. Finished drug product testing 
Finished drug product testing should be performed on a bulk drug 
substance. [243] Ideally sponsors should use the finished drug product for 
analysis; however, if particular quality attributes are detected more 
efficiently in the drug substance by a certain analytical method and in case 
these attributes are critical in the products manufacturing, both, the drug 
substance and the finished drug product should be characterized in a 
comparative manner. In case where different excipients than the reference 
product it uses are processed, these should be identified and toxicology 
data should be provided. Also, when the product formulation or the primary 
packaging (container closure) deviates from that of the reference product 
(e.g., reformulation), this may affect the approach to the subsequent clinical 
testing (e.g., selective and targeted or any other) and additional testing may 
be necessary to minimize safety and efficacy related concerns to the 
biosimilar product; [159] 
9. Stability testing  
Stability testing should be comparative in nature and should comprise 
accelerated and stress testing, including forced degradation studies. Testing 
should be performed under multiple stress conditions such as high 
temperature, freeze / thaw, light exposure, and agitation. The proposed 
shelf life of the biosimilar product should be facilitated with real time data 
and real condition stability data of the biosimilar product. [159] 
EEA 
A continuous manufacturing process is considered a key element in biotechnology-
derived products production. The manufacturing process defines the molecular 
characteristics of the active substance and process- and product-related substances 
and impurities as well as modifications to and variants in protein structures in the 
biological product. A quality target product profile (QTPP) specific for the proposed 
biosimilar product should be pre-defined which serves as the basis for the product – 
and manufacturing process development. When selecting the expression system 
any impacts to the protein (e.g., changes in protein structures or impurity profile, 
etc.,) should be considered.  
It is not necessary that the formulation and / or container closure system of the 
proposed biosimilar product is the same as that of the reference product. When 
differences exist, the impact to the products safety and efficacy should be properly 
justified. In all cases, it should be demonstrated that the chosen formulation is stable 
to environmental and any other influences. Further, it should be demonstrated that 
the product formulation is compatible with excipients, packaging materials, diluents 
                                               
 
[243] 
21 CFR 207.3(a)(4), April 2016; https://www.gpo.gov/fdsys/pkg/CFR-2016-title21-vol4/pdf/CFR-2016-title21-
vol4.pdf 
 [159] 
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference 
Product; Guidance for Industry, April 2015; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.p
df 
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and a proper stability, integrity, activity and strength of the active substance should 
be shown. [199] 
Any changes to the manufacturing process should be assessed in accordance to 
ICH Q5E and described in the application dossier. In order to develop comparable 
quality, safety and efficacy data to establish biosimilarity to the reference product, it 
is always advisable to use a biosimilar product produced with commercial 
manufacturing process conditions.  
The ICH Q5C should be consulted for stability testing. The extrapolation of stability 
data from the reference product is not possible; therefore, additional supportive data 
shall be provided.  
It should be noted that once a biosimilar product has received marketing approval, 
regulations do not require a re-demonstration of biosimilarity. [199] This is also stated 
in the EMA´ similar products guidance document; however, neither the regulations 
nor the guidelines discuss or justify the rationale. [30] 
Besides manufacturing relevant factors, there are other important quality factors that 
should be considered in the comparability program including: 
1. Reference medicinal product comparability  
An appropriate quantity of multiple different batches of the reference product 
should be used. It is recommended that batches of the reference product 
used are identifiable (e.g., brand name, formulation, strength, number of 
batches, lot number, age of batches, etc.); [199] 
2. Biosimilar comparability exercise 
Extensive side-by-side comparative studies are recommended to detect 
differences in quality attributes between the compared products. While the 
proposed finished product, including its product-related substances, should 
demonstrate biosimilarity to the reference product, the process-related 
impurities may vary. However, the process-related impurities should be kept 
at minimum, ideally through a reliable and efficient purification step in the 
manufacturing process. If process-related impurities are minimal, a non-
clinical testing program to qualify the process-related impurities may be 
unnecessary. If possible, quantitative ranges for quality attributes should be 
established for biosimilar comparability purpose. The quantitative ranges 
should be based on the measured ranges for quality attributes from the 
reference product, and the variability range of the reference batches should 
not exceed that of the reference product. Such established ranges in quality 
profile may be helpful in assessing the impact of manufacturing process 
changes to the biosimilar product in order to support comparability 
                                               
 
[199] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; 
EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
 
[199] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; 
EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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demonstration. Where quality attributes measures (pre-change versus post-
change) are out of the specified quality attribute ranges this should be 
justified with respect to its influence on product safety and efficacy; [199] 
3. Analytical considerations 
For analytical considerations, the EMA recommends the adequate 
qualification of methods (regarding their intended purpose) used in 
comparability testing. This is especially important for the methods used to 
determine product characterization. Further, the EMA indicates, that the 
applicant is in charge of ensuring the adequacy of the selected methods. 
Publicly available standards and reference materials such from Ph. Eur. 
should be applied in order to qualify and standardize the methods used. 
However, like the FDA quality guidance, the EMA considers publicly 
available standards such as the Ph. Eur. as inadequate for comparability 
demonstration purpose. Therefore, they cannot replace the reference 
product. Instead, the EMA recommends extensive comparability testing with 
state-of-the-art technologies; assays and sensitive orthogonal methods; 
including knowledge about their limitations. In cases where analytical testing 
samples were extracted or otherwise processed to enable their use in 
certain analytical techniques, these procedures should be described, and it 
should be discussed if and how the used procedure could influence the test 
samples; [199] 
3.1. Physicochemical characteristics 
In the comparison of the physicochemical properties physical and 
chemical characteristics (e.g., texture, physical properties, primary 
and higher order structures of the protein product) will be evaluated 
and the structure of product-related substances and impurities will 
be identified using appropriate analytical test methods. If 
glycosylation structures or variants are found in the biosimilar 
product which were not detected in the reference product these 
should be justified with respect to non-human structures (e.g., 
linkages, sequences or sugars). [199] 
3.2. Biological properties 
In order to study the biological properties, biological assays should 
be used under consideration of their limitations. The assay 
outcomes should be calibrated against an international or national 
reference standard; [199] 
3.3. Immunochemical characteristics 
With respect to the immunochemical characteristics the EMA 
guideline states that immunological functions of monoclonal 
antibodies and related substances should be compared including 
the assessment of the affinity of the two products to the desired 
target as well as the binding affinity of the fragment crystallizable 
                                               
 
[199] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; 
EMA/CHMP/BWP/247713/2012, Rev.1; ; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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(Fc) to relevant receptors. [199] The guidance document refers to the 
similar products mAb guidance document. 
3.4. The purity / impurity profiles 
The purity and impurity profiles should be studied in a quantitative 
and qualitative manner and compared to the results of the 
comparator product. Identified impurities should be documented 
and properly justified with regard to their potential risks (e.g., 
inducing of immune reactions). The qualitative comparison of 
product-related impurities is considered unnecessary as they vary 
between processes; [199] 
3.5. Quantity  
A suitable assay should be used to establish product quantity and it 
should be confirmed that the strength of the biosimilar product is 
similar to that of the reference product. To express the quantity of 
the biosimilar product the same units should be used as used for 
the reference product. [199] 
4. Specifications 
Regarding to the product specifications the EMA guideline references ICH 
Q6B and states that the proposed shelf life of the biosimilar product should 
be supported with full stability data of the biosimilar product whilst 
comparative real-time and real-condition stability studies between the 
compared products are not considered necessary. [199] 
 Overall summary to safety relevant quality considerations 14.8
The following text summarizes the most significant items mentioned above and 
outlines the identified differences between the scientific recommendations regarding 
the quality considerations of the two regions.  
The FDA´s quality considerations document focuses on CMC related information 
that should be considered in the comparability program and be described in the 
CMC section of the drug dossier. Like other topics related to drug approval, the FDA 
encourages applicants to discuss any CMC related questions with the FDA from the 
beginning of the development process. The less voluminous and comprehensive 
EMA quality considerations guidance document focuses on quality requirements for 
a proposed biosimilar product and addresses similar issues as the FDA document, 
although not in such a great detail. However, the grade of regulation is very similar 
as the same topics are covered by the relevant guidance documents. 
Due to the different regulatory approach regarding drug development and -
application as well as approval, the FDA recommends submitting comparative and 
similarity data at an early stage of development; ideally pre-IND. This is not in with 
the EMA. The EMA provides the possibility to request scientific advice, but does not 
                                               
 
[199] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; 
EMA/CHMP/BWP/247713/2012, Rev.1; ; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
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encourage the applicant to provide data at an early stage. The review and approval 
process in the EEA region starts with the submission of the application dossier.  
The requirements regarding process-related impurities differ slightly. Although the 
FDA recognizes that process-related impurities vary between manufacturing 
processes, differences in impurity profiles of the reference product and the proposed 
biosimilar product should be assessed, compared and supported by data in order to 
determine the potential impact to safety and efficacy. In contrast, the EMA guidance 
document only requires documenting and properly justifying identified impurities with 
regard to their potential risks (e.g., inducing of immune reactions).  
Furthermore, while the EMA requires keeping process-related impurities as low as 
possible by applying an efficient and reliable purification step, the FDA recommends 
the testing and confirmation of removing / inactivation of viruses within the 
manufacturing process.  
A slight difference compared to the EMA requirements concerns finished biosimilar 
product formulations and / or container closure systems (primary packaging) that are 
different to that of the reference product. In such a case, additional data may be 
required by the FDA to sufficiently rationalize why the deviation does not affect the 
safety and efficacy of the biosimilar product. With the EMA, the use of a different 
formulation and / or container closure system is also allowed. In such cases and 
along with the common requirements to formulation testing, the impact of the 
different formulation and / or container closure system to the products safety and 
efficacy should be properly justified.  
While the FDA guidance document has specific requirements for stability testing, the 
EMA scientific document has very little information on stability testing and refers to 
ICH Q5C which states that stability data cannot be extrapolated from the reference 
product. The FDA guidance document also refers to the ICH Q5C, but the FDA 
document provides details on required testing such as comparative stability testing 
should include accelerated and stress testing as well as forced degradation studies; 
conducted under multiple stress conditions.  
In the FDA´ s view, real-time data and real-condition stability data should support 
the proposed shelf life of the biosimilar product. Similarly, the EMA requires that the 
proposed shelf life of the biosimilar product be supported with full stability data, but 
notes that comparative real-time, real-condition stability studies between the 
compared products are considered not necessary. However, both guidance 
documents (EMA and FDA) refer to the ICH Q6B for specifications.  
While the EMA similar products - quality issues guidance document states that the 
re-demonstration of biosimilarity is not required by regulations once a biosimilar 
product has received marketing approval, the FDA guidance document does not 
provide any information in order to address that question.  
Overall, the scientific content of the both documents is similar with slight differences 
that make the FDA document more informative and meaningful; and some 
requirements are a little tighter. Some of the slight differences could influence the 
product safety, namely using a different container / closure or delivery device 
system with no EMA requirements requiring additional testing or data to investigate 
the potential impact on the efficacy and safety of the biosimilar product as an 
 - Page 129 of 215 - 
ANALYSIS AND COMPARISON OF GUIDANCE DOCUMENTS … 
 
appropriate justification is considered as adequate. The impact of the container / 
closure or delivery device system to the finished product is illustrated with the Ortho 
Biotech Eprex / Erypo uncoated rubber stopper investigation published in “Kidney 
International” in 2005. [244] The investigation result supports the hypothesis of the 
impact of container / closure or delivery device system to the drug safety. The 
investigation showed that patients with chronic kidney disease treated with Eprex® 
epoetins by subcutaneous administration had an increased incidence of pure red 
cell aplasia (PRCA) caused by leachates from uncoated rubber syringe stoppers.  
Appendix M provides a tabular overview of found similarities and differences 
between regulatory and scientific requirements in the EEA and the USA. 
                                               
 [244] 
The increased incidence of pure red cell aplasia with an Eprex; KATIA BOVEN, Available online 9 
November 2015, http://ac.els-cdn.com/S0085253815507242/1-s2.0-S0085253815507242-
main.pdf?_tid=31043132-6e84-11e6-bd72-
00000aacb362&acdnat=1472542651_e55754230603c365440a4ff75c5ab801 
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15  Improvement potential and suggestions 
On the basis of the EMA-and FDA guidance documents, some potentials for 
improvement were identified that may help improve the safety of biosimilar products.  
 Improvement potential in the European Union and USA 15.1
The largest potential for improvement is related to the overall safety-relevant 
regulatory requirements. The most significant suggestions for improvements for both 
regions are listed and explained below. 
1. Use of a non-EU or non-US licensed reference product 
When using different reference products (e.g., EU reference product and 
non-EU reference product) the generated bridging data may raise the risk of 
potential bias regarding safety data.  
Suggestions: 
 Eliminate the possibility of using a non-EU or non-US reference 
product; or 
 Restrict and clearly define the type of studies where the use of a non-
EU- or non-US reference product is allowed, and  
 Provide regulatory guidance and define quality requirements for 
statistical evaluation of comparative assessments in order to avoid 
errors e.g., within the empirical data collection (probably sampling) 
which may cause potential bias e.g., systematic biased error, or 
random sampling error 
2. Automatic substitution  
The individual US-states allow automatic substitution of biological products 
with interchangeable biosimilar products, providing they have passed the 
biosimilars legislation with or without additional requirements e.g., patient 
and / or physician notification, regarding to the automatic substitution.  
In the EU, some member states allow automatic substitution by national law 
and other does not. The approach in both regions (USA and EU) regarding 
to the automatic substitution may hinder postmarketing surveillance 
activities.  
Further, immunogenicity may be triggered when biological products are 
switched back and forth with the interchangeable biosimilar product. 
Consequences of antidrug-antibody-development could be the loss of drug 
efficacy or serious adverse events which poses a safety risk to patients.  
Suggestions: 
 Harmonize legislation to ensure uniform requirements for automatic 
substitution  
o EU: Establish requirements for automatic substitution in the 
EU legislation (Regulation (EC) No 726/2004) 
o USA: Harmonize individual state provisions on automatic 
substitution restrictions  
 - Page 131 of 215 - 
IMPROVEMENT POTENTIAL AND SUGGESTIONS 
 
o Both: Establish basic requirements regarding information 
obligations to patients and physicians when a biological 
product is substituted and regarding prescription information 
requirements 
 Establish regulations to implement a globally working uniform and 
reliable traceability and identification system to ease postmarket 
surveillance activities 
 In order to avoid immune related consequences, multiple switching 
back and forth between biosimilar products and biological products 
should be restricted by legislation (e.g., substitution only allowed 
when sufficient clinical data are available, automatic substitution not 
allowed at pharmacy level) 
 Switching and multiple switching should only be allowed when 
suffient switching study data are available for each indication 
 Switching studies should become a mandatory part of the approval 
process of an interchangeable biosimilar product 
 In order to gather postmarketing safety and efficacy data, post-
authorization studies (PASS / PAES) should become a mandatory 
post-authorization requirement for biosimilar and interchangeable 
biosimilar products 
 Patient should always be involved in the decision when an 
interchangeable biosimilar product is intended to be used instead of 
the biological innovator product because any safety risk regarding the 
substituted product is with the patient 
3. Labeling and naming and prescription information 
Inconsistencies and lacks in labeling and naming as well as to the 
requirements regarding prescription information may hinder postmarketing 
surveillance activities through identification and transparency issues and 
may lead to prescription errors 
Suggestions: 
 Both regions should use the same labeling and naming convention for 
biological products, biosimilar and interchangeable biosimilar 
products to facilitate global postmarketing surveillance activities 
 Biosimilar products should be clearly identified as such to avoid 
prescription mix-ups with biological products 
 Interchangeable biosimilar product should be clearly identified as 
such to avoid prescription mix-ups 
 The indications for which a substitution of products can take place 
should be clearly stated on the outer packaging together with the 
name of the interchangeable product 
4. Pediatric assessment 
While the pediatric assessment is not required for biosimilar products in the 
EU, it is required for biosimilar products in the USA but not for biosimilar 
products for which an interchangeable status is applied.  
Suggestions:  
 Due to the specifics of biotechnology-derived products (e.g., protein 
instability, structural modifications, and immunogenic behaviour) 
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compared to chemically-synthesized drugs, pediatric assessment 
should always be required in the approval process of biosimilar 
products and interchangeable biosimilar product in both regions.  
Some potential for improvement is related to the clinical safety requirements. The 
most significant suggestions for improvements for both regions are listed and 
explained below. 
1. Extrapolation of data across indications 
Both regions allow extrapolating safety, efficacy and immunogenicity data 
across indications when justified. Studying only one indication may not 
provide adequate data to assess and adopt the potential for safety and 
efficacy issues including immunogenic risks for several indications. 
Suggestions: 
 Tighten the requirements to always require clinical safety-, 
immunogenity- and efficacy study data for each indication that is 
sought independent from previous study or testing results in order to 
demonstrate biosimilarity to the reference product; or 
 Eliminate the possibility of extrapolating data across indications for 
biosimilar products. 
2. Skipping of studies and conduct of post-authorization studies 
Both regions provide the possibility of waiving confirmatory clinical trials 
when the data generated in the non-clinical testing and human PK- /PD- 
studies are sufficient to demonstrate biosimilary comparability. Negative side 
effects may stay undetected if such study is waived. Further, product 
superiority may also stay undetected. The conduct of confirmatory trials as 
well as the extent and size of such study is based on the results derived in 
non-clinical testing and human PK-/PD- studies. Rare side effects may stay 
undetected in the pre-approval phase due to a small extent and size of such 
study. In consequence, such data need to be gathered postmarketing. 
Though, both regions recommend considering PASS / PAES requirements, 
but currently such studies are requested for biosimilar products only on a 
case-by case basis. 
Suggestions:  
 Eliminate the possibility to waive confirmatory clinical trials; 
 The study size should not depend on previous non-clinical study and 
human PK- /PD- study results.  
 A minimum study size should be predefined by regulation and this 
size should be met unless properly reasoned (e.g., orphan disease); 
 In order to gather postmarketing safety and efficacy data post-
authorization studies (PASS / PAES) should become a mandatory 
post-authorization requirement for biosimilar products and 
interchangeable biosimilar products. 
Some potential for improvement is related to the quality safety requirements. The 
most significant suggestions for improvements for both regions are listed and 
explained below. 
1. The re-demonstration of biosimilarity after marketing approval and changes 
to the manufacturing process is not required 
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Both regions do not address the re-demonstration of biosimilarity once a 
biosimilar product has received marketing approval. However, as there is a 
potential safety risk to the patient, especially when an interchangeable 
biosimilar product is used as substitute and is switched back and forth, this 
should be addressed. If changes to the manufacturing process of the 
(interchangeable) biosimilar product occur, it may happen that the 
characteristics of the biosimilar product including its safety profile are 
changed. Thus, it might be possible that after the manufacturing change the 
biosimilar product is less biosimilar to its reference products than it was 
before the process change and as demonstrated by the biosimilarity data in 
the application dossier. Hence, the biosimilar definition would not be 
applicable anymore for the changed biosimilar product and it cannot be 
guaranteed that the product that was interchangeable and / or biosimilar 
before still has this status fully after the change.  
Suggestions:  
 Regulatory authorities should discuss this topic 
 EU and US- legislation and regulations should be modified 
accordingly to address the issue;  
 Scientific guidance documents should be provided to implement 
requirements for re-demonstration after marketing approval when 
changes to the manufacturing process occur. 
No potential for improvement was found for the non-clinical safety requirements. 
 Improvement potential in the European Union  15.2
Some potentials for improvement were identified that may help improve the safety of 
biosimilar products in the EU. The most significant potential for improvement is 
related to the overall safety-relevant regulatory requirements. The suggestions for 
improvements are listed and explained below. 
1. Determination of interchangeability 
Currently, there is no legislation and regulatory process to determine the 
interchangeability of biosimilar products on EU-level and the EMA is not 
responsible and authorized to address this topic. In consequence, 
determination of the interchangeability is made on national level and is 
therefore based on different qualitative and quantitative assessment and 
determination criteria. This approach may hinder global postmarketing 
surveillance activities, may impact patient safety due to different 
determination criteria and may influence drug availability in the different EU-
member states. 
Suggestions: 
 To allow a uniform and competent authority decision on product 
interchangeability, the current decentralized (national) approach 
should be replaced by a centralized European approach by modifying 
the relevant EU- legislation Regulation (EC) No. 726/2004/EC; 
 The term interchangeability should be defined  
 Uniform and equal standards of determination and criteria to assess 
the interchangeability should be established in the EU legislation; 
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 The EMA should become the only authority allowed to assess and 
determine the interchangeability of biosimilar product using a uniform 
and centralized process and as part of the marketing authorization 
process similar to that of the FDA in the USA.  
 The EPAR should contain information to the interchangeability of a 
biosimilar product 
2. Requirements to the container closure system and delivery device 
The EMA similar products – quality issues guidance document provides the 
possibility to use a different container closure system as the reference 
medicinal product uses; provided that its potential impact on the biosimilar 
product safety and efficacy is appropriately justified. [199] However, the EMA 
guidance document does not further detail this topic, neither for biosimilar 
mAb products nor for biosimilar product at all.  
In contrast, the FDA is aware of the safety risks (e.g., immunogenicity) and 
quality issues appearing from interactions between biotechnology-derived 
product and container closure or delivery device systems. The FDA´s 
immunogenicity assessment guidance document recommends maintaining 
detailed raw material data of the container closure system and further 
recommends performing an extensive extractables and leachables 
laboratory assessment in order to evaluate the attributes of the system and 
possible interactions that could lead to degradation of the product structures. 
[60]. 
Suggestions:  
 Tighten the requirements for the use of a different container closure 
system and/or delivery device similar to the FDA requirements. This 
includes defining justification requirements and testing requirements 
for extractables / leachables; 
 Assess these data over shelf life duration; 
 The topic should be more detailed in the relevant EMA guidance 
document on quality issues  
 Requirements to the container closure system and delivery device 
3. Drug shortage pre-notification requirement 
While the FDA requires a notification of six month prior to a discontinuance 
or interruption in product manufacturing that could cause a significant 
disruption of drug product availability, a notification of only two month is 
required within the EU and only if the product ceases to be made available 
on the market (temporarily or permanently). This may lead to drug 
unavailability and could impact patient safety. 
Suggestions:  
 Extent the time frame of the pre-notification requirement from two 
month to six month. 
                                               
 
[199] 
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product; 
EMA/CHMP/BWP/247713/2012, Rev.1; 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.p
df 
 [60] 
Immunogenicity Assessment for Therapeutic Protein Products; Guidance for Industry; April 2014; 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf 
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4. Protection periods 
While the protection period for the biological innovator product is 12 years in 
the USA it is typically 10 years in the EU. Biosimilar products are sooner 
available on the EU- market, but two years postmarketing data of the 
reference product which would be available with the US-protection period, 
cannot be included and evaluated in the the approval process of the 
proposed biosimilar product. 
Suggestions:  
 Extent the protection period of the biological innovator product to 11 
years. 
5. General approach of the regulatory authorities regarding the process of 
marketing authorization 
In contrast to the EEA, the generation of clinical data in the USA occurs in 
the centralized regulatory framework of an investigational new drug 
application and therefore is an inherent part of the application and review 
process with the FDA. Thus, the FDA is involved in and familiar with the drug 
product at a very early stage of drug development. This differs from the 
process in the EEA where the approval process starts at a later stage with 
the submission of the dossier. Further, the FDA encourages the applicant to 
discuss the development program of the proposed biosimilar product and 
other topics at an early stage and additionally offers five different types of 
meetings that address topics specifically of biosimilar products while the 
EMA only offers regular pre-authorization scientific advice meetings.  
Suggestions: 
 The EMA should get involved in the application process at an earlier 
stage and should more actively encourage applicants to seek advice 
and meetings with the EMA.  
 The EMA should provide advice meetings that specifically address 
the topics of biosimilar products. 
 The review, approval and supervision of clinical trials should be 
centralized with the EMA to involve the EMA in the approval process 
at an early stage. 
 Improvement potential in the USA  15.3
There was no significant improvement potential found for the USA other than the 
items already described above.  
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16 Conclusion and Outlook 
 Conclusion 16.1
No major differences between the EU and the USA were identified with respect to 
the overall regulatory-safety standards that apply for biosimilar products established 
by the EU- / and US- law and as recommended in the scientific EMA- and FDA 
guidance documents.  
Except of slight differences, the overall safety-related regulatory requirements 
required by legislation in the EU and the USA are very similar, including 
pharmacovigilance requirements. The FDA regulations (CFR) require stricter 
reporting (e.g., reporting of biological product deviations) and processing (e.g., 
prompt review of adverse events) than that required by the EU and the regulation of 
drug shortage is different in the two regions. By EU regulation, a minimum of one 
qualified person to perform certain safety-related tasks (e.g., batch compliance), the 
FDA does not require that position. Further, the EU legislation has established and 
implemented the black triangle labeling that represents extended monitoring of new 
and high-risk products; a comparable instrument is not implemented yet in the USA. 
While the US- law considers the determination of interchangeability this is not part of 
the EU legislation. And the law in both regions, the EU and USA, does not consider 
the re-demonstration of biosimilarity after a change to the manufacturing process 
occurs post-authorization.  
While the US-law provides the FDA with more authority and power than the EMA is 
provided by Regulation (EC) No. 726/2004, the regulatory requirements established 
by EU legislation provide the manufacturers with more individual responsibility (e.g., 
they are responsible to watch their distributors) than the US-law provides to the US-
American medicinal product manufacturers. The main European legal document for 
medicinal products, Directive 2001/83/EC needs to be transposed into national law 
by the EU-member states while the United States Code applies without transposing 
into national law. In consequence, the EU-member states have more freedom 
regarding the implementation of the EU Directive into their national law. 
Regarding the pharmacovigilance and postmarketing requirements in both regions, 
the EU and the USA, these are very similar for the last few years. In both regions, 
pharmacovigilance includes postmarketing studies, clinical trials, risk evaluation and 
risk mitigation strategies, patient registries and special labeling. Although 
appropriate instruments to monitor and further confirm the safety and efficacy of 
medicinal drug products are available (e.g., postmarketing studies), their application 
is handled differently and on a case by case basis.  
Regarding the regulatory burden and available scientific guidance documents, there 
are some differences between the EU and the USA. The regulatory burden in the 
EU is higher than in the USA due to the European and national legislations and the 
required transformation of EU legislation into national law. The quantity of available 
guidance documents, in particular documents which address the specifics of 
individual product classes, is higher in the EU than in the USA. The scientific value, 
quality and content of the available scientific guidance documents regarding quality 
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issues, non-clinical and clinical requirements as well as overall safety-related 
considerations to biosimilar products is high in both regions.  
The scientific EMA- and FDA guidance documents concerning the quality, non-
clinical and clinical safety requirements for biosimilar products are very similar and 
comparable. The scientific content of the documents is mostly the same, but there 
are small differences (e.g., better explanations, examples) that make the FDA 
documents clearer and more meaningful.  
The most significant differences between the two regions, EU and USA, that were 
identified in the scientific guidance documents and which belong to the safety of 
biosimilar products are related to the: [1] determination of interchangeability; [2] 
automatic substitution of biosimilar products; [3] pediatric assessment requirement; 
[4] the extrapolation of safety and efficacy data including immunogenicity data 
across indications; and [5] testing requirements when using a different container 
closure or delivery device system.  
 Outlook 16.2
Overall, there is a clear trend towards the increasing usage of biosimilar products in 
both the EU and the USA and it is assumed that the scientific requirements and 
regulatory approaches to biosimilar products in the EU and the United States are 
adjusted to each other in the coming decades. It is expected that further scientific 
guidance documents for biosimilar products will be published from both regulatory 
authorities with increasing market experience related to those products. In the 
European Union the topic of product interchangeability must be addressed by 
legislation and in both regions the re-demonstration of biosimilarity after marketing 
authorization when changes to the manufacturing process occur.  
There are several cooperative projects between the EMA and the FDA for biosimilar 
products with the aim to harmonize the scientific practice applied to these products 
in order to minimize regulatory discrepancies and to expedite the availability of 
biosimilar products to patients. [245] To improve pharmacovigilance, the exchange of 
relevant important information (e.g., product risk-assessments and related safety 
issues) and collaboration between regulatory authorities is further developed within 
the pharmacovigilance cluster that was established in 2014. [246]  [247]  [245] Further, 
since the last few years, cooperation is established also in other areas such as 
inspections (e.g., mutual GMP-manufacturing site inspections), parallel scientific 
advice and best regulatory approach. [248] 
                                               
 
[245] 
FDA, European Commission and EMA reinforce collaboration to advance medicine development and 
evaluation, July 2015; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_detail_00236
7.jsp&mid=WC0b01ac058004d5c1 
 [246] 
FDA and European Medicines Agency strengthen collaboration in pharmacovigilance area, February 2014; 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386372.htm 
 [247] 
Guiding principles for the international pharmacovigilance cluster, May 2015; 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/12/WC500179390.pdf 

 [248] 
General Principles EMEA - FDA Parallel scientific advice, EMEA/24517/2009, 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/11/WC500014868.pdf 
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To facilitate the new EU-pharmacovigilance package the EMA offers since July 2015 
the possibility to obtain scientific advice on post-authorization safety studies (PASS) 
within a pilot project that specifically addresses non-mandatory PASS-studies. [249] 
Goal is the establishment of an integrated advice that covers the complete product-
lifecycle and which addresses safety-, quality-, and efficacy aspects of medicinal 
products and facilitates proactive pharmacovigilance strategies. [250] In the USA, 
meetings with the FDA to discuss such topics and other issues are already common 
and part of the product approval process. However, this development let assume 
that the EMA will follow the FDA in their approach and provide advice and meeting 
options to applicants to get involved in the approval process at an earlier process 
stage than current.  
 
**END OF DOCUMENT** 
 
                                               
 [249] 
Scientific advice and protocol assistance, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049.jsp&mid=
WC0b01ac05800229b9 
 [250] 
Post-authorisation safety studies: questions and answers, Question 10. Scientific advice for safety studies 
NEW, July 2015; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000134.jsp&mid
=WC0b01ac0580796d88 
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Appendix A: Schematic diagram of monoclonal antibody production via hybridoma 
technology  
 
Hybridom – Technik ©by Martin Brändli  [251]  
 
(1) Immunization of a mouse; (2) Isolation of B-cells from spleen; (3) Cultivation of myeloma 
cells; (4) Fusion of B-cell and myeloma cell; (5) Selection and screening of suitable cell lines; 
(6) Processing or storage of myeloma cells (7) Antibody production in-vitro (7a), or in-vivo 
(7b); (8) Antibody harvesting
 [251]
  
                                               
 [251] 
Diagram showing the production of monoclonal antibodies via hybridoma technology, Martin Brändli  
Eigenes Werk, CC BY-SA 2.5; https://commons.wikimedia.org/w/index.php?curid=560703 available on 
https://de.wikipedia.org/wiki/Hybridom-Technik 
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Appendix B: Historic milestones in biotechnological development  
Year Who Scientific event 
6000 years 
ago 
Sumerian Beer brewing and fermentation 
1673 Antonie van 
Leeuwenhoek  
Microscoped bacteria 
1864 and 
1876 
Louis Pasteur Pasteurization and active immunizations 
1882 Robert Koch  Discovered the tuberculosis pathogen 
1865 Gregor Mendel Basics of genetics  
1890 von Behring and Kitasato Use of Antitoxins in infectious diseases 
treatment 
1902 Hans Spemann Cloned a newt by embryo splitting 
1906 Paul Ehrlich “Magic bullets” concept 
1909 Wilhelm Johannsen Has coined the terms “gen”, “genotype”, 
“phenotype” 
1919 Károly Ereky Created the term Biotechnology 
1928 Alexander Fleming Discovered mold (fungus) Penicillium 
chrysogenum producing an antibiotic 
substance 
1944 - Large scale antibiotics production  
1952 Briggs and King Transfer of frog cell nucleus  
1953 Watson and Crick Discovered double helical structure of the DNS 
1975 Köhler and Milstein Hybridoma-technology to produce monoclonal 
antidbodies 
1977 Genentech, Inc. Production of human somatostatin in E. coli  
1980 Exxon Discovery and patenting on oil absorbing 
bacteria  
1980 Schell Discovery of Agrobacterium tumefaciens  
1982 Genentech Genetically-engineered Insulin 
1982 Frederick Sanger DNA-sequencing of bacteriophage Lambda 
1986 Janssen-Cilag FDA approval of the first murine Muromonab-
CD3 monoclonal antibody Orthoclone OKT3® 
1988 Harvard University OncoMouse 
1995 J. Craig Venter Sequenzierung des Genoms des Bakteriums 
Hemophilus influenza. 
1996 Various researchers DNA-sequencing of Saccharomyces cerevisae 
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Year Who Scientific event 
1998 James Thomson Isolation of stem-cells from human embryo and 
their cultivation 
1996 Keith Campbell Clone sheep Dolly. 
1998 Roche EMA-approval of Rituximab (trade name 
MabThera®; chimeric anti-CD20-mAb) mAb to 
treat types of the Non-Hodgkin-Lymphoma 
1999 Janssen Biologics B.V. EMA-approval of TNF-alpha-blocker Infliximab 
(trade name Remicade®; chimeric mAb) to 
treat Morbus Crohn and Rheumatoid Arthritis 
2000 Roche EMA-approval of Trastuzumab (Herecptin®) 
humanized mAb to treat breast cancer and 
stomach cancer 
2003 Human genome project Sequencing of human DNA 
2004 ImClone Systems EMA-approval of Cetuximab (trade name 
Erbitux®; chimeric mAb from type IgG1) to 
treat bowel cancer 
2006 Shinya Yamanaka and 
colleagues 
Re-programming of differentiated mouse 
epithelial cells back into embryonically 
condition 
2009 Fresenius Biotech/ Trion 
Pharma 
EMA-approval of Catumaxomab (trade name 
Removab) the first trifunctional mAb to treat 
ascites associated with epithelial cell adhesion 
molecule (EpCAM) -positive carcinoma 
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Appendix C: DNA cloning in expression systems 
In the following the process of DNA-cloning in order to produce recombinant proteins and 
recombinant monoclonal antibodies is described in its basics and illustrated with simplyfied 
figures. Basically, a human DNA-insert, which is a fragment of the human DNA containing 
the gene desired to get cloned, is placed (cloned) into a DNA-plasmide vector. Typically this 
is a plasmid ring, annular DNA-molecules of a phage, that is then transformed (into bacterial 
cells) or transfected (into eukaryotic cells) into a host cell. In the host cell again, the desired 
human DNA-information contained in the plasmide, is replicated without incorporating the 
human DNA-information into the host cell genome. Usually, bacterial cells are used as 
expression systems (e.g., E. coli).
 [252]
 The figure below shows the process described above 
in a highly simplified fashion. 
 
                                               
 [252] 
Der Experimentator: Neurowissenschaften, ISBN: 978-3-8274-2368-9, Seiten 7-32; DOI 10.1007/978-3-
8274-2369-6_1; http://www.springer.com/cda/content/document/cda_downloaddocument/9783827423689-
c2.pdf?SGWID=0-0-45-999954-p174010460 
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Appendix D:  Definitions  
Point 1 of the Annex of Regulation (EC) No 726/2004:  
“Medicinal products developed by means of one of the following biotechnological 
processes: 
— recombinant DNA technology, 
— controlled expression of genes coding for biologically active proteins in 
prokaryotes and eukaryotes including transformed mammalian cells, 
— hybridoma and monoclonal antibody methods.”
 [26]
 
21 CFR 601.2(a) “specified biological products”: 
“…An application for any of the following specified categories of biological products 
subject to licensure shall be handled as set forth in paragraph (c) of this section:  
(1) Therapeutic DNA plasmid products;  
(2) Therapeutic synthetic peptide products of 40 or fewer amino acids;  
(3) Monoclonal antibody products for in vivo use; and  
(4) Therapeutic recombinant DNA-derived products.”
 [27]
 
Article 1 of Directive 2001/83/EC 
“2. Medicinal product: 
(a) Any substance or combination of substances presented as having properties for 
treating or preventing disease in human beings; or 
(b) Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic 
action, or to making a medical diagnosis.”
 [28] 
Part I of Appendix I of Directive 2001/83/EC 
“A biological medicinal product is a product, the active substance of which is a 
biological substance. A biological substance is a substance that is produced by or 
extracted from a biological source and that needs for its characterisation and the 
determination of its quality a combination of physico-chemical-biological testing, 
together with the production process and its control….”
 [28]
 
Section 3.1 of the EMA similar products guidance document:  
“A biosimilar is a biological medicinal product that contains a version of the active 
substance of an already authorised original biological medicinal product (reference 
medicinal product) in the EEA. Similarity to the reference medicinal product in terms 
of quality characteristics, biological activity, safety and efficacy based on a 
comprehensive comparability exercise needs to be established. 
In principle, the concept of biosimilarity is applicable to any biological medicinal 
product. However, in practice, the success of developing a biosimilar will depend on 
the ability to produce a medicinal product which is similar to the reference medicinal 
product, and to convincingly demonstrate the similar nature of the concerned 
products…”
 [30]
 
Section 201(g) of the FD&C Act: 
                                               
 [26] 
Regulation (EC) No 726/2004 Article 3(1) and Point 1 of the Annex; OJ L 136, 30.4.2004, p. 1, Consolidated 
version 05.06.2013; http://ec.europa.eu/health/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf 
 [27] 
21 CFR §601.2(a); April 2014; http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol7/pdf/CFR-2014-title21-
vol7-part601.pdf 
 [28] 
Directive 2001/83/EC Title I, Definitions of Article 1; OJ L 311, 28.11.2001, p. 67, Consolidated version 
16/11/2012; http://ec.europa.eu/health/files/eudralex/vol-
1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf 
 [30] 
Guideline on similar biological medicinal products; CHMP/437/04 Rev 1, 23 October 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf 
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“(g)(1) The term "drug" means (A) articles recognized in the official United States 
Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or 
official National Formulary, or any supplement to any of them; and (B) articles 
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of 
disease in man or other animals; and (C) articles (other than food) intended to affect 
the structure or any function of the body of man or other animals; and (D) articles 
intended for use as a component of any article specified in clause (A), (B), or (C).”
 
[31]
 
Section 351(i)(1) of the PHS Act: 
“(1) The term "biological product" means a virus, therapeutic serum, toxin, antitoxin, 
vaccine, blood, blood component or derivative, allergenic product, protein (except 
any chemically synthesized polypeptide), or analogous product, or arsphenamine or 
derivative of arsphenamine (or any other trivalent organic arsenic compound), 
applicable to the prevention, treatment, or cure of a disease or condition of human 
beings.”
 [32]
 
Section 351(i)(2) of the PHS Act: 
“(2) The term "biosimilar" or "biosimilarity", in reference to a biological product that is 
the subject of an application under subsection (k), means- 
(A) that the biological product is highly similar to the reference product 
notwithstanding minor differences in clinically inactive components; and 
(B) there are no clinically meaningful differences between the biological product and 
the reference product in terms of the safety, purity, and potency of the product.”
 [32]
 
 
                                               
 [31] 
21 USC §321(g); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:21%20section:321%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title21-section321%29&f=treesort&edition=prelim&num=0&jumpTo=true 
 [32] 
42 USC §262 (i)(1), 42 USC §262 (i)(2)(A),(B); April 2015; 
http://uscode.house.gov/view.xhtml?req=%28title:42%20section:262%20edition:prelim%29%20OR%20%28
granuleid:USC-prelim-title42-section262%29&f=treesort&edition=prelim&num=0&jumpTo=true 
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Appendix E: The most significant changes with Regulation (EU) No 536/2014 on clinical 
trials on medicinal products for human use  
1. Legal form is now that of a Regulation  
2. EU-Portal and electronic database (Article 80, 81) that enables a streamlined 
application procedure and which is managed by the EMA 
3. Compilation of only one application dossier (IMPD) containing the information of 
Annex I of the REGULATION  
4. Member states are requested to meet timelines of Articles 6 and 7 when involving 
national Ethics committees (Article 4) 
5. Harmonized assessment and decision procedure with specified timelines (Articles 6-
8) 
6. Amplification of the tacit approval method in Articles 6-8 
7. Ease of reporting procedures by using the electronic EU-database (Article 40) 
8. Depending on the clinical protocol requirements certain adverse events may not 
require to be reported (Article 41) 
9. Cooperation between the EU-Member sates (Article 44) regarding the assessment 
of information required in Article 42 and 43 
10. Articles 25 and 79 specifying conditions of non-EU clinical trials  
11. Improved transparency belonging clinical trial information and publication of clinical 
trial results also of negative outcomes, by using the electronic EU database (Article 
81) and several notification requirements (Article 37) 
12. The GMP DIRECTIVE 2003/94/EC and the GCP DIRECTIVE 2005/28/EC, in so far 
they concern clinical trials, will be replaced by other regulations (Article 63 relates to 
GMP, Article 78 relates to GCP) 
 
 
 
 
- Page 173 of 215 - 
APPENDIX F                   - Page 173 of 215 - 
 
Appendix F: Significant differences between the clinical trials Regulation (EC) No 
536/2014 and 21 CFR Part 312 IND 
Regulation (EC) No 536/2014 21 CFR Part 312 IND 
Focus is on clinical trials at all and their 
adequate conducting 
Focus is on new drugs – within an IND the 
FDA supports for example the drug 
development, the planned design of clinical 
investigations, reviews the adequateness of 
clinical investigations in the view of the 
quality of gathered data/marketing approval, 
etc.,  
Whereas Section '12':  
Regulation uses Risk categories A, B, C for 
CT as specified in OECD Recommendation 
on the Governance of Clinical Trials of 10. 
December 2012 
- 
Article 2 provides definition of “Clinical 
study” and “Clinical trial”. A Clinical trial is a 
category of a clinical study 
§312.3(b) Definition of “Clinical investigation”  
Article 3 defines the objectives of this 
regulation regarding to clinical trials: goals 
are to protect the human being participating 
the clinical trial, generation of solid and 
robust data 
§312.1(a) Scope of an IND is to allow 
shipping of non-approved drugs by law thru 
the US for the purpose of clinical 
investigations (Exemption from pre-market 
approval requirements) 
§312.22(a) IND objectives: Overall: ensuring 
safety and rights of the subjects; Phase I: 
safety assessment; Phase II and III: help 
ensuring qualitative adequate scientific 
evaluation of the investigated drug and 
assessment of the scientific quality of the 
clinical data in order to review the statutory 
appropriateness of the gathered scientific 
data for marketing approval 
Article 5 and Article 80 submission of an 
application trough the EU-Portal developed, 
maintained and managed by the EMA 
Validation of the CT application within 10 
days after submission from NCA of the EU-
member state concerned 
§312.20(a) IND submission to the FDA  
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Regulation (EC) No 536/2014 21 CFR Part 312 IND 
Article 6 timelines Assessment report –Part 
I: within 45 days from the validation date the 
final Part I including its outcome shall be 
submitted through the EU-Portal to the 
sponsor and EU-MS 
Period may be extended to 95 days in total 
for CT on ATMPs or drug products as 
defined in point 1 of the Annex to 
REGULATION (EC) No 726/2004 
(BIOLOGICALS discussed within this 
dissertation)  
N/A 
Article 7 timelines Assessment report –Part 
II: within 45 days from the validation date the 
final Part II including its outcome shall be 
submitted through the EU-Portal to the 
sponsor  
N/A 
Article 8 Decision on the CT application shall 
be a single decision published to the 
sponsor via EU-Portal within 5 days from 
last assessment day (Article 7). The 
decision of the Part I assessment is the 
more crucial decision of both Parts.  
§312.40(b)(1): IND goes into effect 30 days 
after FDA has received the IND submission 
or (b)2 on earlier written notification. FDA will 
confirm the IND receiving date with the 
sponsor 
Article 8 After two years from CT approval 
date the CT approval expires if no study 
subjects have been recruited unless the 
sponsor applies for extension 
§312.45 After ≥two years from CT approval 
date the CT approval turns into an inactive 
status if no study subjects have been 
recruited. Prior to change the IND status 
FDA will notify the sponsor 
§312.44 After ≥five years of inactive status of 
an IND the IND will be terminated by the 
FDA 
Article 12 withdrawal possible at any time 
until the reporting date. Reason for CT 
withdrawal shall be published via EU-Portal  
§312.38(a) an effective IND could be 
withdrawn at any time 
§312.38(b): FDA shall be informed after the 
IND is withdrawn 
§312.38(c):If an Safety issue is reason for 
the withdrawal of an IND the FDA shall be 
informed promptly and the reason for the 
withdrawal shall be provided 
Articles 18-23 assessment and decision on 
substantial modifications to the CT 
§312.30(b)(1) changes in a protocol that 
significantly affects the subjects safety 
 
Article 36 Notifications: start of CT within 15 
days from start of the CT; First visit of the 
first subject within 15 days from the first visit; 
End of subject recruitment within 15 days 
after end 
N/A 
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Regulation (EC) No 536/2014 21 CFR Part 312 IND 
Article 38 temporary halt or early termination 
of the CT by the sponsor due to subject 
safety (affecting risk-benefit) without delay 
and within 15 days starting from the hold 
date/termination date 
§312.56 (d) if the sponsor realizes an 
unreasonable and significant risk of the 
investigational drug to subjects the sponsor 
shall notify FDA and shall stop the relevant 
investigation asap but no later than 5 
working days after the decision to stop the 
investigation was made 
Article 37 sponsor shall notify about the end 
of a CT within 15 days from the end of the 
CT;  
Within one year after the CT has ended a 
summary report and a report 
understandable to non-qualified persons 
shall be published through the EU-CT-
database and with regard to MAA the clinical 
study report shall be published through the 
EU-CT-database within 30 days after MAA 
has been received 
N/A 
Article 41 Investigator shall report serious 
adverse events to the sponsor without delay 
within 24 hours of becoming aware of the 
event 
312.64(b) Investigator must report serious 
adverse events to the sponsor immediately 
after of becoming aware of the event 
Article 42 reporting line for suspected 
unexpected serious adverse reactions: fatal 
or life-threatening SUSARs ASAP but within 
7 days after notice 
Non-fatal or non- life-threatening SUSARs 
within 15 days after notice 
Non-fatal or non- life-threatening SUSARs 
which later turn into fatal or life-threatening 
SUSARs: ASAP but within 7 days after 
notice 
§312.32 reporting time line of max. 15 days 
for §312.32 c (1)(i), c (1)(ii), c (1)(iii), c (1)(iv) 
after the sponsor determines that the event 
is one out of the listed cases: 
1. Non-fatal or non- life-threatening 
SUSARs after notice (same as in the 
EU),  
2. Findings from other studies,  
3. Findings from animal or in vitro 
testing,  
4. Increased rate of occurrence of 
serious suspected adverse reactions 
§312.32(v): provide additional data to FDA 
upon request within 15 days after requested 
(§312.32(2) reporting time line for fatal or 
life-threatening SUSARs asap but within 7 
days after receipt of event 
informationsame as in the EU) 
Article 52 serious deviations from Clinical 
protocol or regulation shall be reported 
without delay but within 7 days of sponsor 
becomes aware of it 
§312.56(b) deviations by the investigator 
from the agreed clinical documents or 21 
CFR 312 shall be reported to the FDA by the 
sponsor if the investigators participation on 
the trial is ended because of this deviation 
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Regulation (EC) No 536/2014 21 CFR Part 312 IND 
Article 53 Unexpected events which affect 
the subject safety shall be reported without 
delay but within 15 days sponsor becomes 
aware of it 
Refer to §312.32 reporting time line of max. 
15 days for §312.32 c (1)(i), c (1)(ii), c (1)(iii), 
c (1)(iv) 
Article 54 Urgent safety measures in case of 
serious events related to subject safety: 
notification through the EU portal without 
delay but within 7 days from the date the 
measures were implemented 
N/A 
Article 57 clinical trial master file for sponsor 
and investigator 
§312.62 (b) case histories and other records 
§312.57 
Article 58 Archiving of the Clinical trial MF 
25 years after the clinical trial  
§312.57 records related to the investigational 
drug(a) and financial interest (b) shall be 
kept, retention time for these records and 
reports is for 2 years after the date of 
marketing approval  
§312.57 (d) sponsor shall keep reserve 
samples of test articles and reference 
standards as specified in §320.38, §320.63 
with a retention time of 5 years after the date 
of marketing approval 
§312.62 (c) case history record retention 
time for 2 years after the date of marketing 
approval  
Article 61 qualified person acc Article 49(2) 
Dir 2001/83/EC 
N/A 
Article 66 Labelling requirements (outer and 
immediate): Goal is to ensure subject safety 
and solid generated data  
§312.6 Labelling on immediate packaging, 
Goal is to show it is an IND approved 
investigational device. It must not claim 
misleading or not proven information 
Article 76 Damage compensation N/A 
Article 77 clinical trial – corrective measures: 
before they will take place the applicant gets 
7 days’ time to give its opinion 
§312.42 (d) sponsor will be informed by the 
FDA by phone or other fast communication 
about the imposition of the clinical hold and 
receives within 30 days a written statement 
to the clinical hold issue 
§312.42 (c) where possible, before issuing a 
clinical hold the FDA allows discussion of the 
deficiency in order to solve it 
N/A §312.41 (a), (b) The FDA provides advice 
upon sponsors request on an IND. The FDA 
may be request additional data or comments 
on deficiencies at any time during the IND 
N/A §312.47 meetings with the FDA  
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Regulation (EC) No 536/2014 21 CFR Part 312 IND 
N/A Subpart E provisions (drugs to treat life-
threatening and severely-debilitating illness) 
e.g. §312.82 early consultation (e.g. Pre-
IND) possibility in order to reach agreement 
on the planned studies and testings as well 
as to clarify pediatric aspects all in the light 
of the aimed marketing approval or §312.87 
Active monitoring of clinical trials 
 
 
 
 
- Page 178 of 215 - 
APPENDIX G 
 
Appendix G: The modules of the CTD format, guideline documents and contents  
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Appendix H: EU-Dossier requirements for biosimilar products and biological originator 
products 
As illustrated are full quality data plus comparability data required for a biosimilar products 
application while the volume of non-clinical and clinical data is less,
 [4]
 Graphic © by 
European Medicines Agency 
 
 
A biosimilar product application dossier shall provide a full quality dossier and data 
demonstrating comparability with the reference medicinal product by using appropriate 
physico-chemical and in vitro biological tests, non-clinical studies and clinical studies.
 [57]
 
 
 
                                               
 [4] 
ICH GCG ASEAN Training Workshop on ICH Q5C, 30-31 May 2011, Kuala Lumpur; Alberto Ganan 
Jimenez & Brigitte Brake; 
http://www.ich.org/fileadmin/Public_Web_Site/Training/ASEAN_Q5C_workshop_May_2011/SESSION_IVa_
Biosimilars.pdf 
 [57] 
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active 
substance: non-clinical and clinical issues; EMEA/CHMP/BMWP/42832/2005 Rev1, 18 December 2014; 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf 
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Appendix I: Approximate dossier shares of the specific parts in BLA application dossiers 
and abbreviated BLA application dossiers 
Please note, diagram and values are not to scale. The diagram only intends to visualize the 
differences on an approximately basis and to highlight the major differences between the 
data content and volume of a biosimilar products application versus those of biological 
products. As illustrated is the volume of analytical data that have to be generated for 
biosimilar products much higher, while the clinical safety and efficacy data are less. 
 
 
 
Analytical Non-clinical Clinical Pharmacology Clinical Safety & Efficacy
Biologicals Biosimilars 
- Page 181 of 215 - 
APPENDIX J 
 
Appendix J: Significant safety-relevant regulatory standards as established by EU legislation (Directive) 
Directive 2001/83/EC, consolidated version 16.11.2012 
Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 6: authorization requirement for medicinal 
products prior to marketing 
Article 11: add standard sentences in SmPC 
labeling in order to promote the reporting of 
suspected adverse reactions (SAR) by healthcare 
professionals  
 
Article 8(1): drug application to the competent 
authorities 
Article 8(2): applicant being established in the EEA 
Article 8(3): specifies the documents that must be 
submitted within a market authorization application 
e.g., Article 8 (3)(c) requires international non-
proprietary name (INN) recommended by the WHO, 
if available 
Article 8(3)(ca): environmental assessment  
Article 8 (3)(iaa) and (m): risk management plan 
and risk management system 
Article 21: European Public Assessment Report 
(EPAR) requirement  
Article 21a: defines further post-authorization 
measures that the applicant shall take (e.g., post-
authorization efficacy studies (PAES)) 
Article 41: the manufacturer must use the service of 
a qualified person 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 10(2)(a): defines the 'reference product' 
“‘reference medicinal product’ shall mean a 
medicinal product authorised under Article 6, in 
accordance with the provisions of Article 8;” 
 
Article 22 and 22a: allows national competent 
authorities to require further post-authorization 
measures (PAMs) 
Article 46: defines duties of the holder of a 
manufacturing authorization and specifically points 
out compliance with good manufacturing practice 
and good distribution guidelines.  
The holder of a manufacturing authorization must 
conduct self-inspections, must allow competent 
authority inspections at any time, must use the tool 
of a formalized risk assessment and must have an 
implemented quality system.  
If there is a suspicion that one of its medicinal 
products got falsified then the manufacturing 
authorization holder must report this to the 
competent authorities and to the MAH.  
The manufacturing authorization holder must also 
verify that its suppliers, importers and distributors of 
active substances are registered with the 
competent authority and must verify originality of 
the active substances and excipients and must 
qualitatively check them 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 11: defines minimum requirements for the 
summary of the product characteristics (SmPc) and 
details the requirements laid down in Article 23 of 
the Regulation (EC) No 726/2004 for medicinal 
products under additional monitoring, listed drugs 
must be identified by a black symbol.  
 
Article 23 and 23b(1): requires that the marketing 
authorization holder keeps its drug related 
processes to the latest state of the art, technically 
and scientifically, and also requires of the MAH the 
reporting to and approval of any changes that may 
influence the approved drug, by the national 
competent authority.  
Article 23b(1): further requires from the European 
Commission to provide an instrument for examining 
variations (variation-system)  
Article 23(a) at minimum 2 month before a product 
is taken temporarly or permanently from market the 
MAH shall notifiy the competent authority. 
Article 51: requires in paragraph 1 that the qualified 
person shall secure that:  
a) “in the case of medicinal products 
manufactured within the Member States 
concerned, that each batch of medicinal 
products has been manufactured and 
checked in compliance with the laws in 
force in that Member State and in 
accordance with the requirements of the 
marketing authorization; 
b)  In the case of medicinal products coming 
from third countries, irrespective of whether 
the product has been manufactured in the 
Community, that each production batch has 
undergone in a Member State a full 
qualitative analysis, a quantitative analysis 
of at least all the active substances and all 
the other tests or checks necessary to 
ensure the quality of medicinal products in 
accordance with the requirements of the 
marketing authorization”. (pre- and post-
authorization) 
Article 19: defines the actions and instruments of 
the authorities in order to allow reliable and 
scientific based decisions regarding a drug 
application  
Article 24: limits the validity of a marketing 
authorization to five years and requires undergoing 
a once-only renewal afterwards  
Article 52a: registration of importers, manufacturers 
and distributors of active substances that have its 
business in the EU  
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 20: requires that competent authorities shall 
verify the compliance with the legal requirements of 
third country manufacturers and importers and shall 
ensure that third parties used as sub-manufacturers 
are compliant (e.g. by performing inspections)  
Article 31(4): allows the competent authorities to 
suspend the marketing authorization (post-
authorization) of medicinal drugs approved under 
the Centralized Procedure 
Article 55: defines the information to be shown on 
primary packaging/blister packs.  
Article 40: requires a manufacturing authorization 
for drug production, -filling, -packaging and -
presentation and an import authorization for third 
country imports  
Article 54: defines the required safety features of 
the outer packaging  
Article 54(a) outer packaging must show the  
international non-proprietary name (INN), if 
available or the common name of the active 
substance (for up to three active substances 
contained in the drug) 
Article 54a(4) requires that the national competent 
authorities shall list non-prescription medicinal 
products with having a risk of getting falsified and 
provide this list to the European Commission  
Article 56: requires clarity, readability and 
inextinguishably for the information displayed on 
the packaging and the Article 56a requires the drug 
name on the packaging in braille format  
Article 42: requires that the manufacturer is 
inspected by the authorities prior to receive the 
manufacturing authorization  
Article 64: gives the competent authority the right to 
suspend the marketing authorization until the 
labeling is corrected and in accordance to the legal 
requirements 
Article 58: requires an package leaflet  
Article 70: classification of medicinal products into 
non-medical prescriptive and medical prescriptive 
Article 74: changes from the authorities regarding to 
the classification of medicinal products 
Article 59: defines contents of the package leaflet 
and requires a proof of readability  
 Article 101 and 102: requires the member states to 
run a pharmacovigilance system, to self-audit these 
and details the content of a pharmacovigilance 
system 
Article 63: requires that relevant information (please 
refer to Articles 54, 59, 62 of the DIRECTIVE) are 
available in languages of the EU countries where 
the drug is marketed (pre- and post-authorization) 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
 Article 107: requires the MAH to gather information 
related to suspected adverse reactions, to 
scientifically analyze these data and to report them 
via internet-portal (EudraVigilance),  
within clinical trials such information shall be 
handled according Directive 2001/20/EC; 
reporting requirement of 15 days for serious 
suspected adverse reactions after receiving the 
information 
reporting requirementof 90 days for non-serious 
suspected adverse reactions after receiving the 
information,  
all information regarding to adverse have to be 
provided online via EudraVigilance Database 
(Article 24 of Regulation (EC) No. 726/2004) 
Article 76: requires a marketing authorization for 
medicinal products´ wholesale distribution and 
storage and a wholesale authorization (which is 
included in the manufacturing authorization)  
 Article 107a: requires the EU member states to 
collect, analyze and report adverse data as 
described in Article 107 
Article 77: requires authority inspections of 
wholesalers  
 Article 107b: requires the MAH to submit periodic 
safety update reports (PSUR) to the EMA 
Article 80: defines items that have to be fulfilled 
from wholesale authorization holders (distributors) 
e.g., full track and trace system, quality system, risk 
management, keeping distribution records  
 Article 107h: requires the national competent 
authorities and the EMA to follow up on 
manufacturer actions minimizing the risk, to analyze 
EudraVigilance-data and to react accordingly to the 
outcome) 
Article 104: requires the MAH to run a 
pharmacovigilance system and a risk management 
system and to analyze obtained data, MAH 
pharmacovigilance self-inspections 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
 Article 107i: authorizes the competent authorities 
and EMA to initiate a procedure to revoke, suspend 
or refuse a marketing authorization or renewal, or to 
stop distribution 
Article 111: allows authorities to conduct 
unannounced inspections at any time 
 Article 107n-q: details the supervision of post-
authorization safety studies 
 
 Article 116: suspension, revocation and withdrawal 
of marketing authorizations thru the competent 
authorities because , of safety and other reasons 
 
 Article 117a: requires a national system to avoid 
distribution of harmful and falsified medicinal 
products 
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Appendix K: Significant safety relevant regulatory standards as established by EU legislation (Regulation) 
Regulation (EC) 726/2004, consolidated version 05.06.2013 
Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 2: MA holder must be established in the 
Union market community. 
Articles 10a: Post-marketing obligations to the 
MAH: PASS, PAES and further measures 
supplementing the obligations 
Article 18: Monitoring of the manufacturing and the 
Pharmacovigilance system on national level, 
Manufacturing authorization, link to Article 40(3) 
2001/81/EC 
Article 3: Authorization requirement for medicinal 
products prior to marketing 
Article 3 (3): The reference product of a generic 
must be a medicinal product authorized within the 
EU. 
Article 3 (3) only refers to generics and Article 
3(3)(c) only talks about the name and linguistic 
version of the INN for generics,  
 
 
 Article 13 (1): approved medicinal products to be 
entered into the Community register under issuing a 
specific registration number,  
Article 13(2) marketing authorization is published in 
the Official Journal of the European Union including 
the INN of the active substance 
Article 13 (3) MAH to notify the Agency if the 
product marketing is interrupted, temporarily or 
permanently. The notification shall be made at 
minimum 2 months before the interruption happens. 
Article 19: Regarding to national level 
responsibilities links are given to Title IV 
(“Manufacture and Importation”) and XI 
(“Supervision and Sanctions”) of 2001/83/EC Also 
on national level is the monitoring of manufacturer 
as well as monitoring of Pharmacovigilance and 
relevant Inspections on national level (link to Titles 
IX (“Pharmacovigilance”) and XI of 2001/83/EC) 
Article 4: Community to grant and supervise the 
marketing authorization through CHMP (established 
with Article 5) 
Article 14, 14a: MA renewal after 5 years, 
implementation of defined conditions into the MAH 
Risk management system 
Article 27: Monitoring of literature through the EMA 
and maintenance of Eudravigilance 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
Article 6: Documents required in an application – 
link to Directive 2001/83/EC Articles 8(3), 10, 10a, 
10b or 11. With regard to genetically modified 
organisms (GMO) a link to the requirements of 
Directive 2001/18/EC or Directive 90/220/EEC is 
given 
Article 16: Approval of changes/variations, actuality 
of the Pharmacovigilance-system master file, duty 
to supply defined information 
 
Article 7: Medicinal product in application, its 
starting material and other can be tested in an 
official medicines control laboratory in order to the 
opinion preparation process through the committee 
for human medicinal products 
Article 20: Procedure for the suspension of the 
MAA by member states 
 
 
Article 8: (unannounced) inspections as part of the 
application examination process by the committee 
CHMP  
Article 21: Pharmacovigilance Link to article 104 of 
2001/83/EG 
 
Articles 12: Refusal of marketing authorization Article 22: Safety announcements and link to article 
106a(1) of the 2001/83/EC 
 
 Article 23: Black symbol list –extended monitoring  
 Article 24: Eudravigilance database  
 Article 28: Recording and reporting of SARs, link to 
article 107, 107(a), (b), (c) of 2001/83/EC 
 
 Article 28a and b: Measures for approved medicinal 
products taken by EMA and on national level, non-
interventional PASS with link to Articles 107m, 
107n-107p and 107q of 2001/83/EC 
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Appendix L: Significant biological specific safety relevant regulatory requirements as established by US legislation 
21 CFR Part 600-680, 42 USC §262 of the PHS and 21 USC §§ 301 et seq.of the FD&C Act 
Pre-authorization Post-authorization Overall (pre-and post-authorization) 
21 CFR 601.2 Applications for biologics licenses; 
procedures for filing: Requirement of BLA 
submission prior to obtain approval under section 
351 of the Public Health Service Act (Please also 
refer to 42 USC 262(a)) 
BLA approval is based on meeting applicable 
requirements to the establishment(s) and the 
biological product- these requirements shall ensure 
the continued safety, purity, and potency of 
biological products.  
Submitted data shall be originated from:  
-non-clinical laboratory studies, 
-clinical studies that demonstrate that the applied 
product “…meets prescribed requirements of 
safety, purity, and potency; with respect to each 
nonclinical laboratory study…”  
-and, for licensure applications for biosimilar the 42 
USC 262(k)(2)(i) requires data demonstrating 
biosimilarity and, if so,  interchangeability to one 
FDA approved reference product (42USC 
262(k)(5)(A)). 
In view of the product interchangeability the 42 
USC 262(k)(4)defines safety standards that must 
be fulfilled by the biosimilar product 
In 42 USC 262(a)(2)(B) the submission of 
assessments to pediatric studies as defined in 
21 CFR 600.14 Reporting of biological product 
deviations by licensed manufacturers - report 
quality or safety related deviations of products 
realized after products release into the market as 
soon as possible but no later than 45 calendar days 
after the deviation has occurred using the FDA 
Form 3486 – performance of investigations of 
deviations in accordance with 21 CFR Part 211 
(cGMP) 
21 CFR 600.10 Personnel: specifies qualifications, 
restrictions and hygienic requirements to personnel 
in specific functions, requirements for Pathogenic 
viruses or spore-forming organisms, etc.,  
 
Risk Evaluation and Mitigation strategies as defined 
in sections 505(o), 505(p), and 505-1 of the FD&C 
Act (21 USC 355(o), (p); 355-1)  
 
21 CFR 314.50(a)(5) US agent 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
section 505B of the FD&C Act (21 USC 355c) [253] 
is required unless waived: 
-The 21 USC 355c(m)(1) defines that biosimilars 
found to be non-interchangeable (42 USC 
262(k)(4)) to a reference product as new active 
ingredient and therefore a need to submit pediatric 
assessment data, unless waived 
-The 21 USC 355c(m)(2) considers biosimilars 
interchangeable to a reference product not as new 
active ingredient and therefore the conduct of 
pediatric clinical trials and submission of pediatric 
assessment data is not necessaryGeneral Data 
requirements and submission content are given; 
need for environmental assessment under § 25.40 
or claim for exclusion under § 25.30 or § 25.31;  
Monoclonal antibody products and recombinant 
DNA derived products are categorized as specified 
biologics and following sections are not applicable 
to these products: 21 CFR 600.10(b) and (c); 
600.11, 600.12, 600.13, 610.53, 610.62  
 
21 CFR 601.4 Issuance and denial of license:  
Denial of a biologics license application when the 
establishment or product does not meet the 
requirements set out in 21 CFR 
21 CFR 600.80 Postmarketing reporting of adverse 
experiences  
Review of adverse experiences: prompt review 
required 
Individual case safety reports (ICSR) and 
information to be provided 
Reporting requirements: Postmarketing 15 day 
Alert Reports: report serious and unexpected asap 
21 CFR 600.11 Physical establishment, equipment, 
animals, and care: specifies hygienic standards for 
manufacturing and warehouse areas, equipment or 
requirements for spore-forming organisms, animals 
and disease reporting, etc., 
 
21 CFR 310.305 Records and reports concerning 
adverse drug experiences of marketed prescription 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
but no later than 15 calendar days after the initial 
receipt of the information; reporting of periodic 
safety reports 
Postmarketing 15 day Alert Reports – follow up: 
submission of follow-up reports within 15 calendar 
days or on FDA requested 
Periodic adverse experience reports: every 3 month 
for the first 3 years after the BLA got approved, 
from fourth year on an annual basis 
Recordkeeping: 10 years for adverse experiences 
Revocation of biologics license: if BLA owner fails 
establishing and keeping records or if he fails to 
make postmarketing reports required by section 
§600.80 the FDA can revoke its BLA 
Scientific literature. A 15-day Alert report based on 
information in the scientific literature including a 
copy of the published article 
21 CFR 601.28 Approved BLA Annual Reports 
(21CFR 314.80 and 21 CFR 314.98 Postmarketing 
reporting of adverse drug experiences; 21 CFR 
314.81 Other postmarketing reports: Annual report 
(applicable to common drug products) 
42 USC 262(a)(2)(D) and 42 USC 262(k)(5)(C) (21 
USC 505(o)(3); (p) and 505-1) FDA may require 
Postmarketing studies and Risk evaluation and 
mitigation strategy (REMS) 
drugs for human use without approved new drug 
applications 
21 CFR 601.20 Biologics licenses; issuance and 
conditions 
Approval is given only when the product complies 
21 CFR 600.81 Distribution reports  
CDER shall be informed about the distributed 
quantities of products licensed under BLA every 6 
21 CFR 600.20 and 21 CFR 600.21 Establishment 
inspections of licensed manufacturers and 
manufacturers applying for BLA performed by the 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
with all relevant requirements, when the product is 
available for examination and product production 
inspection, when the manufacturing process 
assures the consistency of products safety, purity, 
and potency, after the successful FDA inspection of 
all manufacturing facilities mentioned in the license 
month. Temporary waivers may be possible. FDA (please also refer to 42 USC 262(c)). 
Once every 2 years an inspection of BLA licensed 
establishments will be performed – with or without 
prior notice 
Furthermore:  
Establishment (facility) registration and drug listing:  
Establishments must be registered within 5 days of 
beginning operations. (21 CFR 207.21(a) and 
207.40 and FD&C Act 21 USC 510(c), (d), & (i)). In 
addition, establishments must renew registration 
annually between October 1st and December 31st 
of each year. (21 USC 510(b) & (i)). 
21 CFR 601.2 Applications for biologics licenses; 
procedures for filing - Link to PHS Act (42 U.S.C. 
201 et seq.) that authorizes the FDA to promptly 
suspend biologic licenses if needed to protect 
public health (license suspension) 
 
21 CFR 601.2 Applications for biologics licenses; 
procedures for filing Link to GMP requirements under 
21 CFR 210, -211, -600, -606 is given 
21 CFR 312 IND approval requirement prior to 
conduct a clinical trial 
21 CFR 312.32 Investigational New Drug Safety 
Reports 
42 U.S.C. § 282(j), and section 402(j) Act register 
the clinical trial in ClinicalTrials.gov. database 
21 CFR 601.4 Issuance and denial of license 
validity of a biologics license: until their suspension 
or revocation  
 
21 CFR 601.15 Foreign establishments and 
products: samples for each importation: random 
samples of imported products being forwarded to 
CDER/CBER must consist of two final containers of 
each product lot including relevant shipping and 
identification documents for imports greater than 20 
containers 
 
 21 CFR 601.5 Revocation of license: e.g.,  
-when the FDA cannot perform an inspection in 
accordance to § 600.21  
-a change was not reported as required by § 601.12 
-any other circumstances where the approved drug 
or establishment does not meet the requirements of 
42 USC 262(d) FDA may order a recall of hazardous 
products  
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21 CFR or the applicable standards set out in the 
biologics license  
-etc., 
 21 CFR 601.6 Suspension of license: e.g., in 
situations representing a danger to public health 
 
  21 CFR 601.12 Changes to an approved 
application  
The manufacturer must inform the FDA about each 
change in the biological product, manufacturing 
process, quality controls, equipment, facilities, 
responsible personnel, or labeling set out in the 
approved BLA. 
Prior distribution of a product involved in any 
change the license holder must assess the change 
with respect to its effects. Validations and/or further 
studies must demonstrate that the change has no 
influence to the products safety or effectiveness.  
Three categories of changes (major, moderate, 
minor) with different approval FDA conditions 
(general FDA approval prior distribution for major 
supplement submissions, 30days prior distribution 
approval by FDA of supplement submissions for 
moderate changes and no prior FDA approval for 
minor changes, only notification in annual report) 
The FDA may require a license holder to always 
submit a supplement for any intended change that 
must be FDA approved prior product distribution in 
case of repeated failure to comply with the change 
reporting requirements 
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Pre-authorization Post-authorization Overall (pre-and post-authorization) 
(Like EU-Variation system) 
 21 CFR 601.70 Annual progress reports of 
postmarketing studies: Annual progress reports of 
postmarketing studies including Form FDA–2252 
21 USC 331 Prohibited acts 
21 USC 331 (i)(3) prohibition of counterfeit drugs  
21 USC 355e Pharmaceutical security 
21 USC 355e(a); 355(c)(1) 
21 USC 360bbb-7 Notification requirement by 
awareness of counterfeit drugs 
 21 CFR 610.1 Tests prior to release required for 
each lot:  
Each lot must be tested for its conformity with 
standards applicable for this product after 
completion of its manufacturing process 
Final release testing requirement 
21 USC 502(e)(3) and 21 CFR 299.4 Established 
(official) drug name provided by the FDA 
 21 CFR 610.2 Requests for samples and protocols; 
official release:  
The FDA may require lot samples including its 
release testing protocols for official release. (not 
typical for specified biologics) 
FDA official release requirement (FDA batch 
prerelease) 
 
 21 CFR 610.9 Equivalent methods and processes. 
Requirements prior permission to modify specific 
test methods or manufacturing processes or 
conditions (please also refer to § 601.12) 
 
 21 CFR 610.10 Potency – requirements for potency 
testing 
 
 21 CFR 610.12 Sterility –   
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Requirement to perform sterility testing of each lot 
of each final container material. 
If the CDER responsible person determines the 
data submitted with the BLA of BLA supplement are 
adequate enough to preclude or show un-necessity 
of sterility testing it can be waived. 
 21 CFR 610.13 Purity – product is required to be 
free of extraneous material. Beside purity testing 
further testing shall be performed:  
residual moisture testing on each lot of dried 
product 
testing for pyrogenic substances on each lot of final 
containers (for injection products) by intravenous 
injection into rabbits with a testing dose of at least 3 
milliliters per kilogram of body weight  
21 CFR 610.14 Identity – identity testing to be 
performed on the contents of a final container of 
each filling of each lot after all labeling operations 
have been finished 
 
 21 CFR 610.18 Cultures – Requirements for 
storage and maintenance, Identification and 
verification, Cell lines used for manufacturing and 
testing. 
 
 21 CFR 201.57(c)(1): Boxed Warning to ensure 
safe use because of the drug product 
 
 21 CFR 601.42 Approval with restrictions to assure 
safe use (regarding distribution or use) 
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 Labeling requirements  
21 CFR 610.60 Container label – content 
requirements  
21 CFR 610.61 Package label (please also refer to 
42 USC 262(a)(1)(B)) 
21 CFR 610.62 Proper name; package label; 
legible type 
21 CFR 610.63 Divided manufacturing 
responsibility to be shown 
21 CFR 610.64 Name and address of distributor. 
21 CFR 610.65 Products for export 
21 CFR 610.67 Bar code label requirements 
21 CFR 601.25(d)(5) clear labeling, no false or 
misleading information 
Medication Guide in compliance with part 21 CFR 
208 
Furthermore: Labeling requirements: information 
required in and format as specified by 21 CFR §§ 
201.56, -201.57, and -201.80 as well as in addition 
to the provisions of 21 §§ 601.2(a) and 601.12(f); 
requirements in 21 USC sections 502 and 503 of 
the Federal Food, Drug, and Cosmetic Act, 
21 CFR 210 & 21 CFR 211 cGMP  
42 USC §262(b) no falsely labeling or marking 
 
 21 USC 356c Discontinuance or interruption in the 
production of life-saving drugs (requires to notify 
the FDA 6 month prior potential interruption);  
Cited from Federal Register / Vol. 78, No. 213 / 
Monday, November 4, 2013 / Proposed Rules: 
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“…to notify FDA electronically of a permanent 
discontinuance or an interruption in manufacturing 
of the product that is likely to lead to a meaningful 
disruption in supply (for drugs and biological 
products other than blood or blood components) or 
a significant disruption in supply (for blood or blood 
components) of the product in the United States 
21 USC § 356c (i)(3) Inclusion of biological 
products 
(21 CFR 310.306, 314.81(b)(3)(iii), and 21 CFR 
600.82 (a)(1)) 
 21 U.S.C. 355(r) Postmarket drug safety 
information for patients and providers (improves 
transparency by publishing/posting the summaries 
of postmarket safety evaluations of adverse 
experience reports) 
 
 
- Page 198 of 215 - 
APPENDIX M 
 
Appendix M: Overview of significant similarities and differences between regulatory and scientific requirements in the EEA and USA 
Item  EEA USA 
Overall safety-relevant regulatory requirements 
Definition of biological 
product 
Product, which contains a biological substance that is 
produced or extracted from a biological source. To 
characterize the product and to determine its quality physico-
chemical and biological testing and a well-controlled 
production process is needed  
Product, which is derived from living materials, such as as 
human, animal or microorganisms. Such products are 
complex in nature and usually not fully characterizable  
Comment  The overall definition of biological medicinal products is very similar. Both regions refer to the biological source. 
Definition of biosimilar / 
biosimilarity 
Biological product that contains a version of the active 
substance of an authorized biological innovator product 
(reference product). Biosimilarity to the reference product 
must be established by comparability testing and must be 
demonstrated for of quality characteristics, biological activity, 
safety and efficacy  
Biological product that is highly similar to the biological 
reference product by means of that no clinically meaningful 
differences exist between these products in terms of 
product safety, purity, and potency 
 
Comment Both, the EEA and the USA refer in terms of the similarity to a reference product and to require a similar safety. The US 
legislation additionally clarifies the term “highly similar” by requiring no clinically meaningful differences between the both 
products  
Definition of monoclonal 
antibodies and recombinant 
protein products 
Biological medicinal product Specified biological products [27]. Defined exclusions (21 
CFR §§ 600.10(b) and (c), 600.11, 600.12, 600.13, 610.53, 
and 610.62) apply 
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Item  EEA USA 
Regulatory approval 
pathway for biological and 
biosimilar products 
considered 
Biological products: Centralized Procedure with full application 
dossier according to Article 8 of Directive 2001/83/EC [26] [28] 
Considered biosimilar products (mAbs, recombinant protein 
products): Centralized Procedure with full application dossier 
according to Article 8 of Directive 2001/83/EC 
For some biosimilar products an abbreviated application 
dossier applies but the EMA determines the need of additional 
data on a case-by-case basis for applications based on to 
Article 10(4) of Directive 2001/83/EC  
Biologics License Application with full licensure dossier as 
established in 21 CFR § 601.2(a) (biological products) 
Abbreviated Biologics License Application as established in 
21 CFR § 601.2(k) (biosimilar products). FDA determines 
the need of additional data on a case-by-case basis. 
Comment  Abbreviated approval pathways for biosimilar products exist in both regions. However, in the EEA the same approval pathway 
and dossier requirements as for biological innovator products are mandatory (Centralized procedure).  
Reference product Must be an original biological product authorized in the EEA, 
only one and the same reference product shall be used 
throughout the comparability program. The use of a non-EU 
licensed reference product may be possible for certain clinical 
or in-vivo non-clinical studies when comparative bridging data 
between all three products are provided and the non-EU 
licensed reference product was authorized by a regulatory 
authority using a similar level of approval standards like the 
EMA  
 
Must be a single original biological product licensed by the 
FDA, only one and the same approved product should be 
used as reference product. The use of a non-US licensed 
reference product may be possible for certain comparative 
clinical or animal non-clinical studies when bridging data 
between all three products demonstrate comparability. The 
non-US licensed reference product was authorized by a 
regulatory authority using a similar level of approval 
standards like the FDA 
Comment No significant differences exist. The FDA guidance documents, specifically the Q&A guidance document, discussing the topic 
of using a third-party comparator product and providing more detailed information than the relevant EMA guidance 
documents.  
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Item  EEA USA 
Interchangeability / 
automatic substitution 
The determination of the interchangeability of a biosimilar 
product with a biological innovator product is not part of 
dossier review and not an EMA decision. The responsibility to 
determine a product as interchangeable and decisions about 
automatic substitution rests with the individual EU member 
states (decentralized approach).  
 
If requested by the applicant, the interchangeability status 
as established in 42 USC 262(i)(3) will be reviewed as part 
of the application. The FDA will determine the 
interchangeability status. Theoretical, interchangeable 
products can be automatically substituted for the original 
product at pharmacy level depending on the grade of US 
law enforcement at US state law level  
Comment  Differences exist. The determination of the interchangeability status and decision regarding an automatic substitution is not an 
EMA decision with the EEA but is at national level. While it is a FDA decision in the USA where the US law (USC) provides 
the FDA with the necessary power to determine product interchangeability. Further, once a product is determined 
interchangeable it can be automatically substituted.  
Exclusivity / protection 
periods  
Usually, 10 years with the Centralized Procedure 12 years 
Comment  A difference of 2 years exists.   
Exclusivity period for 
products found to be 
interchangeable 
Not applicable Typically, 1 year 
Comment  The difference is reasoned by different regulatory approaches regarding the interchangeability status of a product.  
Drug Master File (ASMF, 
DMF) 
Active substance master file is not accepted for biosimilar 
product authorization application purpose 
Drug master file is not accepted for biosimilar product 
licensure application purpose 
 No differences exist.  
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Item  EEA USA 
Labeling and naming  Medicinal products shall provide a common name preferably 
the INN (International Nonproprietary Names) and, if such not 
exist, the usual common name. For biosimilar products the 
applicant may either apply the INN used for the reference 
medicinal product or may request a new INN from the WHO. 
The WHO INN proposal envisages a biological qualifier (BQ) 
code that is specifically assigned to all biotechnology-derived 
substances having or eligible to have INNs. In its basic the 
biological qualifier is a four letter random alphabetic code that 
will be added as unique identification code. It is used in 
conjunction with the INN but will remain independent from the 
INN. The BQ scheme may be used voluntarily by any 
regulatory authority and would be recognized worldwide. The 
INN proposal document does not explain if and how the BQ is 
eligible to distinguish between interchangeable and non-
interchangeable biosimilar products in order to avoid 
unintentional substitution. Solution for interchangeable 
biosimilar products is open. 
In order to assist applicants in addressing labeling specifics 
of biosimilar products for submission purpose, the FDA has 
issued recommendations to industry in a labeling guidance 
document which provides information to the content of the 
prescribing information (package insert). However, the 
labeling of interchangeable biological products is not 
considered in this guidance. 
Biological products shall provide a proper name (42 USC 
§262(a)(1)(B)(i); 21 CFR 600.3(k)). Original biological 
products shall use a core name that is the adopted name 
designated by the USAN Council for the relevant biological 
substance when available. The core name is the 
component shared among all related biological products as 
part of the proper name. If the biological product is a 
biosimilar product, or an interchangeable product, the core 
name will be the same as the core name identified in the 
proper name of the relevant innovator product. A product 
unique suffix that is composed of four lowercase letters will 
be attached with a hyphen to the core name of each 
innovator biological product or biosimilar product (e.g., 
innovator product name replicamab-cznm; biosimilars 
name replicamab-hixf). For interchangeable products the 
FDA is still searching for the appropriate suffix format but 
will use the same approach of that of a core name and a 
suffix included in the proper name. 
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Comment  Differences exist.  
While the basic concept of a unique four letter code attachment for biological products is the same, in the EEA, this letter 
code will be provided by the WHO and will amend the INN of biological products. In the USA letter code will be designated by 
the FDA and attached as suffix to the core name and included in the proper name. While the FDA is searching for a well 
working suffix solution for interchangeable products, this is not discussed within the EEA and WHO guidance document.  
There is no EMA guidance document comparable to the FDA´s labeling guidance for biosimilar products available in the EU. 
Prescription information Directive 2012/52/EU requires brand name instead of INN for 
biological products. No information to biosimilar and 
interchangeable products provided.  
There is no difference in prescribing of biosimilar and / or 
interchangeable products and any other medicinal 
products. Either the proprietary name or the nonproprietary 
name shall be documented on the prescription  
Comment Differences exist.  
No information related to biosimilar and interchangeable products is provided in the mentioned EU Directive. In the USA, no 
differences in the prescribing information of biosimilar and / or interchangeable products and any other medicinal products are 
made. 
Pediatric assessement Not required for biosimilar products as the goal of the 
development program is to establish comparability and thus, 
the focus in selecting the primary patient population is laid on 
homogeneity and sensitivity  
Required for biosimilar products not determined to be 
interchangeable as such biosimilar products are 
considered as new active ingredients (21 U.S:C. 355c). 
The requirement can be waived or deferred.  
Not required for biosimilar products determined to be 
interchangeable as such products are not considered 
having a new active ingredient. 
Comment  Differences exist. The FDA handles the topic tighter and considers pediatric safety in her thinking.  
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Container / closure system / 
delivery device 
The use of a different container or closure system as the 
reference medicinal product uses is possible; provided that its 
potential impact on the biosimilar´s safety and efficacy is 
appropriately justified. In contrast to the FDA guidance 
document the EMA guideline does not further detail the topic.  
 
 
 
 
 
 
The FDA may accept slight deviations in the design of a 
delivery device, or container closure system between the 
compared products. This is accepted by the FDA when 
certain defined conditions are met. If the proposed product 
is an interchangeable product, the FDA also reviews if the 
differences between the biosimilar and the reference 
product influence any critical design attributes, product 
performance, etc., or require additional use instructions. 
Thus, the FDA may require additional performance data for 
the delivery device or container closure system. Additional 
testing for leachables under stress- and under real time 
storage conditions should be performed for each product 
and its storage container.  
Comment Differences exist. The FDA requirements are stricter and the FDA guidance document provides more details. 
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Postmarketing surveillance To ensure the safety and efficacy of biological products, post-
approval safety monitoring programs and continued benefit-
risk assessment described in a risk management plan are 
important. The risk management plan should consider and 
address potential risks identified with the reference product.  
From significant importance is the comparison of the type, 
severity and frequency of the known adverse reactions of the 
biosimilar product and the reference product. 
Applicants should consider the possibility of additionally 
required post-approval surveillance; clinical studies or - trials 
such as post-authorization safety studies (PASS) or post-
authorization efficacy studies (PAES).  
Regarding possible future substitutions of mAbs with 
biosimilar mAbs on national level, applicants should monitor 
the developments regarding that topic and should address it 
within the risk management plan.   
A robust post-approval safety monitoring program and risk 
evaluation and mitigation strategies are crucial to ensure 
the safety and efficacy of biological products. The safety 
monitoring program should be designed in that way that a 
differentiation between adverse events of reference and 
proposed product is possible, including any new side 
effects not observed with the reference product in the past. 
Sponsors should also consider the possibility of additional 
post-approval surveillance, clinical studies or – trials. 
Comment No major differences exist. The FDA encourages the applicants to discuss the intended pharmacovigilance system with the 
agency. 
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Quantity and type of 
scientific guidance 
documents for biosimilar 
products 
Various product-class specific scientific guidance documents 
are available.  
One product-specific document for biosimilar mAbs available.  
Three overall guidance with similar content as the FDA overall 
guidance documents for biosimilar products (overall safety-
relevant regulatory requirements, non-clinical- and clinical 
safety issues, quality considerations). No EMA guidance 
document available that specifically addresses the topic of 
clinical pharmacology data for biosimilar products.  
No product-class specific biosimilar product guidance 
available.  
Seven FDA biosimilar products guidance documents, two 
of them procedural; five of them have an overall 
applicability similar to the EMA scientific guidance on 
biosimilar products (scientific/overall safety-relevant 
regulatory considerations, quality considerations, two Q&A 
documents, clinical pharmacology guidance).  
One guidance document addresses clinical pharmacology 
data for biosimilar products.  
Comment Differences exist in the quantity of available guidance documents. No significant differences exist between the available 
guidance documents regarding their quality, scientific contents and topics covered.  
Regulatory specifics The EMA provides advice during scientific advice meetings. The FDA encourages the sponsors to discuss their planned 
biosimilar development program and all significant 
stages/plan early with the FDA. 
The FDA reserves the right to determine type, amount and 
necessity of non-clinical and clinical testing, including 
immunogenicity data on a case by case basis in order to 
sufficiently demonstrate biosimilarity.  
Comment Differences exist. The FDA is involved in the biosimilar development program and thus, in the application process at a very 
early stage and following may better understand the specifics of the proposed biosimilar product and as a consequence, can 
request additional data in a tightly focused way. Applicant and FDA cooperate together.  
Non-clinical considerations  
Approach in order to assess 
biosimilarity 
Totality-of-Data Totality-of-Evidence 
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Comment No differences. 
Approach to developing 
data demonstrating 
biosimilarity 
Stepwise 
Depending on the level of evidence achieved in the structural 
and functional characterization, subsequent non-clinical and 
clinical studies are necessary to conduct more or less 
extensively. 
Stepwise, target-orientated 
The sponsor should evaluate the extent of residual 
uncertainties regarding biosimilarity after each step and 
should address these uncertainties in the next step. The 
approach facilitates a target-oriented approach to non-
clinical and clinical studies.  
Comment No differences.  
Testmaterial for 
comparability exercise 
Appropriate quantity of batches intended for clinical use and 
commercialization 
Appropriate quantity of lots intended for clinical use and 
commercialization 
Comment No differences. 
Steps of the non-clinical 
comparability program 
(1) Extensive and robust structural and functional 
characterization 
(2) animal data including toxicity assessment  
(1) Extensive and robust structural and functional 
characterization 
(2) animal data including toxicity assessment 
Comment No differences. 
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Animal immunogenicity 
data 
Immunogenicity assessment is considered as integral part of 
the comparability program.  
However, animal immunogenicity studies are not adequate to 
detect potential immune reactions to protein products in 
human individuals. Nevertheless, such study data may help 
interpreting in-vivo animal data and blood samples should be 
taken and banked.  
Immunogenicity assessment is considered as integral part 
of the comparability program.  
Animal immunogenicity studies are not adequate to detect 
potential immune reactions to protein products in human 
individuals. Nevertheless, differences in manufacturing 
between the compared products may lead to varied 
immunogenicity and therefore anti-protein antibody 
response measurements in animals could give helpful 
information. 
Comment Slight difference regarding the purpose of animal immunogenicity studies. The FDA considers such data as useful when 
differences in manufacturing are to investigate.  
Non-clinical safety 
pharmacology, reproductive 
and developmental toxicity, 
carcinogenicity studies  
Not necessary  Not necessary  
Comment No differences. 
Clinical considerations  
Evaluation approach Totality-of-Data Totality-of-Evidence 
Comment No differences. 
Testing approach to clinical 
evaluation 
Stepwise Stepwise, progressive 
Comment  No differences. 
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Testmaterial for clinical data 
generation 
Ideally, clinical study data should be generated with biosimilar 
products derived from the commercial manufacturing process. 
Ideally, clinical study data should be generated with 
biosimilar products derived from the commercial 
manufacturing process. 
Comment No differences 
Steps of the clinical 
comparability program 
(1) Comparative human pharmacokinetic studies (PK)  
(2) Comparative human pharmacodynamic (PD) studies and 
clinical immunogenicity assessment 
(3) Clinical efficacy and safety trial(s), and when necessary 
confirmatory PK / PD trials 
(1) Comparative human pharmacokinetic studies (PK)  
(2) Comparative human pharmacodynamic (PD) studies 
and clinical immunogenicity assessment 
(3) Clinical efficacy and safety trial(s), and when 
necessary confirmatory PK / PD trials  
Comment  No differences. 
Extrapolation of 
immunogenicity findings for 
one condition of use to 
other conditions of use 
Extrapolation of immunogenicity data from the confirmed 
indication or condition of use to other uses of the reference 
product should be justified; additional data may be required in 
certain cases.  
Extrapolation of immunogenicity data for one condition of 
use to other conditions of use should be justified for each 
additional indication that is sought. The sponsor should use 
an adequately sensitive study population and treatment 
scheme in order to prognosticate distinctions in immune 
reactions between the comparators across the indications.  
Comment  Differences exist. The EMA may require additional data. 
Extrapolation of clinical 
data across indications 
Possible, when scientifically justified. Additional data may be 
necessary in certain cases  
Possible, scientific justification for each additional 
indication that is sought is required 
Recommendation to study that indication that is sensitive 
enough to reveal clinically meaningful differences between 
the comparators.  
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Comment Differences exist.  
The EMA may require additional data. 
FDA recommends studying that indication that is sensitive enough to reveal clinically meaningful differences. That poses a 
risk that immunogenic potential remains undetected in various indications. 
Immunogenicity studies Pre- and post-approval  
Risk based approach 
Pre- and post-approval 
Risk based approach 
Comment No differences.  
Pharmacokinetic data Comparative PK- studies typically represent an essential part 
in demonstrating biosimilarity and should normally being 
provided. 
The selected PK parameters should be predefined and 
including their limits scientifically justified.  
Comparative PK- studies typically typically represent a 
critical part of demonstrating biosimilarity, and usually, FDA 
expects the results of comparative human PK and PD 
studies to demonstrate biosimilarity.  
The selected PK- parameters and selection criteria should 
be predefined and scientifically justified. 
Comment No differences 
Pharmacodynamic data The choice of PD-markers used in relevant studies should 
depend on their ability to demonstrate the intended clinical 
result.  
PD-measures should be performed within (together with) PK-
studies where possible.  
The selection of PD-parameters should be orientated on 
the relevance to clinical outcomes.  
PD-measures should be performed within (together with) 
PK-studies where possible.  
Comment No differences.  
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PK/PD-study design Comparable cross-over study design (products with short half-
life) or comparable parallel study design (products with a long 
half-life) 
Comparable cross-over study design (products with short 
half-life) or comparable parallel study design (products with 
a long half-life) 
Comment No differences 
PK-/PD- study alternative 
dosing scheme  
Not provided Possible under certain conditions and if properly justified  
Comment  Differences exist. In certain cases, the FDA allows an alternative dosing scheme. 
Skipping of studies A confirmatory clinical study may be unnecessary in cases 
where the data from the structural and functional 
characterization as well as data from the PK- and/or PD-profile 
are able to clearly demonstrate similar efficacy and safety, 
providing that the impurity- and excipients profiles are 
acceptable. 
If the outcomes of the comparative human PK- / PD- 
studies show a meaningful correlation between PK- / PD-
results and clinical effectiveness, comparative efficacy 
studies may be skipped.  
Comment  Differences exist. The EMA also requires an acceptable impurity and excipients profile when it is intended to skip a trial.  
Length of follow-up period 
(Immunogenicity 
assessment) 
One year at minimum for chronically administered products, 
Shorter periods may be possible when justified 
One year at minimum for chronically administered products 
Comment  Differences exist. Shorter periods may be possible with the EMA when this is justified. 
Comparative clinical study 
design 
Comparable equivalence trial design, comparable margins 
should be statistically and clinically pre-specified and justified 
by using the reference product data  
Comparable equivalence trial design with symmetric 
inferiority and superiority margins 
Comment  No differences in trial design. 
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Comparative clinical study 
sample size and duration 
Sample size may vary due to dependency on prior non-clinical 
testing and PK-/PD- studies but should be adequate enough 
to allow the detection of differences between the compared 
products. 
Sample size may vary due to dependency on prior non-
clinical testing and PK-/PD- studies but should be adequate 
enough to allow the detection of clinically meaningful 
differences between the compared products; otherwise 
separate investigation of safety signals is required 
Comment No differences. 
Quality considerations  
Submission of comparative 
and similarity data 
EMA does not encourage the applicant to submit these data 
prior submission of the final application dossier but some open 
items may be discussed during scientific advice meetings. 
FDA encourages the applicant to submit these data at an 
early stage of development  
Comment  Differences exist. The FDA is involved in the approval process at a very early stage of the biosimilar product development 
program.  
Stability Stability data cannot be extrapolated from the reference 
product. 
Requires that stability testing should include accelerated 
and stress testing as well as forced degradation studies; 
conducted under multiple stress conditions. 
Comment  Differences exist as the FDA guidance document provides more detailed information. 
Handling of differences in 
impurity profiles between 
compared products 
Documentation and proper justification of identified impurities 
with regard to their potential risks. 
If differences in impurity profiles of the two products are 
detected, their potential impact to the product safety and 
efficacy should be discussed and supported with relevant 
data. 
Comment  Differences exist. The FDA requires additional data.  
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Differences in formulation 
and / or container closure 
system / delivery device 
The impact of the different formulation and / or container 
closure system to the products safety and efficacy should be 
properly justified.  
Additional data may be required to sufficiently rationale 
why the deviation does not affect the safety and efficacy of 
the biosimilar product. 
Comment  Differences exist. The FDA may require additional data. 
Proposed shelf life Requires that the proposed shelf life of the biosimilar product 
should be supported with full stability data.  
Comparative real-time, real-condition stability studies between 
the compared products are considered not necessary. 
Real time data and real-condition stability data should 
support the proposed shelf life of the biosimilar product. 
Comment  Differences exist. FDA and EMA have different meanings if real time data and real-condition stability data should support the 
proposed shelf-life. 
Re-demonstration of 
biosimilarity after marketing 
approval 
Not required by regulations Not addressed 
Comment  No differences.  
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Executive Summary 
 
Innovative biological medicinal products have the potential to significantly improve a 
patient’s life. Their market access is highly regulated in the EU and in the USA with 
very high safety requirements. When patents of the first original biological products 
reach their expiration date, the cheaper biosimilar products are in the process of 
obtaining marketing approval in order to compete against the innovator biological 
products.  
What safety relevant standards are established for biotechnology-derived biosimilar 
products in both the European Union (EU) and the USA? And, is there potential to 
improve the current safety standards? The applicable scientific guidance documents 
for biosimilar products issued by the European Medicines Agency (EMA) and the 
US-American Food and Drug Administration (FDA) were analyzed and compared 
with respect to their safety requirements.  
No major differences between the EU and the USA were identified with respect to 
the overall regulatory-safety standards that apply for biosimilar products established 
by the EU- / and US- law and as recommended in the scientific EMA- and FDA 
guidance documents.  
Except of slight differences, the overall safety-related regulatory requirements 
required by legislation in the EU and the USA are very similar, including 
pharmacovigilance requirements. The FDA regulations (CFR) require stricter 
reporting (e.g., reporting of biological product deviations) and processing (e.g., 
prompt review of adverse events) than that required by the EU and the regulation of 
drug shortage is different in the two regions. By EU regulation, a minimum of one 
qualified person to perform certain safety-related tasks (e.g., batch compliance), the 
FDA does not require that position. Further, the EU legislation has established and 
implemented the black triangle labeling that represents extended monitoring of new 
and high-risk products; a comparable instrument is not implemented yet in the USA. 
While the US- law considers the determination of interchangeability this is not part of 
the EU legislation. And the law in both regions, the EU and USA, does not consider 
the re-demonstration of biosimilarity after a change to the manufacturing process 
occurs post-authorization.  
While the US-law provides the FDA with more authority and power than the EMA is 
provided by Regulation (EC) No. 726/2004, the regulatory requirements established 
by EU-legislation provide the manufacturers with more individual responsibility (e.g., 
they are responsible to watch their distributors) than the US-law provides to the US-
American medicinal product manufacturers. The main European legal document for 
medicinal products, Directive 2001/83/EC needs to be transposed into national law 
by the EU-member states while the United States Code applies without transposing 
into national law. In consequence, the EU-member states have more freedom 
regarding the implementation of the EU Directive into their national law. 
Regarding the pharmacovigilance and postmarketing requirements in both regions, 
the EU and the USA, these are very similar for the last few years. In both regions, 
pharmacovigilance includes postmarketing studies, clinical trials, risk evaluation and 
risk mitigation strategies, patient registries and special labeling. Although 
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appropriate instruments to monitor and further confirm the safety and efficacy of 
medicinal drug products are available (e.g., postmarketing studies), their application 
is handled differently and on a case by case basis.  
Regarding the regulatory burden and available scientific guidance documents, there 
are some differences between the EU and the USA. The regulatory burden in the 
EU is higher than in the USA due to the European- and national legislations and the 
required transformation of EU legislation into national law. The quantity of available 
guidance documents, in particular documents which address the specifics of 
individual product classes, is higher in the EU than in the USA. The scientific value, 
quality and content of the available scientific guidance documents regarding quality 
issues, non-clinical and clinical requirements as well as overall safety-related 
considerations to biosimilar products is high in both regions.  
The scientific EMA- and FDA guidance documents concerning the quality, non-
clinical and clinical safety requirements for biosimilar products are very similar and 
comparable. The scientific content of the documents is mostly the same, but there 
are small differences (e.g., better explanations, examples) that make the FDA 
documents clearer and more meaningful.  
The most significant differences between the two regions, EU and USA, that were 
identified in the scientific guidance documents and which belong to the safety of 
biosimilar products are related to the: [1] determination of interchangeability; [2] 
automatic substitution of biosimilar products; [3] pediatric assessment requirement; 
[4] the extrapolation of safety and efficacy data including immunogenicity data 
across indications; and [5] testing requirements when using a different container 
closure or delivery device system.  
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